e roche annual report key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment e roche ance report roche annual r eport fhopfufmbalnshnelda roche ltd f bhaosfefml asnwnitzear lranodc trademark legally protec ted wwwrochecom excellence science umschlagausgeschossenengindd key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment lrochearengkey figuresindd year brief group group sale increase billion swiss franc swiss franc dollar division gain market share operating profit exceptional item increase swiss franc billion swiss franc strong sale growth continue productivity improvement time investment research development increase billion swiss franc effective march roche obtain ownership genentech price billion dollar billion swiss franc genentech integration complete net income billion swiss franc compare previous year exceptional item relate genentech transaction integration exclude exceptional item genentech transaction contribute income income attributable roche shareholder increase billion swiss franc core ep constant exchange rate swiss francs board propose dividend increase swiss franc rd consecutive year dividend growth increase payout ratio pharmaceutical pharma sale grow swiss franc dollar twice global market growth rate drive lead cancer medication tamiflu influenza medicine lucentis ophthalmology medicine tamiflu sale grow sharply billion swiss franc follow substantially increase demand pandemic influenza ahn virus swine flu outbreak operate profit margin exceptional item increase percentage point constant exchange rate percentage point swiss franc strong rd pipeline new molecular entity latestage clinical testing new compound enter phase iii clinical trial actemra approve treatment rheumatoid arthritis january diagnostic sale increase swiss franc dollar billion swiss franc twice market growth rate operating profit margin constant exchange rate increase percentage point percentage point swiss franc outlook fullyear sale pharmaceutical group expect grow midsingledigit range expect decrease tamiflu sale billion swiss franc diagnostic sale expect grow ahead market plan research development expense decline slightly compare roche confirm target doubledigit core earning share growth base strong operating free cash flow roche expect reduce debt progressively return net cash position maintain attractive dividend policy state growth rate local currency tamiflu sale constant exchange rate bar unforeseen event lrochearenghighlightsindd pharmaceuticals pipeline focus compound firstinclass bestinclass potential phase phase ii phase iii registration project d projectproduct indication project d projectproduct indication project d projectproduct indication project d projectproduct indication oncology oncology oncology oncology rg secretase inh solid tumour rg avastin multiple myeloma rg mabtherarituxan indolent nhl maint stline rg mabtherarituxan chronic lympocytic leukemia rg antiegfr humab solid tumour rg avastin metastatic melanoma rg xelodaavastin adj colon cancer stline rg cifmek inh solid tumour rg pertuzumab neoadj breast cancer rg xeloda adj breast cancer rg mabtherarituxan chronic lympocytic leukemia rg solid tumour rg trastuzumabdm metastatic bc rdline rg avastinmabthera diffuse large b cell lymphoma relapse rg antiplgf mab solid tumour rg trastuzumabdm metastatic bc stline rg avastin adj colon cancer rg xeloda adj colon cancer combo rg antinrp mab solid tumour rg hedgehog pathway inh basal cell carcinoma rg avastin prostate cancer oxaliplatin rg mdm antag solid hematologic tumour rg hedgehog pathway inh colocrectal cancer rg avastin adj breast cancer rg avastin mbc stline combo docetaxel rg dulanermin cancer rg hedgehog pathway inh ovarian cancer rg avastin ovarian cancer stline rg avastin mbc stline combo standard rg mek inh solid tumour rg anticd humab nonhodgkin lymphoma rg avastinherceptin mbc stline chemotherapy rg pi kinase inh solid hematologic tumour rg antimet humab metastatic nsclc rg avastin adj nsclc rg herceptin meet gastric cancer rg pi kinase inh solid tumour rg abt solid hematologic tumour rg avastin meet gastric cancer rg tarceva nsclc stline maintenance rg antiegfl mab solid tumours chu topoisomerase inh gastric cancer rg avastin adj breast cancer chu antiglypican mab liver cancer rg avastin adj bc triple negative inflammation autoimmune disorder inflammation autoimmune disorder rg avastin mbc combo hormonal rg mabtherarituxan rheumatoid arthritis dmard inflammation autoimmune disorder rg palovarotene emphysema therapy inadequate responder rg antibeta rhumab ulcerative colitis rg lebrikizumab asthma rg avastin ovarian cancer platinum rg xolair pediatric asthma rg antilt alpha mab rheumatoid arthritis rg oxl humab asthma sensitive chu eldecalcitol ed osteoporosis bti vap inflammatory disease rg rontalizumab systemic lupus erythematosus rg avastin mbc ndline rg xolair chronic idiopathic urticaria rg avastin highrisk carcinoid virology virology rg avastin gbm stline rg valcyte cytomegalovirus extension chu serine palmitoyltran hepatitis c virology rg herceptin sc formulation bc treatment ferase inh rg hpv immunotherapy cervical neoplasia rg herceptin adj bc yr treatment chu nitazoxanide hepatitis c rg nucleoside inh prodrug hepatitis c rg pertuzumab mbc ophthalmology rg protease inh hepatitis c rg tarceva nsclc egfr mutation rg lucentis retinal vein occlusion cardiovascular metabolic disease positive stline rg yr peptide agonist type diabete cardiovascular metabolic disease rg tarceva adj nsclc rg antip selectin humab peripheral vascular disease rg aleglitazar cardiovascular risk reduction rg tarcevaavastin nsclc maint stline chu epogin epoch chemoinduced anemia rg hsd inh type diabetes rg sglt inh type diabetes rg anticd humab chronic lymphocytic leukemia rg hsd inh type diabetes rg braf inh malignant melanoma rg abca inducer dyslipidemia central nervous system rg trastuzumabdm mbc ndline rg craf inh polycystic kidney disease rg ocrelizumab relapsingremitte ms rg antioxldl mab secondary prevention rg glyt inh schizophrenia inflammation autoimmune disorder cardiovascular event rg nicotinic receptor alzheimer disease rg mabtherarituxan ancaassociate vasculitis rg bht type diabetes agonist rg actemraroactemra jia systemic onset rg mglur antag treatmentresistant depression rg actemraroactemra early rheumatoid arthritis central nervous system rg ocrelizumab rheumatoid arthritis pjd rg gantenerumab alzheimer disease rg xolair asthma addon therapy rg mglur antag depression rg gabaa agonist alzheimer disease select abbreviation cardiovascular metabolic disease legend rg igf peg amyotrophic lateral sclerosis adj adjuvant treatment inh inhibitor rg taspoglutide type diabete therapeutic protein biologic rg triple reuptake inh depression amd agerelate macular jia juvenile idiopathic arthritis rg dalcetrapib dyslipidemia small molecule degeneration mab monoclonal antibody rg taar partial agonist depression blue type indication antag antagonist maint maintenance treatment rg antiamyloid peptide alzheimer disease bc breast cancer meet metastatic cancer ophthalmology black type additional indication mab combo combine ms multiple sclerosis rg lucentis diabetic macular edema dmard diseasemodifye nhl nonhodgkin lymphoma evo nmda receptor antag treatmentresistant depression antirheumatic drug nsclc nonsmall cell lung cancer rg lucentis amd high dose rgno roche andor genentech manage gbm glioblastoma multiforme pjd prevention joint chu chugai manage ophthalmology herpositive destruction bti biotie optin hernegative r recombinant evo evotec rg antifactor mab geographic atrophy hpv human papilloma virus sc subcutaneous rg tnkase catheter clearance hu humanise phase initial study healthy volunteer possibly patient phase ii efficacy tolerability dosefinde study patient phase iii largescale study patient statistical confirmation safety efficacy registra marketing application file eu andor japan tion approve eu current january umschlagausgeschosseneng indd business innovation answer medical challenge daily work save patient live help million people world excellence science focus unsolved medical problem year roche play pioneer include cancer viral infection metabolic ing role healthcare today world leader central nervous system disorder inflammatory vitro diagnostic supply wide range diag disease roche pioneer personalise health nostic instrument test rapid reliable care aim fit treatment closely pos sible disease detection monitor doctor labora patient need healthcare well safe tory patient world large costeffective biotech company roche bring highly effective drug market world lead supplier prescription drug cancer treatment daily work focus disease area medical need great lrochearengtable contentsindd content key figure inside cover pharmaceutical pipeline inside cover year brief letter shareholder roche group group results outlook group strategy pharmaceuticals pharmaceutical division brief result sale review development highlight research development diagnostic diagnostic division brief result business area highlight research development corporate governance remuneration report corporate governance remuneration report corporate responsibility brief responsible practice patient people society safety security health environmental protection independent assurance report gri statement lrochearengtable contentsindd roche business report letter shareholder letter shareholder franz b humer dear shareholder despitethesustainedglobalfinancialandeconomiccrisiswasaverysuccessfulyearforrochesale inboththepharmaceuticalsandthediagnosticsdivisiongrewtwiceasfastasthemarketgroupsales increasedbyinlocalcurrenciestobillionswissfrancsmainlydrivenbyourleadingmedicine totreatpatientswithcancerviralinfectionsagerelatedblindnessandotherseriousdiseasessalesof theinfluenzamedicinetamifluatbillionswissfrancsalsocontributedsignificantlytorevenuegrowth operatingprofitbeforeexceptionalitemsgrewevenmorestronglythansalesadvancinginlocal currenciestobillionswissfranc willberememberedasoneofthemostimportantyearsinyourcompanyslonghistoryfollowingthe mergeragreementwithgenentechinmarchandtherapidfinalisationofthetransactionwewere abletocompletetheintegrationbytheendoftheyearbycombiningrocheandgenentechwearenotonly increasingoperationalefficiencybutalsopromotinginternalknowledgetransferwearecommittedto strengtheningtherochegroupsinnovativepowerinthelongtermandto providingpatientswithinno vativemedicinesthroughresearchofthehighestquality excellentresearchisandwillremainabasicrequirementforthedevelopmentoftherapiesthataredecisive forpatientshealthandqualityoflifeafterconcludingthegenentechintegrationwewillcontinueto systematicallypursuediverseresearchapproachesforinnovativehealthcaresolutionsthiscreatesscope forcreativityandincreasesthechancesofdevisingsustainablemedicalandtherapeuticprogressfor thisreasongenentechresearchandearlydevelopmentwillcontinuetofunctionasanindependentunit lrochearengletter shareholdersindd severin schwan inadditioncombiningtheactivitiesofthetwocompaniesintheareasofproductdevelopmentproduction andsaleshasalreadygeneratedsignificantincreasesinproductivityouraimistoachievepretaxannual savingsofapproximatelybillionswissfrancsby theoperatingfreecashflowofthegroupincreasedbytobillionswissfrancsdespitesignificant negativecurrencyeffectsrochesstrongoperatingperformanceisalsoclearlyreflectedincoreearning persharewhichadvancedinlocalcurrenciesinswissfranc asaresultofexceptionalcostsofbillionswissfrancswhichwereprimarilyintegrationrelate thegroupsoperatingprofitindeclinedbyinlocalcurrenciesinswissfrancstobillion swissfrancsexceptionalitemsalsoimpactednetincomewhichdeclinedbycomparedwiththe previousyearperiodtobillionswissfrancsexcludingexceptionalitemsnetincomeattributableto rocheshareholdersincreasedby inviewofrochesstrongfullyearoperatingresultsattheannualgeneralmeetingtheboardofdirector willproposeanincreaseofinthedividendfortoswissfrancspershareandnonvote equitysecurityswissfrancssubjecttoyourapprovalthiswillbetherdconsecutive annualdividendincrease lrochearengletter shareholdersindd roche business report letter shareholder therapidspreadofthepandemicahninfluenzavirusswinefluwhichbeganinaprilpre sentedamajorchallengenotonlyforgovernmentsworldwidebutalsoforrocheduringthepastyearwe havebeensupportingtheworldhealthorganizationwhoandnationalgovernmentsinglobaleffort tofightthenewvirusinmayrocheannouncedthatanadditionalmilliontreatmentcoursesoftamiflu wouldbedonatedtoreplenishthewhosregionalandrapidresponsestockpileswehadpreviously grantedsublicencestothreemanufacturerstoproducegenericoseltamivirforpandemicuseinchina indiaandspecifieddevelopingcountriestoensurethatlocalpopulationsintheseareashaveaccessto themedicationinadditioninjulyweinitiatedthetamiflureservesprogramtofurtherimprovetamiflu accessindevelopingcountriesinresponsetotheincreasedwhopandemicthreatlevelournetworkof manufacturingpartnersscaledupproductiontoapproximatelymilliontreatmentcoursespermonth andwearenowabletosupplyuptomillionpacksannuallyifrequire therochegroupreceivedsignificantrecognitionforachievementsinseveralareasduringthepastyear thedowjonessustainabilityindexesnamedrochethenewsupersectorleaderinhealthcare rankingusasthemostsustainablehealthcarecompanyworldwiderocheandgenentechwerealso againvotedbestemployerinanumberofcountries wewouldliketotakethisopportunitytothankthemorethangroupemployeesworldwideforthe outstandingdedicationandprofessionalismduringthiseventfulandchallengingtime scientificexcellenceandinnovationinourcorepharmaanddiagnosticsbusinesseswillcontinuetobethe foundationofoursuccessasidefromoncologywearedevelopingnewtherapeuticsformetabolicand autoimmunediseasesviralinfectionsanddisordersofthecentralnervoussystemastheworldslarg biotechcompanywehaveoneofthemostpromisingrdpipelinesintheworldfromatotalofnew molecularentitiesinclinicaltestingtenarealreadyinlatestagedevelopmentwhichisremarkablebyany standardsinourindustryinthelastyearalonesixnewcompoundsenteredlatephasedevelopment includingpotentialnewtherapiesforbreastcancerandtypediabete duringtheyearwepublishedexcitingearlyphaseclinicaltrialdataonatargetedtreatmentandcom paniondiagnosticinmalignantmelanomapatientswhosecancercellscarryaspecificgeneticmutation malignantmelanomaisthedeadliestformofskincancerthenewcompoundeffectivelyslowedtumor progressionandincreasedpatientsqualityoflifethisisabeaconofhopeinthefightagainstacancer thatuntilnowhasbeenregardedasvirtuallyuntreatable amongthekeyachievementsinourdiagnosticsdivisionarethestartoftherolloutofthecobas modularanalyserseriesforlargemedicallaboratoriesandthelaunchofnewproductsintheaccuchek lineofbloodglucosemonitorsforpeoplewithdiabetes attheendofwilliammburnsceoofthepharmaceuticalsdivisionjrgenschwiezerceoofthe diagnosticsdivisionandjonathankcknowlesheadofrochegroupresearchleftthecorporate executivecommitteeasplannedeachofthemhasmadesignificantcontributionstorochessuccessand helpedwriteanimportantchapterinthecompanyshistoryeverygenerationofmanagershasthetask ofensuringrocheshealthyfutureasanindependentcompanybillburnsjonathanknowlesandjrgen schwiezerhavefulfilledthistaskinanexemplarymannerdrivenbyprofoundconvictiontheyhave lrochearengletter shareholdersindd bringing genentech fully roche group major step road create strong innovative organisation significantlycontributedtorochesstrongmarketpositionandsuccessonbehalfoftheentireboardof directorsandthecorporateexecutivecommitteewewouldliketothankthemfortheirmanyyearsof invaluableserviceloyaltytorocheandforthegreatworkingrelationshipweenjoye inviewoftheiroutstandingindustryknowledgetheboardofdirectorswillproposeappointingwilliam mburnsandarthurdlevinsonchairmanofgenentechboardofdirectorstotheboardofdirectorsof rocheholdingltdattheannualgeneralmeetingonmarch profhorstteltschikandpeterbrabeckhavedecidednottostandforreelectionattheannual generalmeetingweareverygratefulfortheirvaluablecontributionstothecompanyoveraperiodofmany year barringunforeseeneventsweexpectsalesinforthepharmaceuticalsdivisionandforthegroup toincreaseinthemidsingledigitrangeinlocalcurrenciesinthediagnosticsdivisionweexpectfullyear salestogrowconsiderablyaheadofthemarketfurthermoreweareaimingtoachievedoubledigit coreearningspersharegrowthatconstantexchangeratesinweanticipatethatwewillalreadyhave repaidofthedebtraisedtofinancethegenentechtransactionbytheendofbasedonthe groupsstrongoperatingfreecashflowrocheexpectstoreturntoanetcashpositionbytheendof wewillsimultaneouslymaintainourattractivedividendpolicy franzbhumer severinschwan chairmanoftheboard chiefexecutiveofficer exclude tamiflu sale lrochearengletter shareholdersindd bildstreckeengsindd s work starvation diet aggressive brain tumour roche tackle modern medicine great challenge search medicine combat illness effective treatment exist quest require sophisticated technological capability deep insight molecular biology select optimal target drug treatment need understand complex biological mechanism drive disease case avastin target blockade bloodvessel growth factor approach develop genentech scientist starve tumour nutrients oxygen need grow spread fundamentally change way fight cancer avastin currently approve treat type cancer investigate possible treatment different tumour type give hope thousand patient avastin monoclonal antibody treat advanced colorectal breast nonsmall cell lung kidney cancer approve country treatment relapse glioblastoma multiforme aggressive type brain tumour bildstreckeengsindd roche group strong operating performance group sale ope rating profit exceptional item core earning share increase double digit roche anticipate doubledigit rise core eps group remain firmly focus prescription drug vitro diagnostic follow successful integration genentech roche well equip healthcare innovator lrochearenggroupindd roche group thegroupsoperatingfreecashflowincrease stronglyrisinginlocalcurrenciesinswiss strong sale trading result francstobillionswissfrancsthegroup totalsalesgrewbyinlocalcurrenciesin freecashflowremainedstronginincreasingby swissfrancsinusdollarstobillionswiss billionswissfrancstobillionswissfrancs francswiththepharmaceuticalsdivisionaccounting forofgroupsalesandthediagnosticsdivision coreepswhichexcludesexceptionalitem contributingsalesgrowthinbothdivision andamortisationandimpairmentofintangibleasset exceededmarketgrowth increasedinlocalcurrenciesinswiss francs salesbythepharmaceuticalsdivisionincrease inlocalcurrenciesinswissfrancsin significant impact genentech integration usdollarstobillionswissfrancsoralmost change group organisation doubletheglobalmarketgrowthratedemandfor effectivemarchthegroupobtainedfull thegroupscancermedicinesavastinherceptin ownershipofgenentechsubsequentlythegroup mabtherarituxantarcevaandxelodacontinuedto commencedarestructuringofitsuspharmaceuticals growstronglyadditionalmajorgrowthdriversin businessaswellasanumberofglobalfunction thepharmaceuticalsdivisionweretamifluinvirology duringrestructuringandintegrationcostsof andlucentisinophthalmology billionswissfrancswereincurredmainlyin connectionwiththediscontinuationofaconstruction thediagnosticsdivisionachievedsalesgrowthof projectatthemanufacturingsiteatvacavillecalifornia inlocalcurrenciesinswissfrancsinusdol terminationcostsfortheclosureofmanufacture larstobillionswissfrancstherebystrengthene operationsatnutleynewjerseytheclosureofthe thedivisionsleadingmarketshareofaround researchanddevelopmentsiteatpaloaltocalifornia andcostsassociatedwiththeconsolidationofthe thegroupsoperatingprofitbeforeexceptionalitems usadministrativefunctionsinsouthsanfrancisco increasedbyinlocalcurrenciesinswiss approximatelybillionswissfrancsoftheseexcep francstobillionswissfrancsoperatingprofit tionaloperatingexpensesarenoncash itemsrelate inlocalcurrenciesgrewtobillionswiss mainlytoimpairmentsofmanufacturingasset francsbeforeexceptionalitemsinthepharmaceutical divisionandtobillionswissfrancsinthe thegroupfinancedthegenentechtransactionby diagnosticsdivision acombinationofthegroupsownfundsbondsnote andcommercialpaperthegroupraisednetpro atconstantexchangeratesthegroupsoperate ceedsofbillionswissfrancsthroughaserie profitmarginbeforeexceptionalitemsincrease ofbondandnoteofferingsasaconsequenceinter percentagepointswiththepharmaceuticalsdivi expensesincreasedsubstantiallyinand sionimprovingpercentagepointsandthedia financingcostsexceededfinancialincomebybil gnosticsdivisionpercentagepointsduetoan lionswissfrancsbytheendofthegroup unfavourablecombinationofexchangeratemove hadalreadyrepaiddebtofbillionswissfranc mentshoweverthegroupsoperatingprofitmargin beforeexceptionalitemsinswissfrancsincrease comparedtonetincomedecreasedbyto onlyslightlybypercentagepointstowith billionswissfrancsprimarilyduetoexceptional thepharmaceuticalsdivisionimprovingpercent itemsnetincomeattributabletorocheshareholder agepointstoandthediagnosticsdivision declinedtobillionfrancsexcludingexcep decreasingpercentagepointsto tionalitemsnetincomewasdownandnetincome lrochearenggroupindd roche business report roche group attributabletorocheshareholderswashigher weexpecttorepayofthedebtraisedtofinance comparedto thegenentechtransactionbytheendof bythegroupaimstoachievepretaxannual thenetdebtpositionofthegroupisbillion synergiesofapproximatelybillionswissfrancs swissfrancsamovementofbillionswissfranc basedonthegroupsstrongoperatingfreecashflow fromanetcashpositionofbillionswissfranc weexpecttoreducedebtprogressivelyandto ondecemberduetothebillionswiss returntoanetcashpositionbywewillsimulta francsusedinthegenentechtransaction neouslymaintainourattractivedividendpolicy outlook barringunforeseeneventsrocheexpectssale inforthepharmaceuticalsdivisionandfor thegrouptoincreaseinthemidsingledigit range inlocalcurrenciesexcludingtamifluinthe diagnosticsdivisionweexpectfullyear salesto growsignificantlyaheadofthemarketdespite ananticipateddecreaseintamiflusalesfrom tobillionswissfrancsweareaimingtoachieve doubledigit coreearningspersharegrowthat constantexchangerate rocheexpectsresearchanddevelopmentexpendi turestodeclineslightlyinhoweverthegroup focusremainsfirmlyoninnovationanditwill continuetoinvesttosupportitsrichpharmaceutical developmentpipelinewhichcurrentlyinclude tennewmolecularentitiesandadditionalindica tionsforexistingproductsinlatestagedevelopment overthenextmonthsthepharmaceutical divisionexpectstofilemarketingapplicationsfor severalmajorlineextensionsofourkeycancermedi cinesincludingavastinmabtherarituxanand xelodaaswellasfortaspoglutidefortypediabetes lrochearenggroupindd corporate sustainability key achievement responsible name healthcare super sector leader dow jones sustainability index djsi practice reselecte djsi world stoxx indices ftsegood index produce new position paper stem cell clone nanotechnology biobank personalise healthcare value product service launch groupwide phone line webbase system report violation code conduct develop new supplier code conduct describe requirement ethic safety health environment innovation supplier diversity economic sustainability social responsibility patient access oneworld health complete screen roche chemical compound library healthcare find new drug treat diarrhea join publicprivate partnership novo nordisk world diabetes foundation improve care child diabete africa donate million additional tamiflu course replenish stockpile launch tamiflu reserve program increase access develop country provide free treatment patient rochegenentech access programme disclose financial inkind support patient organisation website people global employee listening survey result employee express job satisfaction roche genentech vote science magazine employer seventh time roll globally align performance management compensation principle begin align genentech roche expand global leadership programme portfolio provide key programme stage leadership development talent pipeline society launch new corporate policy philanthropic donation noncommercial sponsorship launch cancer awareness campaign rural south africa train nursing staff offer free screening breast cervical prostate cancer raise awareness disease safety health produce manual energy efficient design standard building environmental launch elearne programme safety security health environmental protection protection employee launch roche environmental awareness chemical technology react programme reduce environmental impact product learn roche achievement area corporate responsibility section report page lrochearenggroupindd roche business report roche group group strategy roche focus develop medicine diagnostic help patient live long well life strive address unmet medical need excellence science genentech fully integrate roche group research development team collaborate project share resource integration ensure future organisation maintain diversity approach essential successful innovation lrochearenggroupindd roche business model change practice medicine focus fitting treatment patient distinctiveness excellence science delivery value stakeholder roche group business webelievethatmedicallydifferentiatedproduct whilethedemandfornewandimprovedtreatment aremorelikelytoobtainregulatoryapprovalandbe keepsgrowingsodoesthepressuretocontrol acceptedbypatientsphysiciansandpayer healthcarecostsinthischangingandchallenge environmentweseektodevelopmedicallydif delivery ferentiatedproductsmedicinesanddiagnostic rocheaimstobenefitallstakeholder offeringsignificantclinicalandhealtheconomic wewanttoimprovethetreatmentoption benefitsoverexistingoptionstoadvancethisgoal availabletopatientsanddoctorsenablemedical wehaverefinedourbusinessmodelalongthree laboratoriestoworkmoreefficientlyandhelp dimensionsourfocusourdistinctivenessandour societiescontainhealthcarecostsweseekto delivery ensurethatpeoplewhoneedourmedicine anddiagnosticshaveaccesstothemseepage focus oursuccessasacompanyisbuiltonscientific peoplewhoworkatrochehaveachancetomake discoveryandinnovationwefocusonprescription theirmarkandimprovelivesweseektoprovide pharmaceuticalsandin vitrodiagnosticsandhave everyrocheemployeewithopportunitiesto nointentionofbranchingoutintootherhealthcare contributeexcellearnandgrowinroche sectorssuchasgenericsoverthecounter medi andgenentechagainreceivedbestemployer cinesormedicaldevice awardsinanumberofcountrie weaimtoprovideourinvestorswithatotal innovationisessentialtoaddressingthemanymedi shareholderreturninthetopquartileofour calneedsthatarestillunmetdespitesignificant industrypeerset progressinthefightagainstsomeofmankindsmost weconductourbusinessesresponsiblyandseek seriousdiseasestherearestillsomedisease tohaveasustainablepositiveimpactonsociety forwhichnotreatmentexistsandpatientsresponse andtheenvironmentinwewereratedasthe ratestomanyavailabletreatmentsareunsatisfactory newsupersectorleaderinhealthcareonthe todaybreakthroughsinscienceandtechnology dowjonessustainabilityindexesrankingusa aretransformingourunderstandingofdiseasebiology theworldsnocompanyforsustainabilityinour andpromisetotransformthepracticeofmedicine sector atrocheweareworkingtoharnessthesediscoverie tomaketomorrowstreatmentssafermoreeffective andmorepersonalisedtobetterfitthemto patientsgeneticprofilesandothercharacteristic lrochearenggroupindd roche business report roche group excellence science distinctiveness roche approach innovation excellence science distinctive way wepromotea diversity approach inourpursuitof innovationgenentechresearchandearlydevelopment gredpharmaresearchandearlydevelopment predrochediagnosticsandchugaioperateinde pendentlywithinthegroupformingthehubsofan innovationnetworkthatincludesallianceswithover outsidecompanies wetakea longterm perspective backedby astablemajorityownershipdatingbackoveryear wekeepoursightsonsustainablelongterm growth ratherthanshortterm gainsthisisreflectedinthecom panysincentivesystemandapproachtosuccession managementandinfarsighte businessmovessuch asourearlyinvestmentsinbiotechnology weseamlessly integrate pharma diag nosticscapabilitiesalongthewholevaluechain fromdiscoverytocommercialisationourworldclass pharmaceuticalsanddiagnosticsresearchorganisation areworkingtogethertocreatebettermorecost effectivetreatmentoptionstailoredtopatientsneed c oec lh ono glo ygie n flm amet mh ao tid os n n e u r c e n c e e tb ai bo ol lo isg virolo dp gh iaa gr nm oa stic u se tinu rv c ep ir hs na np io goh r n ta la hoslr el gm nyaa le tv bc hede rs u oie n et ui x sc gp ua hine sls itr ntrta hy tin eis sl rd e e nfa d ai edn lli da nmg egn w vo io ehnls le oct eci phc lu l mes tl c h ead e nr ui v tabi acls ni oo po dnrln oo ts aipg n ceh u qra e utv b ie soo nh tionsthisexpertiseequipsrochetoplayapioneere roleinadvancingpersonalisedhealthcare gnnaatns aetunesvt pre gre chugai pharmaceutical research early development cinical development commercialsaion tsaelgecet io n lgeeande r aio phase phase phase ii phase ii flng pha ar sk ee iv btarogmeta idkeenrt idiecvaetloonpment c peaoatmseinpbtai snietiyo e nac nd idoia n ugtnloisytic tdaxi oaeudn cphrespcorsbtnga uanncdh aosnsieosrsinmgent diagnostic rna inrm ee rd fe ri nn e nbl cic eo eci sns cu ecuebase duna gn dte ech sn io gog ny omuatonssec mes vra resstance neurodegeneratio sn ignalng pathway ango mge yn ee lsi os ap n ncp e alo l ts es b moo mg uy niy glycoengneee cell boogy dna l sifee nq su mm iec cbnie oc e rn rgcg ae ye n ss cobas r el ai g tih mec pc cl rer mmunom assu acl soi bp al sex potein anx acc lyoc se b ie sl sl ai ng ae ynscise lrochearenggroupindd roche management model enable innovationdriven culture people integrity courage passion decision make accountable transparent structure build innovation roche group management structure ourmanagementmodelisaimedatsustainingand ourorganisationalstructureisdesignedforinnova strengtheningourcultureofinnovationlikeour tionourautonomousresearchanddevelopment businessmodelithasthreeelementsourpeople centresandallianceswithexternalpartnersfoster ourdecisionmakingandourstructure diversitythetrulyglobalscaleofthegroupsre searchdevelopmentmanufacturingandmarkete people operationsprovidesleverageaswellasaglobal oursuccessindrugresearchanddevelopmentour reachforinnovationandmarketsuccess abilitytodeployourcombinedexpertiseinpharma ceuticalsanddiagnosticstoadvancepersonalise healthcareandourskillinbalancinglongerterm investmentdecisionswithneartermdeliverablesall ultimatelydependononethingourpeoplesee pagesrochesemployeesrepresent everycontinentandvirtuallyeverycountryonthe globeandtheybringtotheirworkadiversityof perspectivesandexperiencesthatareakeyingredi entofcreativityrespectfordiversityasharedset ofstandardsofintegritythecouragetoreachbeyond boundariesandapassionaboutwhatwedoarethe elementsthatbindustogetherasacompany decision make thesecondcomponentofourmanagementmodel dse et cs iso iu ot np sr nin ec ei dpl te os bfo er inef fofe rc mti ev de bd yec ais dio ian lom ga uk ein thg tis systematicfactbasedopenandtransparentfor everydecisionthereshouldbeasingleaccountable decisionmakerwhocollectsandcriticallyreview informationandcompetingviewsempowermentis crucialsofaraspossibledecisionmakingshould bedelegatedtothelowestqualifiedlevelinthe organisation lrochearenggroupindd bildstreckeengsindd s pave way new drug rheumatoid arthritis search safe effective new medicine like look needle haystack thousand potential candidate complete journey idea pharmacy shelf know diversity approach produce prom ise idea fast roche build unique innovation network independent research development r centre add tion roche pharmaceutical diagnostic r unit com prise genentech research early development chugai r laboratories japan alliance partner worldwide recent product successful collaboration kind actemraroactemra biological medicine new target use patient rheu matoid arthritis discover chugai codevelope roche actemraroactemra available patient world thank global reach roche group actemraroactemra firstinclass monoclonal antibody treatment rheumatoid arthritis bind interleukin receptor block effect signal protein il key driver inflammation rheumatoid arthritis bildstreckeengsindd pharmaceutical demand key medicine efficiency gain result doubledigit increase sale operating profit thirteen major marketing approval positive result phase iii clinical trial confirm division growth potential pharmaceutical division focus translate excellence science effective medicine patient combine cuttingedge research roche genentech chugai japan partner worldwide global scale reach clinical development manufacture commercial operation lrochearengpharmaceuticalsindd pharmaceutical division brief key figure change change millions chf chf local currency sale sale united states western europe japan international asiapacific cemai latin america canada operate profit exceptional item operate free cash flow research development cemai central eastern europe middle east africa central asia indian subcontinent pharma executive committee december william burns ceo division roche pharmaceutical george b abercrombie north america jennifer allerton informatics silvia ayyoubi human resource ian clark global product strategy jeanjacque garaud development peter hug western europe jonathan kc knowles group research dominic p moorhead finance control christopher murray commercial operation chugai pascal soriot commercial operation ceo genentech klaus strein pharma research jan van koeveringe global technical operation dan zabrowski pharma partnering december corporate governance january ceo genentech clark chief operating ofiicer pharmaceutical division p soriot extend team ad interim lrochearengpharmaceuticalsindd roche business report pharmaceutical pharmaceutical division sale region operational term wasatransformationalyearforthepharma ceuticalsdivisionafterobtainingfullownershipof united states good year genentechinmarchrochemovedswiftlyto asiapacific pharmaceuticals combinethetwocompaniesclinicaldevelopment latin america division double manufacturingandcommercialoperationsgenentech region digit increase sale researchandearlydevelopmentremainsaninde cemai operating profit pendentunitwithintherochegrouppreservingthe integration diversityofscientificapproacheswebelievehelps genentech pro todriveinnovationtheintegrationofgenentechwas western europe ceede swiftly largelycompletebytheendoftheyear japan largely complete end italic growth rate local currency inoperationaltermswasanotherverygood year cemai central eastern europe middle east africa yearforthepharmaceuticalsdivisionwithdouble central asia indian subcontinent digitincreasesachievedinbothsalesandoperate profitabovemarketsalesgrowthwasdriven primarilybystrongdemandforkeymedicinesfrom rdpipelineisnowoneoftherichestinthe thegroupsvirologyandoncologyportfoliosthe industrywitheightnewmolecularentitiescurrently globalspreadofthepandemicahn inphaseiiiregistrationinphaseiiandin influenzavirusledtounprecedenteddemandfor phaseiclinicaldevelopment tamiflufromthesecondquarteronrocheiscooper atingwiththeworldhealthorganizationandnational governmentstoaddressthethreatposedbythe result main newinfluenzastrainandhasincreasedproduction business development capacitytoensureadequatesuppliesoftamiflu inadditiontomarketingauthorisationforthetar salesbythepharmaceuticalsdivisionrosein getedbiologicactemraroactemraforrheumatoid localcurrenciesinswissfrancsandusdollar arthritisintheeuropeanunionandinjanuary tobillionswissfrancsoralmostdoublethe theunitedstatesthedivisionalsogainedapproval globalpharmaceuticalsmarketgrowthratethe fornewindicationsformarketedproductssuch worldwidespreadofthepandemicahn asavastincancerandmabtherarituxancancer influenzavirusledtoverystrongdemandfortamiflu rheumatoidarthritisprogrammesaimedat fromthesecondquarteronoveralltamiflucon expandingtheuseofkeyproductsorsupporte tributedbillionfrancsorpercentagepoint plannedmarketingapplicationsfornewcompound tofullyearpharmaceuticalssalesgrowthexclude resultedinpositivedatafrommajorphaseiii tamifluthedivisionssalesincreaseddriven clinicaltrialssomeoftheseresultshavealreadybeen bydemandforkeyproductsincludingavastin usedtosupportregulatoryfilingsgoodprogress herceptinmabtherarituxanlucentismircera wasmadeintheclinicaldevelopmentofpromising tarcevaactivasetnkaseandactemraroactemra newproductcandidatessuchasocrelizumab rheumatoidarthritismultiplesclerosistdm breastcancerrgmalignantmelanoma pharmaceutical market growth accord im taspoglutidetypediabetesandrg end september schizophreniathecombinedrocheandgenentech state growth rate local currency lrochearengpharmaceuticalsindd integration genentech operational restructuring transformational year pharmaceutical division yearonyearsalesgrowthinthefourthquarter combinedrocheandgenentechportfolioseebelow washeavilyimpactedbyplannedreductionsin pformoreinformationonthedivisionsoperat wholesalerinventorylevelsinseveralmajormarket ingresultsseethefinancereportpartofthis theseresultedinpartfromacomprehensivereview annualreport ofdistributionchannelexposureagainsttheback groundoftheglobalfinancialcrisisinaddition thedivisioncontinuedtogenerateastrongcashflow theharmonisationofdistributionsystemsintheus inoperatingfreecashflowincreasedin followingthemergerofgenentechandroche localcurrenciesinswissfrancstobillion pharmaceuticalstriggeredareviewofwholesaler swissfrancsdrivenbythestrongoperatingper inventorypolicyandsubsequentdestocke formancecontinuouscostmanagementandcash flowgenerationarekeyprioritiesatrochethis allregionscontributedtothedivisionsstrongsale isreflectedinongoingglobalinitiativestoincrease growthintheunitedstatesgrowthofkeyoncology operationalefficiencyandproductivityinarea productstamifluandlucentismorethancompen suchasinformationtechnologymanufacturingand satedforlowersalesofcellceptandbonivaandthe administrationfurtherstimulusisnowbeingprovided voluntarywithdrawalofraptivasalesinwestern bythegenentechintegrationwhichinvolveda europeweredrivenbydemandfortamifluavastin majorreorganisationnotonlyofuspharmaceutical mabtheraandmircerawhichmorethanoffset operationsbutalsoofthedivisionsglobalfunction decliningsalesofneorecormonsalesbychugaiin synergiesarealreadybeinggeneratedasaresult japanincreasedstronglyduetodemandfortamiflu oftheconsolidationinsouthsanfranciscoofadmin keycancermedicinesandactemrasalesinthe istrativefunctionsforthecombinedusorganisation internationalregionasiapacificcemailatin theclosureofthepaloaltositeandthereshapingof americacanadaothersweredrivenbydemand globalmanufacturingoperationsseemanufacture fortamiflukeycancermedicinesandpegasys infrastructure belowweaimtoachievepretax annualsynergiesofapproximatelybillionswiss inthepharmaceuticalsdivisionsoperate francsby profitbeforeexceptionalitemsadvancedsignificantly fasterthansalesrisinginlocalcurrencie inswissfrancstobillionswissfrancsthisstrong manufacturing infrastructure increasewasdrivenmainlybytheperformanceof ourkeypharmaceuticalproductsandongoingmea thecompanyiswellontrackwiththeintegrationand surestoimproveefficiencytheoperatingprofit optimisationofthecombinedrocheandgenentech marginincreasedpercentagepointsinlocalcur supplynetworkandisreshapingitsglobalmanu renciespercentagepointsinswissfrancsto facturingorganisationtoconcentrateactivitiesalign despiteincreasedinvestmentsfornewproduct capacityrequirementsandimproveefficiencyaspart launchesandinresearchanddevelopmentthe oftherealignmentasecondbulkdrugproduction significantincreaseinrdcostsuptobillion unitatgenentechsvacavilleusafacilitywillnotbe swissfrancsreflectsinvestmentinthedivision commissionedandanewunitatrochespenzberg stronglatestage pipelineincludingpromisingcom germanyplantwillnotbecomplete poundssuchasdalcetrapibtaspoglutidepertuzumab andtdmtheriseinrdexpenseswasalso thepharmaceuticalsdivisioncurrentlyoperate drivenbyhigherimpairmentsofintangibleassetsat productionsitesworldwidealthoughconsolidation milliontheseweremillionfrancshigherthan indueprimarilytotheterminationofanumber central eastern europe middle east africa central asia ofprojectsfollowingacomprehensivereviewofthe indian subcontinent lrochearengpharmaceuticalsindd roche business report pharmaceutical collaboration istakingplaceinmanufacturingrochecontinuesto andresearchandtechnologycollaborationsin external partner investinitssupplynetworktoensuredeliveryof additiontenproductoutlicensingagreementswere integral marketedmedicinesandproductsinclinicaldevelop signedamongthemaintransactionswereasecond roche r strategy mentinmayrocheopenedanadditionallargescale licensingagreementwithplexxikonannounce roche multipurposechemicalproductionunitinflorence injanuaryforplxrganovelkinase genentech sign new southcarolinausaanewproductioncentre inhibitorforpolycystickidneydiseaseandafurther partnering agree inkaiseraugstswitzerlandforthemanufactureof agreementwithevotecannouncedinmarchfor ment medicinesinsterileformsincludingliquidand phaseiidevelopmentofevtfortreatment include product lyophilisedvialsandprefilledsyringeswasinaugu resistantdepressionrocheenteredintoaproduct transaction ratedinjuneinaugustrocheexercisedanoption developmentagreementwithtekmirapharmaceutical research technol previouslyheldbygenentechtopurchaseabiologic inmaytoadvancerochesfirsttwornainterfer ogy collaboration manufacturingfacilitybuiltbylonzainsingapore enceproductcandidatesintohumanclinicalteste thestateoftheartfacilitywhichismechanically bothproductcandidateswillbebasedontekmiras completehasbeenmergedwithanexistingbiologic stablenucleicacidlipid particlesnalptechnol manufacturingfacilitybuiltbygenentechthecom ogy binedsingaporeoperationsrochesfirstsuch facilitiesinasiawillplayakeyroleinthegroup genentechpartneringcompletedfourproducttrans globalmanufacturingnetworkinnovemberthe actionsoneoutlicensingdealandresearch toppingout ceremonyforanewtechnicalresearch andtechnologycollaborationsduringtheyearthese anddevelopmentbuildinginbaselswitzerland includeanagreementsignedinjunewithbayhill tookplacethenewfacilityscheduledforcompletion therapeuticsforanexclusivecollaborationforbayhills inwillhouseacentreforthedevelopmentof promisingdrugcandidatebhtcurrentlyin productionmethodsandthemanufactureofclinical phaseidevelopmentfortypediabetesinoctober trialssample genentechsignedanagreementwithsurmodic grantinggenentechanexclusivelicencetouse inresponsetotheworldwidespreadofthepandemic surmodicsproprietarybiodegradablemicroparticle ahninfluenzavirusourmanufacturingorgani drugdeliverysystemtodevelopandcommercialise sationandsupplychainmanagementalsometthe asustaineddrugdeliveryformulationoflucentisthe challengeofensuringadequatetamiflusuppliesto agreementalsoprovidesrocheandgenentech patientsworldwiderocheanditsmanufacture withopportunitiestodevelopadditionalcompound partnersrapidlyincreasedproductioncapacityfor forthetreatmentofophthalmicdisease tamiflutoapproximatelymilliontreatmentcourse permonthandarenowabletosupplyuptomil lionpacksannuallyifrequire sale review select key product pharma partnering update thepharmaceuticalsdivisionssalesgrowthis collaborationwithexternalpartnersisanintegralpart broadlybasedinelevenproductsfromsix ofrochesrdstrategyaccesstoexternalinno therapeuticareasgeneratedsalesofoverbillion vationthroughlicensingandtargetedacquisitionsis swissfrancseachofthesemedicinesthetop asignificantmeansofstrengtheningtherdportfolio threeachievedsalesofoverbillionswissfranc andexpandingthegroupstechnologycapabilitie eachcombinedsalesofthegroupstoppharma inrochepharmaceuticalssignedatotalof ceuticalsamountedtobillionswissfrancsor newagreementsincludingfourproducttransaction oftotaldivisionalsale lrochearengpharmaceuticalsindd product therapeutic area generate sale billion franc sale therapeutic area oncology inflammatory autoimmune disease transplantation central nervous system respiratory metabolic disease bone disease infectious disease cardiovascular disease virology renal anemia ophthalmology italic growth rate local currency salesofthedivisionsoncologyportfoliorose canceruptakeinjapanwhereavastiniscurrently sale division tobillionswissfrancsinledbythekey marketedforadvancedcolorectalcancerremain oncology portfolio productsavastinherceptinmabtherarituxan particularlystrongandisexpectedtobeenhance rise billion swiss franc tarcevaandxelodatogetherthesefivemedicine bytheproductsrecentapprovalforadvancednon lead avastin accountedforaroundhalfoftotalpharmaceutical smallcelllungcancersalesgrowthintheunite herceptin mabthera salesanincreaseofbillionswissfranc statesisbeingdrivenmainlybyuseinadvance rituxan tarceva insalesofantiviralmedicinesforafullyeartotalof breastcancerandthenewindicationsglioblastoma xeloda billionfrancswasdrivenprimarilybydemand andkidneycancerwhilehighpenetrationrate medicine fortamifluoverallsalesoftherenalanemiaportfolio weremaintainedinestablishedindicationssucha account half total pharma remainedstableatbillionswissfrancsinan lungandcolorectalcancer ceutical sale increasinglycompetitivecostsensitivemarketsale inthecombinedinflammationautoimmunetransplan overallsalesoncologyandrheumatoidarthritisof tationportfoliodeclinedtobillionfrancswith mabtherarituxanrituximabfornonhodgkin theexpectednegativeimpactofthecellceptpatent lymphomanhlchroniclymphocyticleukemia expiryintheunitedstateslargelyoffsetbythe cllandrheumatoidarthritisraroseto continuedsuccessofmabtherarituxaninrheuma billionswissfrancssustainedgrowthinthe toidarthritisaswellasstronguptakeofactemra oncologysegmentwasdrivenbyuptakeincll roactemrainjapananditsinitiallaunchmarketsin followingapprovalintheeuforfirstline treatment westerneuropeandelsewhere andintherelapsedrefractorydiseasesettinginthe firstandthirdquartersrespectivelylowersale oncology growthintheusreflectsthehighlevelsofadoption salesofavastinbevacizumabforadvance ofrituxaninitscancerindicationssalesinthera colorectalbreastlungandkidneycancerandfor segmentwereanestimatedmillionswissfranc relapsedglioblastomaatypeofbraintumourrose oroftheproductstotalsalesgrowthinthis tobillionswissfrancssoliddoubledigit segmentisbeingdrivenbyincreasingandearlieruse growthwasrecordedinallregionsdrivenprimarily bycontinueduptakeincolorectalbreastandlung firstline treatment initial treatment give diagnosis lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science unique diversity approach partner understand complex biology disease big challenge face develop new well medicine diagnostic scientific breakthrough likely occur scientist free tackle problem different angle different way scientist freedom believe diversity view culture approach promote creativity especially research early development autonomous research development hub augment alliance provide natural climate innovation pre gre chugai gre pre genentechresearchand rochepharmaresearchand earlydevelopment earlydevelopment nmes phase ii oncology followingtheintegrationofgenentechpredandgredoperate asautonomousinnovationcentresfocusingonnewdrug targetsandnewmolecularentitiesnmestheyhavetheirown inflammation immunology budgetsandexternalnetworksandtakedifferentapproache toturningexcellentscienceintoadvancesinmedicalcarethisnew central nervous system organisationalstructurepreservesthevaluesandculturethat enabledthegenentechsuccessstorywhileatthesametime strengtheningrochepharmasabilitytodevelopnovelmedicine ophthalmology italsomakesiteasierforourpharmaceuticalsanddiagnostic researcherstoshareknowledgeandtechnologiesacrossdivisional virology boundary metaboliccardiovascular lrochearengpharmaceuticalsindd ofmabtherarituxaninpatientswithaninadequate virology roche cooperate responsetooneormoretumournecrosisfactor globalsalesoftheantiinfluenza medicinetamiflu closely world tnfinhibitorsmabtheraiswellestablishedasthe oseltamiviramountedtobillionswissfrancsin health organization government medicineofchoicefollowinginadequateresponse anincreaseoforbillionswissfranc worldwide support totnfinhibitortreatmentandiscurrentlythemarket comparedwiththisveryhighgrowthwa pandemic prepare leaderinthatsegmentintheeu drivenbyunprecedenteddemandfromgovernment ness supply andintheretailpharmacysectorfollowingthepan tamiflu patient salesofherceptintrastuzumabforherpositive demicahninfluenzavirusswineflu need breastcancerincreasedtobillionswiss outbreakwhichbeganinaprilandspreadrapidly francssolidgrowththroughouttheyearwasdriven worldwidesalesforpandemicstockpilingamounted bycontinuinguptakeforearlybreastcancerespe tobillionfrancsforthefullyear ciallyinjapanandanumberofemergingmarket aswellasincreasingmarketpenetrationineastern rocheisworkingwithnationalhealthauthoritiesto europemoderatesalesgrowthintheusand expandapprovalforpandemicuseoftamifluto westerneuropereflectsthehighmarketpenetration includechildrenunderoneyearofageaswellas achievedinbothearlyandadvancedbreastcancer pregnantandlactatingwomenandtogainregulatory intheseregion approvalforalternativemethodsofadministeringthe medicinetoinfantsandyoungchildrenthecompany salesoftarceva erlotinibforadvancedlungand alsocontinuestocooperatecloselywiththeworld pancreaticcancerincreasedtobillionswiss healthorganizationandgovernmentsworldwideto francsdemandisbeingdrivenbyincreaseduse supportpandemicpreparednessandsupplytamifluto ofthemedicineinsecondlinenonsmall celllung allpatientsinneed cancernsclcoutsidetheusandinmetastatic pancreaticcancerthemainsalescontributionscame salesofpegasyspeginterferonalfaa forhepatitis fromwesterneuropeandtheunitedstatesthemore bandctotalledbillionswissfrancsin modestgrowthinussalesreflectsstablepenetration anincreaseofoverthepreviousyeardrivenby innsclcandpancreaticcancerthecompetitive marketshare gainsinmajormarketsgrowthis environmentandreserveadjustmentstakendure beinghelpedbynewstudydatademonstratingthe theyearprimarilyforgovernmentprogramme superiorityofpegasysoverothertreatmentoption involvingdiscount increaseduseinthetreatmentofhepatitisband increasingratesofhepatitisdiagnosisandtreatment salesofxelodacapecitabineforcolorectal inemergingmarket stomachandbreastcancerincreasedtobillion francsdrivenprimarilybystronggainsintheunite ophthalmology statesjapanandchinagrowthisbeingdriven ussalesoflucentisranibizumabforwetage byuseinmetastaticbreastcanceradjuvantcolon relatedmaculardegenerationamdthemost cancerandmetastaticcolorectalcancerinchina commonformofagerelate blindnessroseto themajorityofgrowthiscomingfromuseinpatient billionswissfrancsstrongdoubledigit growth withadvancedstomachcancerwhileinjapanchugai throughoutwasdrivenprimarilybyanincrease recordedsignificantadditionalgrowthinthefourth inthenumberofinjectionsadministeredtopatient quarterfollowingapprovalofanexpandedmetastatic colorectalcancerindication secondline treatment give initial firstline treatment work cancer stop respond adjuvant treatment give surgical removal tumour low risk relapse lrochearengpharmaceuticalsindd roche business report pharmaceutical topselling pharmaceutical roche group millions chf avastin mabtherarituxan herceptin tamiflu pegasys active substance active substance active substance active substance active substance bevacizumab rituximab trastuzumab oseltamivir peginterferon alfaa indication indication indication indication indication colorectal cancer breast nonhodgkin lymphoma herpositive breast treatment prevention hepatitis b c cancer nonsmall cell chronic lymphocytic cancer influenza b lung cancer kidney leukemia rheumatoid cancer glioblastoma arthritis lrochearengpharmaceuticalsindd abovemarket sale growth drive primarily strong demand key virology oncology medicine cellcept neorecormon epogin tarceva xeloda lucentis active substance active substance active substance active substance active substance mycophenolate mofetil epoetin beta erlotinib capecitabine ranibizumab indication indication indication indication indication transplantation anemia advanced nonsmall cell colorectal cancer breast wet agerelate macular lung cancer advanced cancer stomach cancer degeneration pancreatic cancer image scale yearonyear sale growth local currency jointly market genentech novartis lrochearengpharmaceuticalsindd roche business report pharmaceutical fda inthefirstandsecondyearoftreatmentgrowthinthe transplantation grant accelerated numberofpatientstreatedforwetamdandeasier salesofcellceptmycophenolatemofetilforthe approval reimbursement preventionofsolidorgantransplantrejection use avastin decreasedcomparedwithtobillion relapse glioblas anemia swissfrancssalesintheustheproductslarg toma aggressive form inahighlycompetitivepricesensitive marketsale marketdeclinedsharplyfrommayonwardsfollowe brain tumour oftherenalanemiamedicationmirceramethoxy expiryoftheuspatentthecontinuingerosionof january polyethyleneglycolepoetinbetawhichisnow ussalesthroughgenericcompetitionisbeingoffset agency approve availableinovermarketsworldwideshowe tosomeextentbysolidgrowthelsewhereespecially actemra treat consistentgrowththroughoutrisingto inlatinamericaandjapan ment adult patient millionswissfrancssalesarebeingdriven rheumatoid primarilybythesuccessoftheproductinthepre arthritis respond tnf dialysissegmentcombinedsalesofthegroup atthebeginningofaprilrocheandgenentech inhibitor therapy establishedanemiamedicinesrochesneorecormon announcedaphasedvoluntarywithdrawalofthe andchugaisepoginepoetinbetadeclinedto psoriasismedicineraptivaefalizumabfromthe billionswissfrancsoutsidejapanthecombined usmarketthedecisionreflectsourcommitment marketshareofrochesanemiafranchisemircera topatientsafetyandwasbasedontheassociation andneorecormoncontinuestoincreasedespite ofraptivawithanincreasedriskofprogressive competitionfromnewmarketentrantsthedecline multifocalleukoencephalopathypmlarareand inneorecormonsalesofwasduemainlyto usuallyfataldiseaseofthecentralnervoussystem increasedpricepressureasnewbiosimilarsenterthe aspartofthemeasuresagreedbetweentheus marketincontrasttheslightdeclineofepoginin foodanddrugadministrationfdaandgenentech japanreflectsstabilisationoftheproducts theraptivamarketinglicencewasrevokedinjuly marketshareinthedialysissegmentandcontinue genentechcontinuestomonitorpatientsafety expansioninthepredialysissette inflammation autoimmune disorder development highlight followingeumarketingapprovalinjanuaryby key marketed product yearendthenovelrheumatoidarthritisramedicine roactemratocilizumabknownasactemraoutside europehadbeenlaunchedinteneucountrie inthepharmaceuticalsdivisionfiledmajor includinggermanyfrancespainandtheunite newmarketingapplicationsandgainedmajor kingdomsalesuptakeintheinitialeuropeanlaunch regulatoryapprovalsseetableppositiveresult marketshasbeenstrongfollowinglaunchesin frommajorphaseiiiclinicaltrialsinvestigate additionalmarketsincludingswitzerlandindiaand additionalindicationsforexistingkeyproductsorwith brazilactemraroactemraisnowavailableinover newproductssuchastaspoglutideandocrelizumab countriesworldwidetheresponsefromphysician werealsoreportedseetablepthefollowe isveryencouragingglobalsalesroseto summariespresentapprovalsfilingsandmajor millionswissfrancsininjapanwhereactemra clinicaltrialresultsforkeymarketedproductsby wasapprovedforrainadultsandforrelatedpedi indication atricindicationsinapriladoptionandmarket penetrationareprogressingwellwithdoctorsalready actemraroactemra usingthemedicineasafirstlinebiologictreatmentin approval injanuarytheusfoodand manypatientssalesinjapanamountedtomillion drugadministrationfdaapprovedactemrafor swissfrancsanincreaseof thetreatmentofadultpatientswithmoderatelyto lrochearengpharmaceuticalsindd division file major marketing application gain major approval major regulatory filing product active substance indication andor dosage form country avastin bevacizumab relapse glioblastoma multiforme switzerland firstline metastatic breast cancer combination eu usa japan standard chemotherapy switzerland ed eldecalcitol osteoporosis japan epogin epoetin beta chemotherapyinduced anemia japan herceptin trastuzumab advance herpositive gastric cancer eu switzerland lucentis ranibizumab macular edema follow retinal vein occlusion usa mabthera rituximab rheumatoid arthritis patient inadequate eu switzerland rituxan response diseasemodifye antirheumatic drug prevention joint damage firstline chronic lymphocytic leukemia usa relapse refractory chronic lymphocytic leukemia eu usa switzerland rg methoxy renal anemia japan mircera poly ethylene glycolepoetin beta tarceva erlotinib nonsmall cell lung cancer firstline maintenance eu usa switzerland chemotherapy advance pancreatic cancer japan xeloda capecitabine adjuvant colon cancer combination oxaliplatin eu switzerland major regulatory approval product active substance indication andor dosage form country avastin bevacizumab relapse glioblastoma multiforme usa switzerland metastatic breast cancer combination docetaxel eu switzerland firstline metastatic renal cell carcinoma combination usa interferon alfaa unresectable advanced recurrent nonsquamous japan nonsmall cell lung cancer mabthera rituximab relapse refractory chronic lymphocytic leukemia eu switzerland rituxan firstline chronic lymphocytic leukemia eu rheumatoid arthritis guidance retreatment patients usa inadequate response antitnf therapy actemra tocilizumab rheumatoid arthritis sign symptom eu usa roactemra xeloda capecitabine advanced refractory colorectal cancer combination japan oxaliplatin avastin include supplemental indication update january indication use patient previously treat methotrexate long pursue p accelerate approval fda lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science take longterm view biotech milestone sale biotech medicine sale estimatedsale biotechmedicinesorbiologic todayaccountforof rochespharmaceuticalsale apercentagethathasrisen significantlyinrecentyear biologicsnormallyhaveamore targetedeffectandarebetter toleratedthanconventional chemicalmedicine rochefound researchon rocheand recombinant roferona rocheacquires mabthera neorecormon avastin actemra institutefor monoclonal genentech insulin rituxan herceptin roactemra molecular antibody firstjoint genentech biology production project discover develop commercialise new medicine take time vision stay leading edge innovation essential invest early promise new technology pharmaceutical company embrace biotechnology lead acquire majority stake genentech today biotech product helping improve live countless patient variety disease area number maker biologic invest polymerase chain reaction pcr technology infancy decision help global market leader molecular diagnostic technology invest today rna interference rnai offer way target turn specific gene rnaibase medicine prove ground break new approach fight disease help patient lrochearengpharmaceuticalsindd avastin test study different tumour type positive outcome achieve major phase iii trial disease area product indication study oncology mabtherarituxan indolent nonhodgkin lymphoma prima firstline maintenance treatment avastin secondline metastatic breast cancer ribbon xeloda adjuvant treatment colon cancer xeloxa herceptin herpositive stomach cancer toga tarceva nonsmall cell lung cancer firstline maintenance treatment saturn overall survival data tarceva avastin nonsmall cell lung cancer firstline maintenance treatment atlas inflammation actemra rheumatoid arthritis progression joint damage lithe year datum actemra juvenile idiopathic arthritis systemic onset tender ocrelizumab rheumatoid arthritis patient inadequate response stage previous treatment methotrexate ophthal lucentis macular edema follow central retinal vein occlusion cruise mology lucentis macular edema follow branch retinal vein occlusion bravo metabolism taspoglutide type diabete temerge severelyactiverheumatoidarthritisrawhohave regulatoryfilingsinthisindicationsjiaadebilitate hadaninadequateresponsetooneormoretumour anddifficulttotreat diseasethataffectsthewhole necrosisfactortnfinhibitorsactemrathefirst bodyrepresentsanareaofhighunmetmedicalneed interleukin receptorinhibite monoclonalanti bodyapprovedtotreatramaybeusedaloneorin avastin combinationwithmethotrexateorotherdisease theglobaldevelopmentprogrammeforavastinisone modifyingantirheumaticdrug ofthemostcomprehensiveundertakingsincancer researchsincechemotherapymorethanclinical filing inseptemberrochefiledanapplication trialsworldwidewitharoundpatientsare withtheeuseuropeanmedicinesagencyemea currentlyinvestigatingtheuseofavastininapproxi toexpandthemarketingauthorisationforroactemra matelydifferenttumourtypesincludingcolorectal toincludeinhibitionoftheprogressionofjointdamage breastnonsmallcelllungbrainstomachovarian andimprovementofphysicalfunctioninpatient prostateandothersandindifferentsetting withratheeufilingissupportedbypositivetwo advancedorearlystagediseaseresultsfrom yeardatafromthephaseiiilithetrial phaseiiitrialsinvestigatingthemedicinespotential inpatientswithmetastaticprostateovarianand clinical milestone aninternationalphaseiii stomachcancerareexpectedin studytendermetitsprimaryendpointinnovem bershowingthatactemraroactemrasignificantly approval inmaythefdaapprovedtheuseof improveddiseasesignsandsymptomsinchildren avastininpatientswithpreviouslytreatedrelapse withsystemiconsetjuvenileidiopathicarthritissjia glioblastomamultiformegbmthemostaggressive andconfirmingtheresultsofearlierjapanese formofbraintumourundertheagencysaccelerate studiesrocheplanstousethedatatosupportglobal approvalprogrammetheeuscommitteefor lrochearengpharmaceuticalsindd roche business report pharmaceutical follow eu medicinalproductsforhumanusechmpissueda suggestthatavastinisactiveinpatientswithearly market application negativeopinioninseptemberregardingroches stagecoloncancerfurthertrialsinvestigatingavastin roche sep applicationforapprovalofthesameindicationthe intheadjuvantsettingearlystage diseaseafter tember chmp usandeufilingswerebasedonstrongclinical surgerytoremovethetumourincolonbreastand issue positive resultsfromthephaseiibrainstudyseveral lungcancerareongoingresultsareexpectedin recommendation december investigatorle studiescontinuetoexploretherole fromaseparaterochesponsoredinternational use herceptin ofavastininrelapsedgbminadditionalarge phaseiiistudyavantassessingavastinincom advance rochesponsoredphaseiiistudyavaglioinover binationwithchemotherapyforearlystage colon positive stomach patientswithnewlydiagnosedgbmiscurrently cancerinoctoberpatientrecruitmentwascomplete cancer filing underwaywiththeaimofglobalfiling forbeatriceaphaseiiitrialinvestigatingavastin base strong inearlyhernegativeandhormonereceptor phase iii datum rochereceivedeuapprovalinjulyforavastinin negativebreastcancer ing herceptin extend survival combinationwithdocetaxelacommonlyusedchemo patient therapyinthefirstline treatmentofmetastatic fullresultsofribbonaphaseiiitrialofavastin operable breastcancertheexpandedindicationfollowseu assecondline treatmentinwomenwithadvance positive stomach approvalforcombinedavastinandpaclitaxelin hernegativebreastcancerwhohadpreviously cancer inadditioninaugustthefdaapprovedavastinin receivedchemotherapywerepresentedatthesan combinationwithinterferonalfaa forthetreatment antoniobreastcancersymposiumindecemberthe ofmetastaticrenalcellcarcinomathemostcommon studymetitsprimaryendpointshowingthatwoman typeofkidneycancerthisfollowseuapprovalof whoreceivedavastinincombinationwithcommonly thesameindicationin usedchemotherapiesassecondline treatmenthad aimprovementinprogressionfree survival innovemberchugaireceivedapprovalinjapanfor comparedwithchemotherapyalonegenentechand avastinforthetreatmentofadvancednonsmallcell rocheplantofiletheribbondataintheus lungcancer andtheeuin filing chugaifiledasupplementaryapplication herceptin inoctobertoexpandtheapprovedindicationsfor filings followinganeumarketingapplicationby avastininjapantoincludemetastaticbreastcancer rocheinseptemberthechmpissuedapositive basedontheresultsoftheeavadoand recommendationindecemberfortheuseofherceptin ribbon trialsandjapanesestudiesinnovember inadvancedmetastaticherpositivestomach genentechfiledtheavadoandribbon datawith cancerthisrecommendationwasissuedinrecord thefdawiththeaimofconvertingthecurrent timereflectingthehighunmetmedicalneedandthe acceleratedapprovalforhernegative breastcancer strengthofthedatafromtogaseebelow receivedintofullapprovalandallowe avastintobecombinedwithfurtherstandard clinical milestone resultsfromtheinternational chemotherapiesinnovemberrochealsofiledthe phaseiiitogatrialpresentedattheascomeetingin ribbon datawiththeeuauthoritie juneshowedthatcombiningherceptinwithstandard chemotherapyxelodaorintravenousfluorouracil clinical milestone fullresultsofthefirstphaseiii pluscisplatinextendsthelivesofpatientswith trialofavastininearlystagecoloncancernsabp cwerepresentedattheannualmeetingofthe americansocietyofclinicaloncologyascoin june mayalthoughthestudydidnotmeetitsprimary progressionfree survival time patient live endpointofimprovingdiseasefreesurvivalthedata disease get bad lrochearengpharmaceuticalsindd fiveyear followup data confirm long term benefit year adjuvant herceptin treatment herpositive breast cancer advancedinoperableherpositive stomachcancer mabtherarituxan oncology onaveragebynearlythreemonthstomonth approval rochereceivedeuapprovalinfebruary patientswithtumoursexhibitinghighlevelsofher formabtheraincombinationwithchemotherapyfor experiencedevengreaterbenefitfromtheaddition previouslyuntreatedchroniclymphocyticleukemia ofherceptintheirliveswereextendedbymorethan cllandinaugustforuseinpatientswithrelapse fourmonthstomonthsonaverage orrefractorydiseasecllisthemostcommonform ofadultleukemiainnovembertheusfoodand inoctoberrocheandhalozymeannouncedthe drugadministrationfdaissuedacomplete startofaphaseiiitrialinvestigatinginfusionfree responsetotwosupplementalbiologicslicense subcutaneousadministrationofherceptinfor applicationssubmittedbygenentechandbiogen womenwithherpositive breastcancerthenew idecforapprovalofrituxanplusstandardchemo subcutaneousformulationisbasedonhalozyme therapyinpreviouslyuntreatedortreatedcllthe enhanzetechnology fdahasnotrequestedanynewdatatocomplete itsreviewoftheseapplicationsthecompanieswill fiveyear followupdata fromtwolargestudie continuefinallabeldiscussionswiththeagencyand evaluatingadjuvantherceptininherpositive early remaincommittedtomakingrituxanincombination stagebreastcancerwerepresentedatthesan withchemotherapyanfdaapprove optionforpeople antoniobreastcancersymposiumindecembercon withcll firmingthelongterm benefitsofoneyearoftreatment withherceptinnandbcirgconducte clinical milestone inseptemberrochegenentech bythenorthcentralcancertreatmentgroupand andbiogenidecannouncedpositiveresultsfroman thebreastcancerinternationalresearchgroup internationalphaseiiistudyprimashowingthat respectively showedthatherceptinreducedtherisk mabtherarituxanmaintenancetherapycansignifi ofthecancerreturningbyaboutonethirdcompare cantlyincreasethetimeuntilthediseaseprogresse withpatientsreceivingchemotherapyaloneinboth innewlytreatedpatientswithadvancedfollicular studiesormoreofwomenreceivingoneyear lymphomaacommontypeofnonhodgkins lym ofherceptinwerealiveandfreeofthediseaseatfive phomabecauseprimametitsendpointduringa yearsfollowup preplanned interimanalysisthestudywasstoppe earlyrocheandgenentechplantofiledatafrom lucentis primawiththeeuandushealthauthoritiesto filing basedontheresultsofbravoandcruise expandthecurrentmarketingapproval seebelowindecembergenentechfiledasupple mentaryapplicationwiththefdaforapprovalofuse updatedresultsfromthephaseiiicllstudywere inpatientswithmacularedemafollowingretinalvein presentedattheannualmeetingoftheamerican occlusion societyofhematologyindecembertheyshowe thatpatientswithpreviouslyuntreatedcllsurvive clinical milestone resultsofthephaseiiibravo theirdiseaselongerwhentreatedwithmabthera andcruisestudiesannouncedinjulyshowedthat rituxancomparedwithchemotherapyaloneclli lucentisimprovedvisioninpatientswithswellingin thefirsttrialtodemonstrateimprovedoverallsurvival theretinamacularedemaduetobranchretinalvein withaspecificfirstline treatmentforcll andcentralretinalveinocclusionrvorespectively rvooccurswhenbloodflowthrougharetinalvein mabtherarituxan rheumatoid arthritis becomesblockedcausingswellingmacularedema approval inoctoberthefdaapprovedupdate andhemorrhagesintheretinawhichmayresultin rituxanprescribinginformationthatincludesguidance blurringorvisionlossinallorpartofoneeye onretreatmentoflaterstage rheumatoidarthritis lrochearengpharmaceuticalsindd roche business report pharmaceutical rapatientswithaninadequateresponsetoanti thefdasoncologicdrugsadvisorycommittee tumournecrosisfactortherapiesclinicaltrialdataon recommendedagainstapprovingtarcevaforthisuse themedicinesabilitytoimprovephysicalfunction theagencyisnotboundbythisrecommendation andslowjointdamageforuptotwoyearswerealso injanuaryfollowingthesubmissionbyosioffurther addedatthesametimegenentechreceivedacom datathefdaextendedthereviewperiodforthe pleteresponsefromthefdafortheuseofrituxan applicationandisnowexpectedtomakeadecision plusmethotrexateinpatientswithmoderatelyto byaprilinseptemberchugaifiledasupple severelyactiverawhonolongerrespondtotreat mentarymarketingapplicationinjapanforapproval mentwithadiseasemodifyingantirheumaticdrug oftarcevainpancreaticcancer includingmethotrexategenentechisworkingwith thefdatodeterminenextstepsregardingthefile clinical milestone resultsfromaphaseiiistudy forthisindication atlasreleasedinfebruaryshowedthattarceva incombinationwithavastinforfirstlinemaintenance filing injunerochesubmittedacombine treatmentofpatientswithadvancednsclcsignifi filingtotheeuhealthauthoritiestoextendthemar cantlydelayedthetimetodiseaseprogressioninjuly ketingapprovalformabtheraasafirstline biologic rochegenentechandosiannouncedthatthe therapyforrheumatoidarthritisrathenewindi saturntrialhadmetanimportantsecondaryend cationsbeingsoughtareforpatientswhohavehad pointofextendingoverallsurvivalinpatientswith aninadequateresponsetomethotrexatethecurrent advancednsclcwhoreceivedtarcevaimmediately standardtreatmentoptionandfortheprevention afterinitialchemotherapythisbuildsonearlier ofjointdamageacrossallrapatientpopulationsthe resultsfromsaturnshowingthattarcevaimprove combinedfilingfollowedpositiveresultsfromthe progressionfree survivalthetrialsprimaryendpoint imagesereneandmirrortrialswhichshowe thatmabtheraimprovesthesignsandsymptom xeloda ofraandcansignificantlyreducetheprogression approval inseptemberchugaireceivedapproval ofjointdamagerocheisnolongerpursuingapproval injapanforadditionalindicationsforxelodaand forathirdindicationoriginallyincludedinthecom avastinxelodacannowbeusedincombinationwith binedfilingforuseinpatientswhohavenothad oxaliplatinchemotherapywithorwithoutavastin previoustreatmentwithmethotrexatebasedona inthetreatmentofpatientswithmetastaticcolorectal reassessmentoftheriskbenefit ratiointhispatient cancer population filing rochefiledanapplicationintheeuin tarceva decemberforapprovalofxelodaincombinationwith approval inseptemberthechinesehealthauthor oxaliplatinfortheadjuvantpostsurgicaltreatment itiesapprovedtarcevaforthesecondline treatment ofpatientswithearlycoloncancerbasedon ofpatientswithadvancednonsmallcelllungcancer datafromthephaseiiinoxeloxatrial nsclc filing inmarchrocheandosipharmaceutical research development submittedapplicationstotheemeaandthefda respectivelyforapprovaloftarcevaasmaintenance toensureastrongflowofsuitablecandidatemolecules therapyinpatientswithlocallyadvancedormetastatic intoitsdevelopmentpipelinerochehasbuilta nsclcwhosediseasehasnotprogressedfollowe uniqueinnovationnetworkofindependentresearch firstline chemotherapybothfilingswerebasedon anddevelopmentcentresinadditiontorocheand datafromthephaseiiisaturntrialindecember genentechitincludeschugaiinjapanandalliance lrochearengpharmaceuticalsindd roche genentech chugai partner worldwide form unique innovation network base diversity approach withmorethanpartnerorganisationsworldwide areabouttostartphaseiiidevelopmentatthe rg target thispromotesadiversityofresearchapproache sametimewearealsoexploringnewindicationsand inhibitor abnormal aswellasenablingaccesstonewtechnologiesand formulationsforexistingproductsincludingformu braf exemplify roche group promisingdrugcandidate lationsofherceptinseeabovepandother personalise health biologicmedicinesthatcanbeadministeredbymore care approach genentechresearchandearlydevelopmentgre convenientsubcutaneousinjectioninsteadofintra currently latestage continuestooperateasanindependentunitsimilarly venousinfusion clinical development thenewlyformedpharmaresearchandearlydevel malignant opmentorganisationpredenjoysfulloperational followingtheintegrationofgenentechsrd melanoma roche develop autonomygredcontinuestobeinspiredbythe projectsintothegroupsglobalpharmaceutical dia g nostic test valuesandculturethatledtogenentechssuccess portfoliorocheandgenentechconducteda identify patient whilepredwillexpandrochescapabilitiesto comprehensivereviewoftherdpipelineinthe tumour bringnovelmedicinestopatientsatthesametime fourthquarterthisresultedindecisionstoterminate carry abnormal subjecttoexistingthirdparty obligationsbothunit anumberofearlystage developmentproject braf gene arenowfreetoshareinformationandtechnologie omeofwhichhaverevertedtopartnercompanie thatcansupportandenhancetheiractivitie theterminationswhichwereprimarilydrivenby clinicaldataarepartofanongoingefforttoprioritise closecooperationbetweenthepharmaceutical resourcestowardsahighlydifferentiateddevelopment divisionandrochediagnosticsisakeystrategic portfoliooffirstinclass orbestinclass medicine advantageforourcompanythetwodivisionscan shareintellectualpropertytechnologiesandresearch atthebeginningofthedivisionsrdpipeline findingsfreelyamongotherthingsthisallowsroche includedprojectsinclinicaldevelopmentphasei tocombineandleveragebothdivisionsleadership toiiioftheseinvolvednewmolecularentitie inthekeyfieldofmolecularbiologyinadditionit nmesandinvolvedadditionalindicationsten enablesdiagnosticsexpertisetobeseamlesslyinte nmesareinorabouttoenterlatestage develop gratedintoallpartsofthepharmaceuticalsrd mentseetablepthirtyprojectsinvestigating processseepthisiscentraltorochesgoalof additionalindicationsforexistingproductsarein advancingpersonalisedhealthcareanapproach phaseiiithepharmaceuticalspipelineisshownin thatseekstotailortreatmentstospecificpatientsub thefoldoutinsidethefrontofcoverofthisreport populationsbasedonemergingscientificunder furtherdetailsareavailableatwwwrochecom standingofbiologyanddiseaseatthemolecularlevel oncology overthenextfewyearsthedivisionaimstoexpand rochesclinicaldevelopmentpipelineinoncology itsproductportfoliowithanewgenerationof includesnewmolecularentitiesthepharma medicinesforpatientssufferingfromcancermeta ceuticalsdivisionisfurtherstrengtheningitsoncology bolicandautoimmunediseasesviralinfection portfoliothroughnewtargetedtherapeuticoption anddisordersofthecentralnervoussystemcns andexpandingintonewindicationsfourcompound latestagedevelopmentofpromisinganticancer progressedintolatestageclinicaltestingin compoundssuchaspertuzumabandtdm herpositivebreastcancerrgmalignant rgplxcollaborationwithplexxikonisa melanomaandrgleukemialymphomaison targetedinhibitorofabnormalbrafthatexemplifie trackinadditiontwonovelcompoundsinthe therochegroupspersonalisedhealthcareapproach metabolicandcnsportfoliosaleglitazarcardio usingbiomarkersanddiagnostictoolsbrafisa vasculardiseaseinhighrisk typediabetespatient proteinthatrelaysgrowthsignalsinsidecellsincer andrgnegativesymptomsofschizophrenia taintypesofcancergeneticchangesmutation lrochearengpharmaceuticalsindd roche business report pharmaceutical excellence science seamless collaboration process lead healthcare company strength pharmaceutical diagnostic equip advance personalise healthcare organisational realignment imple mente pharmaceutical diagnostic division year enable collaborate seamlessly value chain discovery commerciali sation particularly important personalised healthcare start early drug development process diagnostic division begin technology expertise help identify potential drug target screen lesspromise candidate compound select suitable patient clinical trial case collaboration result drug couple companion diagnostic guide treatment pharmaceutical research early development clinical development commercialisation market target lead phase phase phase ii phase iii filing selection generation phase iv discovery exploratory proof confirmatory phase phase concept phase companion diagnostic biomarker development dx launchpostlaunch assessment feasibility utility target identification tailor prescribing monitor patient selection diagnostic lrochearengpharmaceuticalsindd close cooperation pharma ceutical diagnostic division key strategic advantage roche leadtoproductionofabnormalbrafthatisalway tdmgpresentedatthesanantoniobreast activeandcausesuncontrolledproliferationofcancer cancersymposiumindecembershowedanobjective cellsmutatedbrafisfoundinapproximately responsetumourshrinkageinofwomenwith ofmalignantmelanomasthemostdeadlyformofskin advancedmetastaticherpositivebreastcancer cancerfollowingpositivephaseiresultsaphaseii thathadworsenedfollowingprevioustreatment clinicaltrialwasinitiatedinseptembertoinvestigate rginpreviouslytreatedpatientswithbraf rggdccollaborationwithcurisisa mutationpositivemalignantmelanomaandaphase novelcompoundtargetingthehedgehogsignalle iiitrialinpreviouslyuntreatedpatientsbeganin pathwaywhichisthoughttobeimplicatedinseveral januaryadiagnostictestisbeingdevelopedin cancersfollowingpositivephaseiresultsapivotal collaborationwithrochemoleculardiagnosticsto phaseiistudyinvestigatingrgasapotential identifypatientswhosetumourscarrytheabnormal treatmentforadvancedbasalcellcarcinomacom brafgeneandarethereforemostappropriatefor mencedinfebruaryrgisalsobeingevaluate treatmentwithrg inphaseiistudiesasafirstline therapyformeta staticcolorectalcancerandinthemaintenancetreat rggathefirsttypeiiglycoengineere mentofovariancancer fullyhumanisedanticdmonoclonalantibody iscurrentlybeinginvestigatedinlatestageclinical inflammation autoimmune disorder trialsasapotentialtreatmentforchroniclymphocytic rochehaseightnewcompoundsindevelopmentfor leukemiacllandnonhodgkinslymphoma chronicandprogressiveautoimmuneandinflammatory nhldatafromphaseiistudieswerepresente diseasessuchasrheumatoidarthritisraand attheeuropeanhematologyassociationmeete asthmafiveofwhichareinphaseiioriiiclinicaltest injunecllandtheamericansociety ingphaseiiiprogrammesarecurrentlyinvestigate ofhematologyindecembercllandnhl thenextgeneration anticd antibodyocrelizumab aphaseiiistudyinpatientswithcllwasinitiate inseveralrasettingsincludinginpatientswho indecember respondinadequatelytothecurrentstandardofcare methotrexateortotumournecrosisfactortnf pertuzumabrgisaherdimerisation inhibitorsthefirstofthesestageinpatientswho inhibitorthatisbeingstudiedincombinationwith didnotrespondtotreatmentwithmethotrexate herceptinandstandardtherapyinherpositive wasreportedtohavemetitsprimaryendpointin breastcanceraphaseiiistudycleopatra decemberwhileoveralladverseeventsreportedin evaluatingtheadditionofpertuzumabtoherceptin thisstudywerecomparablebetweentheocrelizumab andchemotherapyinthefirstline treatmentof andplacebotreatmentgroupsahigherpercentage patientswithadvancedmetastaticdiseaseanda ofseriousinfectionswasobservedinthepooledocre phaseiitrialneosphereinvestigatingneoadjuvant lizumabgroupscomparedwiththeplacebogroupan presurgicaltreatmentwithpertuzumabareongoe additionalmajorphaseiiistudyscriptinpatient withinadequateresponsetotnfinhibitorsisex trastuzumabdmtdm rganovelanti pectedtoreportindosinginthefilmstudy bodydrugconjugatethatcombinesanantiher inpatientsnotpreviouslytreatedwithmethotrexate monoclonalantibodyandapowerfulcytotoxicagent hasbeenstoppedfollowingreassessmentoftherisk isbeinginvestigatedinthesecondandthirdline benefitprofileinthispatientpopulationaphaseiii treatmentofmetastaticherpositivebreastcancer programmeinvestigatingocrelizumabinthetreatment aphaseiiitrialemiliainvestigatingtdm oflupusnephritisbelongwasalsodiscontinued inthesecondline treatmentsettingbeganinthe followingreassessmentoftheriskbenefit profile firstquarterpositiveresultsfromaphaseiistudy lrochearengpharmaceuticalsindd roche business report pharmaceutical new molecular entity ongoing plan latestage study compound indication status market potential ocrelizumab rheumatoid arthritis phase iii study stage meet primary endpoint good class fourth quarter result additional study expect trastuzumabdm herpositive metastatic phase iii start quarter class breast cancer secondline treatment pertuzumab herpositive metastatic phase iii start class breast cancer rg ga nonhodgkin lymphoma phase iii start fourth quarter good class chronic lymphocytic chronic lymphocytic leukemia leukemia rg plx malignant melanoma registration study start january class rg advanced basal pivotal phase ii start quarter class gdc cell carcinoma rg negative symptom positive phase ii result fourth quarter class schizophrenia phase iii plan start aleglitazar cardiovascular high risk phase iii plan start quarter class type diabete taspoglutide type diabete positive phase iii result temerge fourth good class quarter additional result expect dalcetrapib dyslipidemia phase iii enrolment ongoing class cardiovascular high risk metabolic cardiovascular disease patientswithtypediabetesaleglitazarrg rochesmetabolicandcardiovascularportfolioof isaperoxisomeproliferatoractivatedreceptorppar newmolecularentitiesatvariousstagesofclinical coagonistwithdemonstratedeffectsonbloodfat developmentincludesthreepromisinglatestage bloodpressureandbloodglucoseforthereductionof compoundsdalcetrapibrgjttlicense cardiovascularmorbidityandmortalityinpatientswith fromjapantobaccoisanovelcholesterolest typediabetesaphaseiiiprogrammealecar transferproteincetpinhibitorforthemanagement dioisexpectedtobeginrecruitmentearlyin ofcholesterollevelsinthebloodrecruitmentforthe phaseiiidalheart programmeisontrackanew virology imagingstudydalplaquewasannouncedinthe rochecurrentlyhastwodirectantiviralagentsin lastquarterofandpatientrecruitmenthas developmentforthetreatmentofhepatitisc commencedtaspoglutidergbim thenucleosidepolymeraseinhibitorrgcolla licensedfromipsenisaonceweekly humangluca borationwithpharmassetandtheproteaseinhibitor gonlikepeptideglphormoneanalogueforthe rgitmn collaborationwithintermune controlofbloodglucoselevelsinlateinitial bothoftheseoralagentsenteredphaseiibstudie resultsfromfivephaseiiitrialsinthetemerge duringtheyearrgandrgarebeinginve programmeshowedthattaspoglutideconsistently tigatedincombinationwithpegasysandcopegus providespowerfulanddurableglycemiccontrolin ribavirinandincombinationwitheachotherin lrochearengpharmaceuticalsindd cancer disease group distinct disorder medical challenge aninterferonfree regimenresultsfromaphasei focus unmet medical studyinform investigatingrgcombine need withrginhepatitiscwerepresentedatthe annualamericanassociationforthestudyofliver diseasescongressinnovembertheyshowedforthe cancer accordingtothelatestinternational glyt inhibitor firsttimethatanalloralinterferonfreeregimen agencyforresearchoncanceriarcestimate rg canleadtosignificantviralsuppressioninpreviously inovermillionpeopleworldwidewere codevelope chugai treat untreatedpatientsandpatientsinwhomprevious diagnosedwithcancerandsomemilliondiedof ment negative treatmenthasfaile thediseasetheiarcanticipatesthatcancerwill symptom schizo surpassheartdiseaseastheleadingcauseofdeath phrenia area central nervous system worldwideinandalsoforecaststhatby high unmet medical therocheportfoliohasnovelcompoundsin therewillbeovermillionnewcasesandmillion need rg developmentfordisordersofthecentralnervoussys deathsperyearfromcancerineuropealoneone potential enable patient temincludingschizophreniamultiplesclerosisand inthreepeoplecanexpecttodevelopcancerintheir well establish social otherseriousconditionsoneofthesecompoundsis lifetimecancerisnotonediseasebutagroupof relationship rgaglycinetransportertypeglytinhibitor morethandistinctdisorderseachwithitsown parti cipate discoveredbyrocheitisbeingcodevelopedglobally medicalchallenge day activity withchugaiforthetreatmentofthenegativesymp ducing burden tomsofschizophreniaanareaofhighunmetmedical nonhodgkin lymphoma agroupofover patient caregiver alike needrghasthepotentialtoenablepatientsto cancersthataffectthelymphaticsystemthisclass betterestablishsocialrelationshipsandparticipate ofcancercurrentlyaffectsovermillionpeople ineverydayactivitiesreducingtheburdenforpatient worldwidefollicularlymphomaaccountsforabout andcaregiversalikeindecemberrocheannounced oneinfourofallcasesofnonhodgkinslymphoma thataphaseiitrialwithrghadmetitsprimary itcanoccuratanytimeduringadulthoodthough andsecondaryendpointsimprovingboththenegative peoplearetypicallydiagnosedduringtheirsixtie symptomsandthepersonalandsocialfunctione anditaffectsasmanymenasitdoeswoman ofpatientswithschizophreniathecompoundwas welltoleratedatalldosestestedrochehasnow chronic lymphocytic leukemia themostcommon decidedtoinitiatephaseiiiclinicaltestingwiththe typeofleukemiainadultsaccountingforapproximately firsttrialplannedtostartin ofallformsofleukemiatheincidenceof cllinwesterncountriesisaroundper alsoindecemberrocheanditsdevelopmentpartner anditistwiceascommoninmenasinwoman biogenidecreportedpositiveresultsfromaphaseii trialwiththehumanisedanticdmonoclonal colorectal cancer cancerofthelargeintestine antibody ocrelizumab rginpatientswith orrectumwhichaccountsforovermillionnew relapsingremitte multiplesclerosisoneofthelead casesaroundofallnewlydiagnosedcancer ingcausesofneurologicaldisabilityinyoungadult worldwideeachyearitisthesecondmostcommon ocrelizumabshowedastrongeffectversusplacebo causeofcancerdeathsineuropeandthethird withahighlystatisticallysignificantreductioninsign mostcommonworldwide ofdiseaseactivityasmeasuredbybrainlesionsthe primaryendpoint kidney cancer thistypeofcancerisnewlydiag nosedinaroundpeopleandcause deathsworldwideeveryyearratesthatareexpecte toincreaserenalcellcarcinomaaccountsfor ofallkidneycancer lrochearengpharmaceuticalsindd roche business report pharmaceutical breast cancer themostcommoncanceramong hepatitis b c thehepatitisbandcviruse womenworldwideovermillionwomenarenewly hbvhcvwhicharecommonlytransmittedthrough diagnosedandoverdiefromthedisease bloodtoblood contactcauseacuteandchronicliver eachyearasthereareseveraldifferenttypesof diseasepotentiallyleadingtoliverfailurecirrhosis breastcancerknowledgeoftumourcharacteristic andlivercancerworldwidemillionpeopleare isimportantfortreatmentdecisionssome thoughttobechronicallyinfectedwithhbvahighly ofwomenwithbreastcancerhavetumourswith infectiousvirusthatisresponsibleforanestimated abnormallyhighlevelsofaproteinknownasher onemilliondeathsannuallymorethanmillion herpositive tumoursareparticularlyaggressive peoplearoundtheworldareinfectedwithhcvand fastgrowing andlikelytorelapse tomillionnewcasesoccureachyearhepatitisc isthemainreasonforlivertransplantationarecent lung cancer themostcommonformofcancer studyonthehcvrelate burdenofdiseasein worldwideandtheleadingcauseofcancerdeath europeancountriesestimatedthatbetweenseven thereareanestimatedmillionnewcasesannually andninemillionpeopleoroverofthepopulation nonsmall celllungcanceristhemostcommon areinfectedwithhcv formaccountingforapproximatelyofallcase influenza flu ahighlycontagiousdebilitate pancreatic cancer aparticularlyaggressivedisease viralillnessthatoccursmainlyintheautumnand thatisextremelydifficulttotreatitkillsahigher wintermonthsintemperateclimatesandyearround proportionofpatientsinthefirstyearafterdiagnosis intropicalareasitcanbeparticularlydangerous thananyothercancerthefifthleadingcauseof foryoungchildrentheelderlyandpeoplewith cancerdeathsinthedevelopedworldpancreatic chronichealthproblemswhoareatgreaterriskof cancerclaimsnearlyliveseveryyear influenzarelate complicationspandemicsorglobal epidemicsarecausedbynovelstrainsofinfluenza gastric stomach cancer accountsforovermillion towhichpeoplehavenoimmunitypandemicsoccur newcasesandsomedeathseachyearmaking everytoyearsandhavebeenassociatedwith itthesecondlargest causeofcancerdeathsworld significantlevelsofillnessanddependingontheviral widethevastmajorityofcasesoccurinasiawhere straindeathaccordingtotheworldhealthorgani withlungcanceritistheleadingmalignancyadvanced zationthecurrentlycirculatingpandemicahn stomachcancerisassociatedwithapoorprognosis influenzavirusappearstobeascontagiousas themediansurvivaltimeafterdiagnosisisapproxi seasonalinfluenzaandisspreadingfastparticularly matelymonthswithcurrentlyavailabletherapie amongpeopleagedtoyearsthediseaseis generallyclinicallymildbutsevereillnesscanoccur anemia occurswhenthelevelofredbloodcell andorthehemoglobintheycontainfallsbelow autoimmune disorder occurasaresultofa normalstarvingorgansandtissuesofoxygenitis mistakenimmuneresponsetothebodysowntissue seeninoverofpatientswithchronickidney thecausesareunknownrheumatoidarthritis renaldiseasewhichaffectsmorethanmillion multiplesclerosisandlupuserythematosusareamong peopleworldwideinadditionanemiaaffectsthree themostcommonautoimmunedisorderswhichaffect outoffourcancerpatientsundergoingchemotherapy millionsofpeopleworldwide patientswithuntreatedanemiamayneedblood transfusionsthepotentiallongterm effectsofanemia rheumatoid arthritis ra achronicprogressive includecardiovasculardiseaseinrenalpatient inflammatorydiseaseofthejointsandsurrounde whileinpatientswithcanceritisassociatedwith tissuesthatisassociatedwithintensepainirrever diminishedqualityoflife iblejointdestructionandsystemiccomplication lrochearengpharmaceuticalsindd bcellsatypeofimmunecellareknowntoplaya keyroleintheinflammationassociatedwithra severalkeycytokinesorproteinsarealsoinvolve includingtnfalfainterleukin il andinter leukin il il hasbeenidentifiedashaving apivotalroleintheinflammationprocessaround millionpeopleworldwidearethoughttobe affectedbyra diabete recognisedasaglobalepidemicbythe worldhealthorganizationtheinternationaldiabete federationestimatesthatsomemillionpeople worldwidewillhavediabetesbyaccordingto thewhotypeadultonsetdiabetesaccountsfor aroundofallcasesuncontrolledtypediabete canleadtoseverecomplicationssuchascardio vasculardiseasestrokeblindnessamputation andkidneyfailureresultinginsignificanthealthcare burdenstosociety schizophrenia aseverementaldisordercharacter isedbyprofounddisruptionsinthinkingthataffect languageperceptionandthesenseofselfaccorde towhoestimatesschizophreniaaffectsapproxi matelymillionpeopleworldwideandismostcom moninadultsagedbetweenandyearsthe symptomsofschizophreniaarebroadlycategorise aspositivenegativeandcognitivepositivesymptom arepsychoticbehaviourssuchashallucinationsand delusionsnegativesymptomsareassociatedwith disruptionofnormalbehaviourandemotionssuchas inabilitytosustainplannedactivityoralackofmotiva tionandinterestindaytoday livingcognitive symptomsincludetroublefocusingorpayingattention persistentnegativesymptomsareamajorcauseof chronicdisabilitythereiscurrentlynomarkete productavailabletotreatthenegativesymptomsof schizophrenia lrochearengpharmaceuticalsindd take aim innovative medicine skin cancer roche world leader vitro diagnostic syste atically apply diagnostic expertise research development new medicine help develop pharmaceutical target biological mechanism rise cancer example rg plx currently test phase ii clinical trial possible treatment malignant melanoma type skin cancer rg novel highly selective braf kinase inhibitor target destroy cancer cell harbour specific cancer cause gene mutation call braf identify patient tumour carry mutation consider likely respond target medicine roche develop companion diagnostic test rg promise compound development treatment braf mutationpositive patient malignant melanomas deadly form skin cancer oral medicine selective kinase inhibitor develop roche collaboration plexxikon bildstreckeengsindd bildstreckeengsindd diagnostic sale grow ahead market strong uptake new product contribute market share gain key segment immunoassay tissue diagnostic business area launch major new product roche believe help drive abovemarket growth effort enhance operational efficiency ongoing division contribute high operating profit division continue expand effort order improve productivity profitability lrochearengdiagnosticsindd diagnostic division brief key figure change change millions chf chf local currency sale sale professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic operating profit operate free cash flow research development diagnostic executive committee december jrgen schwiezer ceo division roche diagnostic manfre baier apply science roland diggelmann asiapacific dirk h ehler professional diagnostic christian hebich finance service michael heuer emea europe middle east africa latin america alexander keller global platform support frank lennartz human resource hany massarany tissue diagnostic daniel oday molecular diagnostic frank pitzer regulatory affair quality management clausjoerg ruetsch legal michael tillmann north america robert yates business development december corporate governance chief operating officer roche diagnostic january associate member lrochearengdiagnosticsindd roche business report diagnostic diagnostic division sale region roche diagnostic rochesdiagnosticsdivisionistheworldsleade division global supplierofin vitro diagnosticsivdsivdtest europemiddle leader billion testsperformedinalaboratoryoratthepointofcare eastafrica dollar vitro onbloodandothersamplesfrompatientsarea japan diagnostic market criticalsourceofobjectiveinformationabouthealth asiapacific division strive develop system anddiseaserochesdiagnosticinstrumentsand testing reagentshelpdoctorsdetectdiseasesselectappro latin america efficient provide priatetreatmentsandmonitorpatientsresponsesto result high medi careinadditionscientistsusethedivisionsresearch north america cal value productstogainabetterunderstandingofthe causesofdiseaseanddiscovernewtreatment italic growth rate local currency inovercountriesthedivisionservescustomer spanningtheentirehealthcarespectrumfrom hospitalsandcommercialmedicallabstophysicians togetherrochespharmaceuticalsanddiagnostic topatientswithconditionsrequiringthemtoselft division work advance personalise inrochehadashareoftheglobalivd healthcare activity align help increase marketvaluedatanestimatedbillionusdollar drug rd productivity discover target inannualsale medicine drive development companion diagnostic potential revalue diagnostic inform majority clinical strategic priority decision account medical spending changingdemographicsnewtechnologiesand diagnostic division outperform mountingpressureonbudgetsandpricingareamong market emerge seven e country thetrendsshapingthehealthcaremarket notably china accelerate growth thediagnosticsdivisionsstrategicprioritiesare expand local organisation designedtorespondtothesetrendsandcapitalise investing programme bring product onthegrowthopportunitiestheypresent market quickly test efficiency pillar division division intend improve profitability business roche automate diagnostic system combination strong sale embody decade engineering innovation growth efficiency initiative target virtually future advance include enhance workflow area operation report contain integration capability support elec information progress tronic patient record management testing efficiency product high medical value critical sustain competitiveness growth novel roche test mark significant advance oncology cardiology major therapy area increase invest ment biomarker research trial figure market growth market share market size demonstrate clinical utility new test estimate base company independent report roche analysis yield innovation e market brazil russia india china south korea mexico turkey lrochearengdiagnosticsindd sale instrument placement strongly result main business onscheduleintheeuandothermarketsinthe divisional sale secondhalfoftheyearrocheexpectsthismajor growth broad development additiontoitscobasfamilyofmodularserum base extend busi workareasystemstoenhanceitscompetitiveness ness area inthediagnosticsdivisionrecordedsale significantlyinbothclinicalchemistryandimmuno major regional ofbillionswissfrancsanincreaseofinlocal assaysaltogetherthedivisionlaunchedover market japan currenciesinswissfrancsinusdollars majorproductsin business area overthiswasmorethantwicetheestimate launch major ivdmarketgrowthrate thediagnosticdivisionsoperatingprofitrosein new product localcurrenciesinswissfrancstomillion allfivedivisionalbusinessareascontributedtosale swissfrancsandtheoperatingmarginatconstant growthledbyprofessionaldiagnosticsanddiabete exchangeratesadvancedpercentagepoint careimmunoassaysandsinglestripbloodglucose theseincreaseslargelyreflectsalesgrowthtightcost monitoringsystemsremainedthesebusinesse managementandthesignificantonetimeexpense primarygrowthdriversmoleculardiagnosticscore recordedinincludingthoserelatingtotheven bloodscreeningandvirologysegmentsdelivereda tanaacquisitioninswissfrancsthemargindecrease solidsingledigitriseinoverallsalesintheapplie bypercentagepointstoduetoaparti scienceunitstrongdemandforthemagnapureand cularlyunfavourablecombinationofexchangerate lightcyclerproductlinesfuelledfurtherabovemarket movementsformoreinformationonthedivision growththetissuediagnosticsbusinessacquire operatingresultsseethefinancereportpart incontinuedtogrowwellaheadofthemarket ofthisannualreport drivenmainlybyitsadvancedtissuestainingportfolio instrumentplacementswereagainupsignificantly efficiency gain forthedivisionasawholeandwereamajorgrowth initiativestosimplifycoreprocessesconsolidate driver servicesstreamlineproductportfoliosandreduce timetomarketareinplaceatanumberofmajorsite geographicallytheemeaandasiapacificregion insuchinitiativescontributedtosignificant contributedmosttogrowthwithallfivebusiness costsavingsandhelpedthedivisionlimitheadcount areasrecordingsolidsalesgainsinthesemarket growthdespitetheacquisitionofswisslaband tissuediagnosticsremainedtheprimarygrowth innovatisanddespiteasubstantialsalesforce driverinnorthamericainjapanprofessionaldiag increaseinchinanotablesuccessesincludedthe nosticsandappliedsciencegrewmoderatelyand consolidationofregionalcallcentresthecreation tissuediagnosticsachievedhighdoubledigitgrowth ofsharedservicecentresinnorthamericaand butdivisionalsalestherewereflatoveralllargely reductionsinmanufacturingcostsexistingandnew duetoreducedgovernmentivdreimbursementand programmeswillbeintroducedatmoresitesto lowerresearchfunde improveproductivityfurtherandachieveadditional costsaving salesintheemarketsgrewandaccountedfor overoftotaldivisionalsalesrevenuesincrease investmentinthesemarketsandstrongdemandfor immunoassaysandotherleadingedgerocheproduct contributedtothisstrongabovemarketgrowth thefirsttwomodulesofthecobasanalyser state growth rate local currency seriesforhighthroughputlaboratorieswerelaunched emea europe middle east africa lrochearengdiagnosticsindd roche business report diagnostic roche topselle diagnostic sale millions chf accuchekmobile cobase cobasc cobastaqman cobastaqscreen mpxt accuchek blood glucose cobas e module cobas c module cobas ampliprep cobas ampliscreen meter insulin pump modular analytic modular analytic cobas taqman cobas taqscreen system elecsys cobas integra market segment market segment market segment market segment market segment diabete management immunoassay clinical chemistry virology blood screen lrochearengdiagnosticsindd industryleade portfolio product clinical testing blood screen life science research coaguchekxs ventanaihcreagent magnapurelc sysmexxti genomesequencerflx coaguchek meter immunohistochemistry magna pure system sysmex analyser genome reagent light cycler system sequencer market segment market segment market segment market segment market segment coagulation advanced gene expression hematology dna sequence monitor tissue stain research image scale yearonyear sale growth local currency lrochearengdiagnosticsindd roche business report diagnostic business area highlight coagulationmonitoringsalesincrease reinforcingrochesleadershipinthissegment immunoassay sale professional diagnostic abovemarket growth salesofthetopsellingcoaguchekxsmonitor major major new product forpatientusewereupstronglyagainhelpe growth driver increa rocheprofessionaldiagnosticsisaleadingsupplier bycontinuedrobustdemandineuropeandexpande ing roughly ofinstrumentstestssoftwareandservicesfor medicarereimbursementforhomecoagulation time market laboratoriesandofdecentralisedtestingproductsto testingintheusstudiesindicatethatselftesting growth rate new cobas modular supportclinicaldecisionmakingatthepointofcare helpspatientsonanticoagulantstokeeptheir system inthebusinessareahadashareof medicationwithinthetherapeuticrangeandcan roche professional aglobalmarketestimatedatbillionusdollar reducecomplication diagnostic strong competitor professionaldiagnosticsfullyearsalesgrewnearly inaugustprofessionaldiagnosticsbeganrollingout immunoassay twiceasfastasthemarketrisingtomillion thecobasmodularanalyserseriesforhigh testing clinical swissfrancsimmunoassayandclinicalchemistry throughputlaboratoriesineuropeandothermarket chemistry systemsforlaboratoriesthetwolargestsegment thatrecognisecemarkcertificationtheresponse bysalesremainedtheprimarygrowthdriver tothisnewflagshipcobasplatformhasbeen regionallysalesoutpacedmarketgrowtheverywhere overwhelminglypositivewithmorethanorder exceptnorthamericawheretheindustryasawhole shippedbytheendoftwoclinicalchemistry experiencedflatornegativesalesgrowthinmost modulescandcwerelaunchedin segmentsasaresultoftheeconomicdownturn bytheendoffourcobasclinicalchemistry andimmunoassaymoduleswillbeavailableworld theimmunoassaybusinessgainedfurthermarket wideincustomisableconfigurationsthenew shareonsalesgrowthofthiswasroughlythree platformisbasedonthesameproventechnologie timesthemarketgrowthrateclinicalchemistrysale asthesmallercobasandcobassystem grewaheadofthemarketadvancingtheplace withexpandedsamplehandlingandworkflow mentrateforcobasmodularanalysersparticularly capabilitiesandenhancedqualitymanagement thecobasseriesformidsizelaboratorie featurestomeettheneedsoflaboratoriesperforme remainedhighfuellingsalesinboththesesegment uptomilliontestsperyear professionaldiagnosticsimmunoassaybusiness inseptemberrocheconcludedanexclusivelicense hasconsistentlygrownatdoubledigitratesforthe agreementwithstvincentshospitalsydney lastnineyearsthankstoalargeinstalledbaseand australiaforworldwidepatentrightsrelatingto steadilyexpandingtestmenunewtestsintroduce theuseofgrowthdifferentiationfactorgdf inliketheelecsysilinterleukinimmuno forthediagnosisofcardiacdysfunctionelevate assayanaidinthemanagementofcriticallyill circulatinglevelsofgdfcanhelpidentifyhigh patientsandthehighsensitivityelecsystroponint riskindividualswithavarietyofcardiovascular assaydiagnosisofheartattackandcardiacrisk conditionsfromstablecoronaryarterydiseaseto stratificationwereimportantgrowthdriversin heartfailuretogetherwithanagreementsignedwith professionaldiagnosticslaunchedsiximmunoassays hannovermedicalschoolhannovergermanyin andfiveneworsecondgenerationclinicalchemistry januaryalsorelatingtogdfandroches testsforavarietyoftherapyareasincludingcardi ownpatentsinthisfieldthislatestagreement ologywomenshealthandcriticalcarein willfurtherstrengthenrochesleadingpositionin thebusinessareawillexpanditstestmenufurther thediagnosisofcardiovasculardisease particularlyintheuswhereitexpectstolaunch eightimmunoassays lrochearengdiagnosticsindd new accuchek portfolio deliver solid sale growth difficult market diabete care market leadership strengthen combowhichwaslaunchedinninemarketsdure excellent uptake rochediabetescaredevelopsandcommercialise andbycontinuedstrongdemandforaccu late accuchek bloodglucosebgmonitoringandinsulindelivery chekinfusionset product helped drive abovemarket sale systemsthatenablepeoplewithdiabetestomanage growth diabete theirconditionmoreeffectivelyitistheindustry inseptemberdiabetescareannouncedinterim care leaderwithashareoftheglobalbgmonitore datafromitsaccuchekviewoutcomestudy marketworthnearlybillionswissfrancsinglobal thedataindicatethatpeoplewithtypediabete salesselfmanagementisacornerstoneofdiabete whoarenotreceivinginsulincanimprovetheir carebecausesomanydailyactivitiesaffectblood glycemiccontrolbytestingandanalysingtheirbg glucoselevelsfrequentbgtestingcanlowertherisk levelsinastructuredwayandtranslatingtheresult ofseriouslongtermdiabeticcomplicationslike intoappropriateactionthemonthstudyunder strokeamputationandblindnesswhilehelpingpeople scoresrochescommitmenttoenhancingthemedical withdiabetestomaintainandimprovetheirquality valueofdiabetesselfmanagementthefinalresult oflife willbeannouncedinjune indiabetescaressalesincreasedto molecular diagnostic new product lie molecular diagnostic millionswissfrancsthiswassignificantly foundation future growth important aheadofglobalmarketgrowthwhichwasflat rochemoleculardiagnosticsdevelopsandcommer new blood screening account duetotheeconomicdownturnallregionsexcept cialisesadvanceddiagnosticandbloodscreene contribute signifi japandeliveredsalesgrowthwithstrongsale platformsandtestsbasedonrochesproprietary not competitive gain contributionsfromemergingmarketstheaccuchek realtimepolymerasechainreactionpcrtechnology market avivaandaccuchekperformabgmonitore thefastgrowinghighlycompetitivemolecu systemsremainedtheprimarygrowthdriversaccu lardiagnosticsmarketisvaluedatbillionswiss chekavivarochestopsellingbgmonitore francsrocheistheleaderwithamarketshare systemcontinuedtopoststrongdoubledigitsale growth moleculardiagnosticsfullyearsalesadvance tomillionswissfrancsgrowthwasledbysolid introducedinfebruarytheaccuchekmobile gainsintheemearegionespeciallyinthecore thefirstandonlystripfreebgmonitoringsystem bloodscreeningbusinessthefullyautomatedcobas experiencedexcellentuptakeinitslaunchmarket taqscreenmpxtestavailableineuropesince andcontributedtomarketsharegainsinthehigh andlaunchedlastyearintheuscontributedstrongly valuecustomersegmentattheendofitwa togrowthinthissegmentwithsignificantcom availableinnineeuropeancountriesaccuchek petitivegainsinseveralmarketsthismultiplexblood mobilesenhancedeaseofuseisappreciate screeningtestdetectsfiveviraltargetsinvirology especiallybypeoplewithinsulindependentdiabete thelargestsegmentbysalesmoleculardiagnostic whoneedtotesttheirbgfrequentlythelaunch retaineditsleadingmarketsharewithsale ofthesleekaccuchekavivananoandaccuchek growthstrongvirologysalesandnewbloodscreene performananodesignedespeciallyforyounger accountsinportugalspainthailandandtheuk usershasalsobeenasignificantsuccessattheend resultedinabovemarketdoubledigitsalesgrowth ofthesenewsinglestripmeterswereavailable intheasiapacificandemearegion inovermarket sinceitseulaunchinaprilrocheslightcycler salesofinsulindeliverysystemsshoweddoubledigit mrsaadvancedtesthasexperiencedpositiveuptake growthfortheyearhelpedbyexcellentuptakeof incountrieswherereportingmethicillinresistant thenewinteractiveinsulinpumpsystemaccuchek staphylococcus aureusmrsainfectionsiscustomary lrochearengdiagnosticsindd technolo ggi lyre cns oa e na grm ie ne e rt ed f ee h r ri n e ts nd ii gbl cis c e ec se n st c r u e c u b se r un gn dte ec h sn io g lo g n fo rm ula tio n lle c e ts vir alresi sta nce n eur ode ge ner atio sn gn al li ng p h w ay n gi mg e yn ee ls ib ip n oi ncpo e alol tl e sg b c iy emol llo bg uy ioni loty gy pharma oncology inflammation neuroscience metabolism virology diagnostic anatnev gniniat eussit roche business report diagnostic excellence science expertise molecular biology major disease area year roche division amass tremendous expertise molecular biology today apply knowledge wide range technology pursuit new test target treatment major focus area oncology inflammation neuroscience metabolism virology time work gain insight molecular mechanism cause drive disease cancer drug development programme roche example involve biomarker research aim validate treatment target identify patient likely respond new drug year cancer research molecular level help develop new strategy close ultimate goal day cure cancer n l sif ee q ec ni ce ngce xc ce el lll ai ng ae lyn sc ise ni mm icb rl oe arg ayn cobas r el ai lg tiht mec pc cl rer u n ss ayu c solt bi ap slex protein anac lo ysb isas lrochearengdiagnosticsindd roche develop test new pandemic flu virus week virus report orrequiredstudiesindicatethatthetestsspeed ofdevelopingcervicalcancercouldhelpincrease test hospital itreliablyidentifiesmrsacarriersinlessthantwo thesensitivityofscreeningforhpvinfectionsthatcan acquire infection hoursversusonetothreedaysusingconventional leadtocervicalcancerwhenhpvdnatestingis like mrsa human papillomavirus methodscanhelpsignificantlyreducethespreadof performedinconjunctionwithapapsmearmore infection thispotentiallydeadlymicrobeinhospitalsscreene womenwillbeidentifiedwithprecancerouscervical fastestgrowing formrsaisoneofthefastestgrowingsegment diseaseduringthefirstroundofcancerscreene segment molecu inthenorthamericanmoleculardiagnosticsmarket enablingappropriatemedicalinterventionaddition lar diagnostic andisexpandinginemeaandsomeasiapacific allybecauseofthegreatersensitivityofhpvdna roche launch marketsrocheexpectstolaunchthelightcycler testingwomenwhoarehpvdnanegativemay competitive new product mrsaadvancedtestintheusin potentiallybedeferredtolongerscreeninginterval segment moreoveridentificationofhpvgenotypesand europe indecembermoleculardiagnosticslaunchedit providesactionableinformationguidingtheclinician newfullyautomatedcobassystemineurope toinvestigatefurtherthosewomenatthehighestrisk andothermarketsthatacceptcemarkcertification forcancer thesystemisdesignedtomeetthecurrentand longtermmoleculardiagnostictestingneed apply science broadbase growth demand instru ofmidtohighthroughputlaboratoriesandroche rocheappliedsciencesuppliesscientistsinacade ment reagent expectsittobecomeasignificantgrowthdriver miaandthebiotechandpharmaceuticalindustrie pandemic flu testing major thetestmenucurrentlycomprisesdualtargettest withinstrumentsandhighlyspecificreagentsandtest sale driver roche forchlamydia trachomatisctandneisseria kitsforabroadrangeofresearchapplicationsthe applied science gonorrhoeaengthebacteriathatcausechlamydia globallifescienceresearchmarketvaluedatbillion infectionsandgonorrheaandascreeningand usdollarsgrewapproximatelyin genotypingtestforhumanpapillomavirushpv themostcommonsexuallytransmittedinfection appliedsciencessalesfortotalledmillion whichisresponsiblefornearlyallcervicalcancer swissfrancsanincreaseofovertheprevious worldwideinaustraliaandnewzealandwhere yearthemagnapureandlightcyclerproductline thecobassystemhasbeenavailablewiththe nucleicacidsamplepreparationnapandquanti ctngtestssinceseptemberthemarketresponse tativepolymerasechainreactionqpcranalysis hasbeenverystrongnextgenerationoncology wereagainthebiggestcontributorstogrowthwith andmicrobiologyassaysforthesystemareindevel salesuphelpedbystrongdemandforinstrument opment andreagentsforpandemicinfluenzatestingand surveillanceinmayappliedsciencedevelopedand inaugustmoleculardiagnosticscompletedenrolment launchedtherealtimereadyinfluenzaahn ofpatientsintoitspivotalathenaclinicaltrial detectionsetforresearchusejustweeksafterfirst thetrialinvolvingapproximatelywoman reportsofthenewpandemicfluvirusinmexico isdesignedtoassessthevalueofscreeningwomen thesetenablesrapidaccuratedetectionoftheviruss forcervicalcancerusingrochescobashpv rnageneticmaterialthefdagrantedemergency assaytogetherwithastandardpapsmearinitialtrial useauthorizationofthekitinnovembermakingit datawillbeavailableinfebruaryandrocheexpect availableforclinicaluseinspeciallycertifiedlaborato tofilethefullathenadatasetwiththefoodand riesintheusothersignificantnewproducts drugadministrationfdainthesecondquarterof includethefullyautomatedmagnapuresystem ifapprovedtheassaywhichprovidesan forhighthroughputnapuptakebyacademic aggregateresultforhighriskhpvgenotypesand andindustrialcustomershasbeenrobustsincethe individualresultsforhpvgenotypesand systemsgloballaunchinseptember thegenotypesthatputwomenatthegreatestrisk lrochearengdiagnosticsindd roche business report diagnostic significant product launch business area total cellanalysissystemsshowedverystrongsalesgrowth throughputbenchtopversionofthegenome indrivenmainlybythexcelligenceproduct sequencergsflxsysteminisexpectedto l linebutalsopartlyattributabletotheacquisitionof spurfurthergrowththegsjuniorsystemwillclose innovatisaginmarchappliedscienceslatestreal themarketgapbetweenlowthroughputtraditional timecellanalyserthexcelligencertcadp sequencingandtheultrahighthroughputofinstru dualplateinstrumenthasbeenagrowthdriver mentslikethegsflxsystemputtingnextgeneration sinceitsworldwidelaunchinaprilitsvalueasa sequencingtechnologywithinthereachofthousand cancerresearchtoolwasenhancedfurtherbythe ofadditionalresearchersworldwide novemberlaunchofthexcelligencesystem cimplateacultureplateenablingscientist tissue diagnostic rapid penetration new l tostudycellmigrationandinvasiondynamically market e inrealtimeovertheentiretimespanofanexperiment rochetissuediagnosticsventanamedicalsystem thismayhelpresearchersidentifymoleculartarget innorthamericaistheworldsleadingsupplierof fornewdrugsthatinhibitcancercellsabilityto tissuebasedcancerdiagnosticsitsinstrumentsand invadenearbytissuesandmigratemetastasise reagentsystemsareusedinhistologycytologyand todistantpartsofthebody drugdiscoverylaboratoriesworldwideinthe unithadashareofthetissuediagnosticsmarket microarraysalesrosenearlyfourtimesthe whichisvaluedatoverbillionswissfranc globalarraymarketgrowthrategrowthwasfuelle bycontinuedstrongperformanceofnimblegen tissuediagnosticsrecordedsalesofmillion innovativesequencecapturetechnologieswhich swissfrancsinaincreaseovertheeleven ideallycomplementthebusinessareasnextgenera monthssalesconsolidatedayearearlierfollowingthe tionsequencingsystemsandbytheintroduction ventanaacquisitioninfebruaryonacompa ofthehighresolutionhighthroughputms rablebasissalesrosesignificantlyoutpace microarrayscanner themarketwhichisestimatedtobegrowingat salesofdnasequencingreagentsshowedarobust thebusinessareascoreadvancedtissuestaine increasebutoverallsalesofdnasequencing portfolioremainedtheprimarygrowthdriverwith systemswereflatduetotheeconomicdownturnand immunohistochemistryihcreagentsforcancer theresultingdeclineinresearchfundingparticularly diagnosisandadvancedstaininginstrumentsfuelle intheustheusadministrationsstimulus robustgrowthinthissegmentplacement packageforbiomedicalresearchisexpectedtoalle ofthefullyautomatedbenchmarkultrasuccessfully viatethesituationinthelaunchofamedium launchedinnorthamericaandeuropein lrochearengdiagnosticsindd roche biomarker programme drug develop acceleratedsteadilyduringtheyearthisisthefirst research development andonlysystemtoperformsimultaneousihcand situhybridisationishtestingonasinglecontinu rochesdiagnosticsdivisioncontinuestoinv diagnotic divi ousandrandomaccessplatformenablingsample heavilyininnovationinresearchanddevelop sion focus tobeaddedandremovedatanytimewithoutinter mentrdcoststotalledmillionswissfranc r spending highgrowth area ruptingworkflowfullyearsalesofthesymphony anincreaseofoverrdcostsasaper like molecular diag slidestaininginstrumentandhematoxylinandeosin centageofsalesremainedstableatproject nostics immuno reagentsforthehighvolumeprimarystainingmarket accountingforasignificantshareofrdspende assays tissue grow inandwhichwillremainfundingprioritiesin diagnostic includetheathenatrialofrochemolecular tissuediagnosticswonmarketshareinallregion diagnosticscobashpvscreeningandgeno withespeciallystronggainsinasiapacificandlatin typingtestintheusdevelopmentofthecobas roche work americaitsuccessfullyleveragedtheexistingroche modularanalyserseriesanddevelopmentof potential companion infrastructuretoexpeditethehiringofsalesperson anextgenerationmoleculardiagnosticplatform diagnostic test group key nelandtheintroductionofnewproductsinemea formidtohighthroughputivdtestingandblood disease area inter asiapacificandlatinamericacontributingto screeningthedivisionalsoinvestedindeveloping est particularly oncol abovemarketgrowthintheseregionsbythecloseof newproductsinitstissuediagnosticsbusiness ogy thebusinessareahadestablisheditsownsale expansionoftheimmunoassaymenuwillbeafurther organisationsinsixoftheemarketsandmostofit majorfocusofrdinvestmentin majorinstrumentsandihcreagentswerealready registeredandavailableinbrazilindiachinaand thedivisionsrdproductivityhasimprovedin mexicorocheisaddressingtheincreasingdemand recentyearssincethenumberofmajorproduct forfullyautomatedproductsinemergingmarket launcheshasincreasedsignificantlyandthedivision whichiscontributingtostrongmarketsharegain expectstobeanotherexcellentyearinterm ofstrengtheningitsproductportfolioseecharton pandthetablesofmajor product launch intissuediagnosticslaunchednewihc pp reagentstoaidindiagnosingvariouscancersinclud ingleukemialymphomaandcancersofthecolon thediscoveryandvalidationofbiomarkersisessential andprostateworkingcloselywithrochespharma torealisingthepromiseofpersonalisedhealthcare ceuticalsdivisionitcontinuedtodevelopexploratory inpharmaceuticalrdtheyhavemanyusesfrom teststhatmayonedayleadtocompaniondiagnostics identifyingnewtherapeutictargetsandscreeningout forrochetherapiesasadirectresultofthiscollabo unpromisingdrugcandidatestoselectingappropriate rationtissuediagnosticsexpectstwoherassay patientpopulationsforclinicaltrialsintheclinic toreceiveceivdmarkinginthefirsthalfof biomarkertestsincreasinglyprovideinvaluableinfor foruseasaidsinassessingbothbreastandgastric mationforearlydiagnosisandaboutdiseasepre cancerpatientsforwhomherceptintreatmentis dispositionprognosisandthelikelihoodoftreatment beingconsidere responseresponsepredictioncontributingtoear liermoretargetedtherapeuticinterventionsroche ivdportfolioalreadyincludescompaniondiagnostics contributingtomoreeffectivetreatmentinanumber ofconditionsincludingherpositivebreastcancer precancerouscervicalchangescausedbyhuman papillomavirusinfectionhepatitisbandcinfection andcytomegalovirusdisease lrochearengdiagnosticsindd roche business report diagnostic everydrugbeingdevelopedatrochehasabiomarker morelikelythanseronegativepatientstoachieve programmeassociatedwithitanddiagnosticsex asignificantimprovementintheirdiseasefollowe pertiseandadvicearemadeavailableforeachof mabtherarituxantreatmentthiscouldsignal theseprogrammesattheendofrochehad amajoradvanceoverthecurrenttrialanderror fivebiomarkertestsinlatestageandsixinearlystage approachtotreatingrainwhichpatientscycle clinicalvalidationforuseaspotentialcompanion throughvarioustreatmentoptionsuntilanoptimum diagnostictestsandoverexploratorystage responseisachievedrochealreadymarketsassays diagnosticprogrammesintheareasofoncology forrheumatoidfactorandanticcp metabolismvirologyautoimmuneandinflammatory diseaseandcentralnervoussystemdisordersthere hastobeastrongcaseforabiomarkersabilityto detectdiseaseorpredictaclinicaloutcomebeforeit movesintolatestagevalidationwheretheaimisto establishclinicalvalidityconclusivelythroughfurther testingonsamplescollectedinongoingdrugtrial giventhepharmaceuticalsdivisionsstrongoncology portfolioidentifyingandvalidatingbiomarkersto supporttheuseofrochesmarketedanddevelop mentalcancermedicinesisnaturallyamajorfocusof researchencouragingprojectsincludeapcrbase testforbrafveacancercausinggenemutation associatedwithpoorprognosisinseveralcancer includingmalignantmelanomadevelopedbyroche moleculardiagnosticsthetestwasprovenessential forselectingsuitablepatientsinaphaseitrial withthebrafkinaseinhibitorrginmetastatic melanomargwhichselectivelytarget andinducescelldeathintumoursharbouringthe brafvemutationmarkedlyprolongedprogression freesurvivalinpatientsinthetrialwhotestedpositive forthemutationthetesthasalsobeenuse successfullyinclinicaltrialstoidentifymutation positivecolorectalcancersifrgisapprove rocheexpectstolaunchthebrafvetestasthe companiondiagnostic twootherhighlypromisingbiomarkersthathave alreadyreachedlatestageclinicalvalidationarerheu matoidfactorandanticycliccitrullinatedpeptide anticcpantibodiesthatarefoundinthebloodof manyrheumatoidarthritisrapatientsananalysis ofpooleddatafromtwoclinicaltrialswithmabthera rituxaninrashowthatpatientswhoareseropositive foreitheroftheseantibodiesaretwotothreetime lrochearengdiagnosticsindd glossary immunoassay alaboratorytestthatdetectsor measuresatargetsubstanceinasampleusing biomarker acharacteristicthatcanbemeasure animmunochemicalreactioninwhichanantibody andevaluatedasanindicatorofanormalbiological bindstoaspecificantigenthetargetcanbeadrug processadiseaseprocessoraresponsetoathera aproteinoravirusforexample peuticinterventionelevatedlevelsoftheprotein herincancerforexampleareabiomarkerfora immunohistochemistry ihc amethodofstaine highprobabilityofresponsetoherceptin biologicaltissuesamplestodeterminethepresence levelandlocationofspecificproteinsincellsusedin cell analysis methodsofmeasuringthepropertie thediagnosisofcancerandotherdisease ofcellsincludingtheirsizeandshapecellular parameterssuchasthepresenceofspecificprotein situ hybridisation ish amethodofstaine andcellularprocessessuchasproliferationand biologicaltissuesamplestoidentifythepresenceand growthcellanalysistechnologiesplayanimportant copynumberofspecificgenesorgeneticmutation roleindrugdevelopmentandproduction incellsusedinthediagnosisofcancerandother disease ce mark certification certificationthatanin vitro diagnosticivdproductcomplieswithallsafety polymerase chain reaction pcr alaboratory healthandenvironmentalrequirementsforuseinthe methodwidelyusedinresearchandindustrytomake europeanunioncertifieddiagnosticsarereferre millionsofcopiesofadnasequenceofinterest toasceivds veryquicklyrealtimepcrsimultaneouslyamplifie copiesandquantifiesthetargeteddnamolecule clinical chemistry abranchofdiagnosticscom prisingteststhatdetectandmeasurechangesin virology inmoleculardiagnosticstestingtodetect thechemicalcompositionofbodyfluidsandtissue certainseriousandprevalentviralinfectionseghiv todiagnoseorpredictthecourseofadisease andhepatitiscortomonitortheirtreatment dna sequence methodsofdeterminingthe orderofnucleotidesmolecularbuildingblocksin geneticmaterialknowinganindividualsdna sequencecanprovideinsightsintogeneticchange whichcontributetohumandiseaseorinfluence treatmentresponsehighthroughputtechnologie readthousandsofsequencesatonce human epidermal growth factor receptor aproteininvolvedinnormalcell growthandfoundatincreasedlevelsinsome cancersincludingsomebreastandgastriccancer cancercellsmaybetestedinthelaboratoryfor herlevelstohelpchoosethemostappropriate treatment lrochearengdiagnosticsindd roche business report diagnostic product launch diagnostic division major product launch business area product market quarter professional diagnostic elecsys immunoassay plgf placenta growth factor sflt eu q soluble fmslike tyrosine kinase diagnosis preeclampsia elecsy il interleukin immunoassay aid management eu q critically ill patient elecsys troponin assay test cardiacspecific troponin level eu q predict mortality risk patient acute coronary syndrome highsensitivity elecsys troponin immunoassay diagnosis eu q heart attack cardiac risk stratification q sysmex xti mid highthroughput hematology analyser contractual territory test capability blood body fluid emea q cobas c clinical chemistry module cobas analyser series eu q highthroughput laboratory throughput testshour cobas p cobas p automate storage retrieval modules eu q barcode primary secondary sample tube cobas c clinical chemistry module cobas analyser series eu q throughput testshour diabetes care accuchek mobile integrate lance blood glucose monitor eu q device employ unique strip technology replace test strip continuous tape test accuchek aviva nano accuchek performa nano sleeker version eu q accuchek aviva accuchek performa meter offer enhance feature set accuchek combo interactive insulin delivery system combine insulin eu q pump blood glucose meter broad datum management capability meter function pump remote control accuchek active new version exist meter feature extend eu q memory number failsafe capability molecular diagnostic lightcycler mrsa advanced test automate realtime pcrbase test eu q methicillinresistant staphylococcus aureus test identify mrsa carrier hour cobas p instrument amplilink software preanalytical eu q instrument unite primary tube handle fully automate sample prepa ration amplification detection molecular diagnostic cobas platform automate dna extraction realtime pcr eu q amplification detection test human papillomavirus chlamydia trachomatis neisseria gonorrhoeae apply science nimblegen ms fully automate highresolution microarray scanner worldwide q use nimblegen dna microarray xcelligence rtca dp dual plate system highly flexible mediumthroughput worldwide q system realtime noninvasive cell analysis lightcycler system highthroughput quantitative pcr analysis worldwide q magna pure highthroughput system prepare nucleic acid sample worldwide q pcr analysis tissue diagnostic inform egfr dna probe detect extra copy epidermal growth emea apac q factor receptor egfr gene abnormality associated nonsmall cell lung cancer benchmark xt advance stain instrument latam apac q benchmark ultra advanced staining system continuous random additional european processing stat capability market latam q japan q intend use confirm antiherneu primary antibody inform emea apac q dna probe expand include analytical claim perfor mance gastric breast tissue sample eu european union emea europe middle east africa apac asiapacific latam latin america united states lrochearengdiagnosticsindd major product launch plan business area product market quarter professional diagnostic cobas e immunoassay module cobas modular analyser series eu q highvolume laboratory throughput testshour q elecsy immunoassay eu qq cobas c cobas c clinical chemistry module cobas q modular analyser series throughput testshour respec tively cobas p cobas p automate storage retrieval module q barcode primary secondary sample tube cobas c advanced clinical chemistry module cobas modular eu q analyser series feature automate reagent loading enable consolidation broad test menu throughput testshour cobas b benchtop multiparameter analyser blood gas electrolyte eu q cooximetry metabolite use point care hiv combi min improved combination assay hiv antigen p eu q hiv antibodie enable reliable early detection infection human immunodeficiency virus diabetes care accuchek mobile integrate lance blood glucose monitor device additional eu employ unique strip technology replace test strip market qq continuous tape test apac q accuchek combo interactive insulin delivery system combine insulin additional eu pump blood glucose meter broad data management capability market q meter function pump remote control apac q qq accuchek aviva nano sleeker version accuchek performa meter qq offer enhance feature set molecular diagnostic lightcycler mrsa advanced test automate realtime pcrbase test q methicillinresistant staphylococcus aureus cobas ampliprepcobas taqman cmv ce ivd viral load monitoring test eu q enable physician improve management cytomegalovirus cmv disease solid organ transplant patient coba taqscreen dpx test multidye blood screening test design eu q simultaneously provide quantitative result parvovirus b qualitative result hepatitis virus cobas ampliprepcobas taqman hiv v secondgeneration test q unique dualtarget design enable detection separate region hiv genome cobas taqman hiv v ce ivd high pure virology test offer manual eu q sample preparation option customer lowvolume workload apply science gs junior system economical benchtop nextgeneration dna sequence worldwide q system small laboratory nimblegen cgx multiplex arrays microarray highresolution analysis worldwide q chromosomal abnormality capable analyse sample simultaneously xcelligence rtca ht instrument automate highthroughput cell analyse worldwide q screening seqcap ez exome v insolution enrichment capture technology target worldwide q nextgeneration sequence nextgeneration ultrahigh density nimblegen microarray worldwide qq tissue diagnostic dual colourdual hapten situ hybridisation ish kit enable target gene eu q detection control single slide use molecular marker specifically support test ventana antiher neu b primary antibody ventana dna eu qq probe ce ivds assess likelihood response herceptin treatment breast gastric cancer patient benchmark gx economical lowvolume advanced tissue stain platform eu apac q automates slide processing step bake stain ceivd molecular probe target enzyme topa cell surface eu qq receptor igfr use aid diagnose manage breast lung cancer discovery ultra platform immunohistochemistry situ hybridisation eu q research offer significant improvement ease use workflow apac japan flexibility latam q plan launch delay occur result adverse regulatory decision factor eu european union emea europe middle east africa apac asiapacific latam latin america united states lrochearengdiagnosticsindd read gene help save life day precision speed count modern molecular diagnostic work improve genome sequencer read build block highly variable gene matter day instead week long take achieve precision conventional sequence method day help extend improve live transplant patient currently investigate use sequencer hla human leukocyte antigen genotype blood stem cell stem cell transplantation perform treat number disease include leukemia donor recipient cell need hlacompatible possible treatment successful study show genome sequencer flx system power ful research tool highresolution hla genotype critical people need transplant close match donor recipient hla gene small risk transplant rejection life science research use diagnostic procedure bildstreckeengsindd bildstreckeengsindd corporate governance roche commitment stakeholder reflect operate business focus value creation management culture conform modern standard corporate governance group policy communicating transparently remuneration report roche success depend ability dedication people recognition form basis remuneration policy system lrochearengcorporate governanceindd corporate governance rochecomplieswithallrelevantcorporategovernance attheagmonmarchtheboardofdirector requirementsinparticularwithallapplicablelaws willnominatedeannejuliusandbeatriceweder theswissstockexchangesixswissexchange dimauroforreelection totheboardandarthurd directivesincludingthecommentariestheretoand levinson william burn election new theswisscodeofbestpracticeforcorporategover member board term year nancepromulgatedbytheswissbusinessfederation asprovidedbythearticlesofincorporationpeter economiesuissethecompanysinternalgovernance brabeckletmatheandhorstteltschikhavedecide frameworkparticularlyitsarticlesofincorporation toretireasmembersoftheboardofdirectorsafter andbylawsembodiesall theprinciplesneededto manyyearsofdistinguishedservicetheboardof ensurethatthecompanysbusinessesaremanage directorsthanksfortheirdedicationandtheirmany andsupervisedinamannerconsistentwithgood contributionstoroche corporategovernanceincludingthenecessarycheck andbalances corporate executive ourprintedannualreportcontainsselectedlinksto committee therochewebsitewwwrochecomreadersare thusprovidednotonlywithasnapshotofourcom panyatthereportingdatebutarealsodirectedto william burns ceo division roche pharma sourceswhichtheycanconsultatanytimeforupto ceutical jrgen schwiezer ceo division roche date informationabout corporate governance diagnosticsandjonathanknowlesasheadgroup rochewhereaseachannualreportcoversasingle researchretiredondecemberandtherefore financialyearendingdecemberourwebsite steppeddownasmembersofthecorporateexecutive containsinformationofamorepermanentnaturea committeetheboardofdirectorsthankstheleave wellasthelatestrochenewsamendmentsto membersofthecorporateexecutivecommitteefor ourcompanysarticlesofincorporationandbylaw theirdedicationandtheirmanycontributionstoroche andchangesinthecurriculavitaeofthemember oftheboardofdirectorsandthecorporateexecutive theboardofdirectorsofrocheholdingltdwill committee publish timely fashion nominatewilliammburnsforelectiontotheboard ourwebsitewheretheycanbeaccessedbyanyone attheagmonmarch lookingforthisinformation aspartofthegenentechtransactionpascalsoriot wasappointedasceoofgenentechincandas board director anewmemberofthecorporateexecutivecommittee inaprilpascalsoriotrelinquishedhisrole attheth annualgeneralmeetingagmof asceogenentechincasofdecemberand rocheholdingltdonmarchshareholder wasappointedascoodivisionrochepharmaceu reelectedjohnibellandrhoffmannandfranzb ticalsstartingonjanuary humerasmembersoftheboardofdirectorsfor atermofthreeyearsasprovidedbythearticlesof incorporationatitsorganisingmeetingimmediately followingtheagmtheboardofdirectorshas approveditscommitteesstructureanditscommittee membershipsasshownonpage httpwwwrochecomaboutrochecorporategovernancehtm lrochearengcorporate governanceindd roche business report corporate governance board director december leave dr franz b humer prof bruno gehrig andr hoffmann prof pius baschera prof sir john irving bell peter brabeckletmathe lodewijk jr de vink dr andreas oeri dr deanne julius walter frey prof beatrice weder di mauro prof horst teltschik dr wolfgang ruttenstorfer lrochearengcorporate governanceindd board director year birth term end elect board director dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e dr wolfgang ruttenstorfer b e prof horst teltschik b e prof beatrice weder di mauro b e new propose member board director nominate election annual general meeting william burns march dr arthur levinson secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january lrochearengcorporate governanceindd roche business report corporate governance corporate executive committee december leave dr severin schwan william burns dr jrgen schwiezer dr erich hunziker silvia ayyoubi prof jonathan knowles dr gottlieb keller pascal soriot burkhard g piper osamu nagayama perolof attinger richard scheller ren kissle right new member january leave daniel jeanjacque garaud dan zabrowski lrochearengcorporate governanceindd corporate executive committee year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceutical dr jrgen schwiezer ceo division roche diagnostic prof jonathan kc knowles head group research dr gottlieb keller general counsel silvia ayyoubi head human resource pascal soriot ceo genentech inc coo division roche pharmaceutical january daniel oday coo division roche diagnostic enlarge corporate executive burkhard g piper head business area roche diabete care committee perolof attinger head communications osamu nagayama president ceo chugai richard scheller head genentech research early development gre head roche pharma january jeanjacques garaud research early development pre dan zabrowski head pharma partnering secretary corporate executive committee ren kissle kpmg klynveld peat marwick goerdeler sa reporting year statutory auditor kpmg ag roche holding ltd auditor charge john morris chief compliance officer dr urs jaisli member december new member january leave daniel jeanjacque garaud dan zabrowski lrochearengcorporate governanceindd roche business report corporate governance asofjanuarydanielodaywasappointedas majorshareholdersarelistedinthefinancereport coodivisionrochediagnosticsandasanew note roche group consoli memberofthecorporateexecutivecommitteea date financial statement equity attributable ofdecemberburkhardpipersteppe roche shareholder related party downasamemberoftheenlargedcorporateexecu pagesandandinnotetothefinancial tivecommitteeandisreportingtodanieloday statement roche holding ltd significant shareholderspage inaprilrichardschellerwasappointedto andrhoffmannvicechairmanoftheboardof theenlargedcorporateexecutivecommittee directorsandandreasoerimemberoftheboard hereportsdirectlytogroupceoseverinschwan ofdirectorsandchairmanoftheboardscorpo astheformerheadofgenentechresearchhe rategovernanceandsustainabilitycommittee leadsgenentechsresearchandearlydevelopment serveintheirrespectivecapacitiesontheboardand gredwhichwilloperateasanindependentcentre committee representative share withintherochegroup holdersgroupwithpooledvotingrightsandreceive theremunerationsetforthintheremuneration jeanjacque garaudwasappointedasheadof reportonpageandinthefinancereport rochepharmaresearchandearlydevelopment notetotherochegroupconsolidatedfinancial predandasanewmemberoftheenlarge statementsrelatedpartiespageandnote corporateexecutivecommittee tothefinancialstatementsofrocheholdingltd boardandexecutiveremunerationpage danzabrowskiasheadofpharmapartneringwas nootherrelationshipsexistwiththeshareholder appointedasanewmemberoftheenlargedcorpo withpooledvotingright rateexecutivecommittee therearenocrossshareholding capital structure information relate informationonrochescapitalstructureisprovide inthefinancereportnotestothefinancial corporate governance statement roche holding ltd additionaldetailsarecontainedinthe group structure shareholder articlesofincorporationofrocheholdingltd rochesoperatingbusinessesareorganisedinto changesinequityaredetailedinthefinance twodivisionspharmaceuticalsanddiagnosticsthe report note financial statement pharmaceuticalsdivisioncomprisesthetwobusiness rocheholdingltdpage segment roche pharmaceutical chugai thecompanyhasasharecapitalof whereasgenentechastheformerthirdsegmentha swissfrancsdividedintofullypaid beenintegratedintorochepharmaceuticalsthe bearershareswithanominalvalueofswissfranc diagnostic division consist follow eachtherearenorestrictionsontheexercise businessareasappliedsciencediabetescare ofthevotingrightsofthesesharesupondeposit moleculardiagnosticsprofessionaldiagnosticsand sharescanbevotedwithoutanyrestriction tissuediagnosticsbusinessactivitiesarecarriedout thereisnoauthorisedorconditionalcapital throughgroupsubsidiariesandassociatedcompa inadditionnonvotingequity niessignificantsubsidiariesandassociatedcom securitiesneshavebeenissuedinbearerform paniesarelistedinthefinancereportnoteto therochegroupconsolidatedfinancialstatement httpwwwrochecomaboutrochecorporategovernance subsidiariesandassociatespagesto articleofincorporationhtm lrochearengcorporate governanceindd theydonotformpartofthesharecapitaland withtheexceptionoffranzbhumernoneofthe confernovotingrightseachnesconfersthesame membersoftheboardofdirectorshasbeena right share participate available memberofrochescorporateexecutivecommittee earningsandinanyliquidationproceedsfollowe orservedinanexecutivecapacityatanygroup repaymentofthesharecapitalrochesne subsidiaryduringthethreefinancialyearsprecede andtherightspertainingtheretoincludingthe thecurrentreportingperiod provisionsprotectingtheinterestsofnesholder theinternalorganisationoftheboardofdirector aredescribedinofthearticlesofincorporation andthedivisionofauthorityandresponsibilitie ofrocheholdingltd betweentheboardandmanagementtheremitsof information debt instrument theboardcommitteesandtheinformationand beenissuedandonoutstandingbondsisprovided controlmechanismsavailabletotheboardinit finance report note roche dealingswithcorporatemanagementaregoverne groupconsolidatedfinancialstatementsdebt bythebylaw board director roche holding ltd additionalinformationonemployeestockoption organise ensure group isprovidedinthefinancereportnoteto business conduct responsibly therochegroupconsolidatedfinancialstatement focusonlongtermvaluecreationtothisendthe employeestockoptionsandotherequity roche board delegate certain responsibility compensationbenefitspage committee composition rochehasissuednooptionsapartfromemployee chairperson january describe stockoptionsstocksettledstockappreciation committee authority rightsssarsandoptionsissuedinconnection responsibility define detail bylaw withdebtinstrument board director neithertheoptionsawardedtoemployeesnor allthecommitteesexceptthepresidiumarechaire thedebtinstrumentswhichhavebeenissuedhave byindependentdirector anyeffectonrochessharecapital accordingtothebylawsoftheboardofdirector attherequestofanyofitsmembersaboard board director corporate executive meeting chairman present committee convene roche board meet year informationoneachmemberoftheboardof assessthechairmansperformancethismeete director include year attend chairman chair electedandtheyearsinwhichtheirtermsend byoneofthevicechairman member corporate executive committeeislistedonpagestocurricula vitaeandotherinformationincludinginformation httpwwwrochecomaboutrochemanagement boardofdirectorshtm board membership available httpwwwrochecomaboutrochemanagement internet executivecommitteehtm theannualgeneralmeetingelectsthemember httpwwwrochecomaboutrochecorporategovernance oftheboardofdirectorsinstaggeredelection articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance inwhicheachnomineeisvotedonseparatelysee annualgeneralmeetingshtm article incorporation roche httpwwwrochecomaboutrochecorporategovernance hold ltdand minutes thannual articleofincorporationhtm general meeting roche holding ltd hold httpwwwrochecomaboutrochecorporategovernance committeeshtm march httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance theboardofdirectorshasestablishedasystemof remunerationcommitteethreemeeting controlswhichiscontinuouslymonitoredbythe approxtohourseach auditcommitteeandbythecorporategovernance themembersofthecorporateexecutivecommittee andsustainabilitycommitteeandconsistsofthe areinvitedtoattendforandreportinpersonon followingelements agenda item concern reportsonfinancialandoperatingrisksrisk situation warrant member enlarge managementsystem corporateexecutivecommitteemayalsobeinvite systemofinternalcontrolsoverfinancialreport toattendtheboardcommitteesinvitethechair ingseepageandinthefinancereport man board corporate executive internalaudit committeememberstodeliverreportsatcommit groupcomplianceofficerandcompliance tee meeting elect commission officersinsubsidiarie independentexpertreportsandcallontheservice safetyhealthandenvironmentalprotection consultant risk management system department subject continuous review finding corporatesustainabilitycommittee present audit committee scientificandethicsadvisorygroupseag board internalauditregularlybriefstheaudit forissuesrelatingtogeneticsandgeneticengi committeewithreferencetoongoingauditreport neeringestablishedin membersofinternalauditattendauditcommittee eachyearseveralblackoutperiodsareimpose meetingsasdoexternalauditorsforinformation duringwhichsenioremployeesareprohibitedfrom ontheexternalauditorsseepage tradingincompanystockthefollowingblackout management contract fall periodsareineffectfor scope subsection decembertofebruary sixdirectiveoninformationrelatingtocorporate apriltoapril governance junetojuly octobertooctober remuneration shareholding loan blackoutperiodscanbechangedbythechairman alldetailsregardingremunerationshareholding oftheboardofdirectorsifcircumstanceswarrant andloansaresetforthintheseparateremuner intheboardofdirectorsmetforfivemeet ationreportonpagestoandinthefinance ingseachfromtohoursinlengthoncefora reportnotesandtotherochegroup fulldaymeetingandonceforathreedayvisit consolidatedfinancialstatementsequityattribut toamajorsubsidiarywhichincludedaboardof abletorocheshareholdersandrelatedpartie directorsmeetingtheboardcommitteesmet pagesandandarelistedinthenote asfollowsin andtothefinancialstatementsofrochehold presidiumoftheboardofdirectorsnomination ing ltd board executive remuneration committeethreemeetingsapproxhour boardandexecutiveshareholdingspages auditcommitteefourmeetingsapproxto hourseach corporategovernanceandsustainabilitycom mitteethreemeetingsapproxhourseach remuneration committee member permit con tribute attend remuneration committee meeting matter concern deliberate decide figure indicate actual length meeting additional information provide finance report note include director extensive premeeting preparation roche group consolidated financial statement risk postmeete followup activity management lrochearengcorporate governanceindd participatory right shareholder auditcommitteeseearticleofthebylaw theparticipatoryrightsofshareholdersaredefine thestatutoryauditorsparticipatedinallfour inrochesarticlesofincorporation asroche meetingsoftheauditcommitteein sharesareissuedtobearertherearenorestriction onadmissiontoannualgeneralmeetingswith thereportsofstatutoryauditorsontheconsoli theexceptionthatsharesmustbedepositedwithin datedfinancialstatementsandonthefinancial aspecifiedperiodbeforethedateofameeting statementscanbefoundonpagesand andanadmittancecardmustbeissuedintheshare respectivelyofthisyearsfinancereport holder nameasprovidedinofthearticle incorporation shareholder elect kpmgreceivedthefollowingremunerationfor berepresentedbyanothershareholderatanannual theirservicesasstatutoryauditorsofrochehold general meeting article incorporation ingltdandotherrochecompanie contain restriction exercise voting right quorum requirement stipulate conformity millions chf swiss codeofobligation auditing service underofthearticlesofincorporation auditrelated service shareholdersrepresentingshareswithanominal tax consultancy service valueofatleastmillionswissfrancscanrequ total theplacementofitemsontheagendaofan annualgeneralmeetingthismustbedoneno thestatutoryauditorsareelectedeachyearbythe laterthandaysbeforethedateofthemeete annualgeneralmeeting change control defensive measure ernstyoungltdreceivedthefollowingremunera thearticlesofincorporationcontainnoprovision tionfortheirservicesastheauditorsofgenentech onthemandatorybidruleswisslawapplie andchugai therearenochangeofcontrolclausesthose componentsofremunerationbasedonrochene wouldbeterminatedintheeventofanacquisition millions chf andvestingperiodrestrictionsonpreexiste chugai genentech awardswouldberemovedsothatallsuchoption chugai audits couldbeexercisedimmediately consult service provide genentech relationship statutory auditor chugai attheannualgeneralmeetingofrocheholde total ltdonmarchtheshareholdersvote toappointkpmgagkpmgasstatutoryauditor informationonhowlongtheauditorsandauditor inchargehavebeenservinginthesecapacitiesis providedonpagethestatutoryauditor participateinauditcommitteemeetingstheypre httpwwwrochecomaboutrochecorporategovernance parewrittenandoralreportsontheresultsoftheir articleofincorporationhtm auditstheauditcommitteeoverseesandassesse httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm theauditorsandmakesrecommendationstothe httpwwwrochecomaboutrochecorporategovernance boardforinformationontheresponsibilitiesofthe articleofincorporationhtm lrochearengcorporate governanceindd roche business report corporate governance information policy irregularitiesorcomplaintsintheircorresponding provide article incorpora motherlanguageviaaspeakup hotlinethe tion corporatenoticesarepublishedintheswiss chiefcomplianceofficerreportsregularlytothe official gazette commerceandinotherdaily corporategovernanceandsustainabilitycommittee newspapersdesignatedbytheboardofdirector basler zeitung finanz und wirtschaft lagefi nonapplicabilitynegative disclosure le temps neue zrcher zeitung itisexpresslynotedthatanyinformationnot rochereportsitshalfyearandfullyearresultsin containedormentionedhereinisnonapplicable businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative formatsandatmediaeventsinadditiondetaile declarationasprovidedinthesixswissexchange firstandthirdquartersalesfiguresarepublishe corporategovernancedirectiveandthecom eachyearinaprilandoctoberthemostcurrent mentarythereto listofpublicationdatesisavailableinenglishand germanontheinternet allrelevantinformationanddocumentsinclude allmediareleasesinvestorupdatesandpre sentationstoanalystandinvestorconferencesare availableontheinternetfurtherpublication canbeorderedbyemail faxortelephonebasel webmasterrochecomtel fax thecontactaddressforinvestorrelationsis f hoffmannla roche ltd investor relations corporatefinancebaselswitzerland telfax additionalinformationincludingdetailsonspecific contactpersonsisavailableontheinternet chief compliance officer thechiefcomplianceofficerwithhiscompliance officersnetworkiscommittedtoensuringthat rochecorporateprinciplesareconsistentlycom pliedwiththroughouttherochegroupand alsoservesasacontactpersonforshareholder employeescustomerssuppliersandthegeneral publiconissuesrelatingtotheimplementationof andcompliancewiththeseprinciplesemployees andotherpartieswhobecomeawareofviolation ofrochecorporateprinciplescanbringthem totheattentionoftheirmanagersorsupervisorsor reportthemtothechiefcomplianceofficerur jaislidirectphonenumber emailursjaislirochecomsuchdisclosures httpwwwrochecommediahtm willbetreatedconfidentiallyinadditionasofthe httpwwwrochecominvestorshtm endofemployeesmayanonymouslyreport httpwwwrochecominvestorscontactshtm lrochearengcorporate governanceindd remuneration report summary tionpolicyisdesignedtofostervaluecreationand rochessuccessdependsontheabilitiesand reinforceacultureofperformanceandinnovation dedicationofitspeoplerecognitionofthisforms anditappliestononmanagerialemployeesaswell thebasisofourremunerationpolicyandsystem astomanagersthekeyprinciplesunderpinningthis policyare oneoftheprimaryaimsofourremunerationpolicyis focusonvaluecreation toencouragealongtermfocusandalignmanage payforperformance mentsinterestswiththeinterestsofrochesshare enablingemployeestoshareinthecompany holdersandholdersofrochesnonvotingequity success securitiesne fairnessandtransparencyinremuneration decision thisremunerationreportwillbesubmitte abalancedmixoflongandshortterm separatelyforapprovalattheannualgeneral remunerationcomponent meet marketcompetitiveness theremunerationofcorporateexecutive committeececmembersandothersenior basepaybonusesblockednonvotingequity rocheexecutivesiscomprisedof securitiesnesawardsofstocksettledstock basesalary appreciationrightsssarsandaperformance bonus shareplansupporttheseprinciplestheseremu specialstockawardsnonvotingequity nerationcomponentsarelinkedtoourcompanys securitiessubjecttovestingperiodyear financialperformanceandcommercialsuccessand stocksettledstockappreciationright thusaligntheinterestsofrocheemployeeswith ssar thoseoftheshareholderstheamountoftheseparate performanceshareplanpspawards componentsofremunerationforeachindividual withtheexceptionofseverinschwanandsilvia memberofthecorporateexecutivecommitteeis ayyoubinoneofthececmembersreceivedan shownintheindividualdescriptionoftheremunera increaseinbasesalaryin tionofthecorporateexecutivecommitteeinthis basedonrochessharepriceperformanceno report neswillbeawardedforthepspcycle thessarsgrantedinand base pay havestrikepricesabovethecurrentnespriceand basepaylevelsaredeterminedaccordingtomarket havenovaluefortherecipientsthiscanchange dataforspecificpositionsandindividualemployees ifrochesfuturenespriceimprove abilitiesexperienceandperformanceovertimepay therehasbeennochangeinthebaseremunera increasesarelinkedtoindividualperformanceand tionoftheboardofdirectorssince stock optionsstocksettle stock appreciation right pleaseseetherestofthisreportforfulldetail ssar april base pay corporate executive remuneration policy committee generally increase time gottlieb keller result difference base pay rochefundamentallyreneweditsremunerationpolicy receive calendar year table inandreviseditwithminorchangesin increase base pay april itispartofaframeworkofemployeepoliciesaimedat finance report note roche group consolidate financial statement relate party motivatingandretainingcurrentemployeesattracting note financial statement roche holding talentednewonesandhelpingallrocheemployee ltd board executive remuneration board execu toperformatconsistentlyhighlevelsourremunera tive shareholding lrochearengremuneration reportindd roche business report remuneration report alsotakeintoaccountprevailingmarketcondition isbasedonathreeyearcomparisonofthetotal affordabilityandthecompanysoveralleconomic shareholderreturntsrwithcompetingcompa situation niesintherewerethreeoverlappingperfor mancecyclespsppspand bonus pspofwhichpspclose bonusesareawardedinrecognitionofindividualcon ondecember tributionstovaluecreationwhichgobeyondnormaljob expectationsandtheyaremeanttobeanincentive detailsforthepspcalculationandaddi tocreateorstrengthennewbusinessopportunitie tionalinformationaresetforthinremuneration andstriveforoutstandingresultsbonusamountsare ofmembersofthecorporateexecutivecommittee linkedtogroupordivisionalbusinessperformance dperformanceshareplanpsppage achievement individual functional measurableandqualitativeperformanceobjective remuneration board director theremunerationcommitteeoftheboardofdirector corporate executive committee define corporate executive committee eachyeartheremunerationcommitteewhichis membersbonusesindecemberbasedonresult entirelycomprisedofindependentexternalmember achievedfor oftheboardofdirectorssetsremunerationforthe membersoftheboardofdirectorsandthecorporate special stock award executivecommitteecashpaymentsbonuse innonvotingequitysecuritieshavebeen optionsstocksettledstockappreciationrightsand grantedtoaselectednumberofrocheemployee policydecisionsaboutpensionbenefitstheterm theawardsvestimmediatelybutareblockedfor oftheperformanceshareplanaredeterminedannu threeyearsrecipientshavetheoptiontoextendthe allybytheboardofdirectorsactinguponrecommen blockingperiodtotenyearsthegrantofthosenon dationsfromtheremunerationcommitteethe votingequitysecuritieswasawardedaspartofthe remunerationcommitteecontinuouslytrackssalary bonuspaymentsforwiththeaimtobothimme trendsinthemarketandreportstotheboardof diatelyrewardtheachievementofspecificobjective directorsinformationonthiscommitteesremitand andtofostertheinterestinalongtermpositive itsproceduresformakingremunerationdecision development canbefoundinthebylawsoftherocheboardof director stocksettle stock appreciation right ssar stocksettledstockappreciationrightswereintro followingtherevisionoftheremunerationpolicy ducedonjanuarythusestablishingauniform includingmarketcomparisonswiththeworldsmajor systemofremunerationthroughoutrochessar pharmaceuticalcompaniestheremunerationcom entitleholderstobenefitfinanciallyfromanyincrease mitteehasdeterminedthebonusesandremuneration inthevalueofrochesnonvotingequitysecuritie ofthechairmanoftheboardofdirectorsthemem betweenthegrantdateandtheexercisedatedetaile bersofthecorporateexecutivecommitteetakinginto informationisavailableonpageandpageto considerationpersonnelchangesindoingsothe followingchangeswerenote performance share plan themembersofthecorporateexecutivecommittee peer set abbott laboratories amgen astella astra andothermembersofseniormanagementcurrently zeneca bayer becton dickinson biogen idec bristolmyers someindividualsworldwideparticipateinthe squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer sanofiaventis takeda performanceshareplanpspthepspwasestab httpwwwrochecomaboutrochecorporategovernance lishedinforperiodsofthreeyearseachand articleofincorporationhtm lrochearengremuneration reportindd afurtherimportantstepforthetransferofdutie boardofdirectorsandbyeachmemberofthecorpo fromthechairmantotheceohasbeencomplete rateexecutivecommitteeforincomparison withthecompletionoftheintegrationofgenen withfiguresforpreviousyearsandanoutlookonthe techaccordinglytheboardplanstoreducethe chairmansremunerationdevelopmentfor chairmansbasepayinfordetailedinfor mationseepage remuneration ondecemberwilliammburnsjonathan remuneration member board kcknowlesandjrgenschwiezerretiredfrom director inthemembersoftheboard company consequently step ofdirectorsreceivedtheremunerationshown membersofthecorporateexecutivecommittee inthetableremunerationofmembersoftheboard asofjanuarydanielodayhastaken ofdirectorsbelowfortheirboardactivitie overaschiefoperatingofficercooofthe diagnosticsdivision remunerationofallmembersoftheboardofdirector asofjanuarypascalsoriothastakenover willagainremainunchangedforthenon hisnewfunctionascooofthepharmaceuticals executivemembersoftheboardofdirectorswerenot division awardedanysharesnonvotingequitysecuritie thefollowingpagesprovidedetailedinformationon list member position committee mem theremunerationearnedbyeachmemberofthe berships chairmanship remuneration member board director additional compensation remuneration committee memberschairs chf chf additional special compensation fb humer remuneration chairman board director b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik compensation serve board roche subsidiary b weder di mauro exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair g high total remuneration member board director remuneration serve vicechairman board lrochearengremuneration reportindd roche business report remuneration report remuneration member corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee stocksettledstockappreciationrightsssar dollarsswissfrancsforherparticipation stockoptionsorrestrictedstockunitsrsusin atacourseonauditcommitteesinaneweraof horstteltschikreceivedhonorariaamountingto governanceatharvardbusinessschool eurosswissfrancsforservingon theboardsofseveralrochesubsidiariesingermany stock optionsstocksettle stock appreciation right beatricewederdimaurowasreimbursedus ssar bonus bonus bonus bonus special stock award block nonvoting equity security cash payment block value total cash payment cash payment chf number period year chf chf chf chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee day value grant nonvoting equity security chf ne calculation value consideration reduction value block period reduce market value year year exclude contribution ahvivalv swiss social security programme provide retirement disability unemployment benefit day value grant nonvoting equity security chf ne calculation value consideration reduction value block period reduce market value year lrochearengremuneration reportindd forthemembersoftheboardofdirectors b bonus receivedremunerationtotallingswiss inthebonusforsomeofthemembersofthe franc corporateexecutivecommitteeisdividedintwopart forthreeortenyearsblockednonvotingequity noadditionalremunerationwaspaidtomembersof securitiesgrantedinand theboardofdirector cashpaymentdueforpaymentattheendof april remuneration member corporate executive committee thegeneralprovision withtheelementofblockednonvotingequity assigningauthorityfordecisionsoncorporateexecu securitiesthebonusreflectsanevenstrongerlink tivecommitteeremunerationtotheremuneration tothelongtermperformanceofthecompany committeeandtotheboardofdirectorsareoutline onpageofthisremunerationreportfor themembersofthecorporateexecutivecommittee remuneration member board director receivedremunerationtotallingswiss remuneration member corporate executive franc committee af h exclude ahvivalv c stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee stock optionsstocksettle stock appreciation right ssar blackschole value describe stock optionsstocksettle stock appreciation right ssar value accord annual report atthepresenttimethestocksettledstockappreci franciscofrommarchtodecember ationrightsgrantedinandmostof receivedallowancesandtaxequalisationtotalle whichcannowbeexercisedfollowingtheendof swissfranc thevestingperiodinfebruaryhavenovaluefor therecipient membersofthecorporateexecutive committeeadditionallyreceiveannualexpenseallow ancesofswissfrancstotallingswiss strike price table stock option ssar francswhilepascalsoriotwhowasbasedinsan lrochearengremuneration reportindd roche business report remuneration report performance share plan psp thesecuritiesmarketpricesanddividendyield themembersofthecorporateexecutivecommittee ieontotalshareholderreturntsrtoreducethe andothermembersofseniormanagementcurrently effectofshorttermmarketfluctuationssecurity someindividualsworldwideparticipateinthe pricesareaveragedoverthethreemonthsoctoberto performanceshareplanpsp decemberpriortothestartofaperformancecycle andoverthethreemonthsoctobertodecember inthepspmovedtooverlappingthreeyear attheendofthecycleifrochesecuritiesperform performancecycleswithanewcyclebeginningeach aswellasorbetterthanthoseofofthepeer yearintherewerethusthreecyclesinprogress setandinadditionrochestsrincreasesatleast psppspandpsp duringacycletheboardofdirectorscanelect thepspendedondecember toincreasethemaximumnesawardbyasmuch astwofoldintheeventthataninvestmentinroche undertheprovisionsofthisplananumberofnon securitiesunderperformstheaveragereturndelivere votingequitysecuritiesneshavebeenreservedfor bythepeercompaniesfewerornoneswillbe theparticipantsineachcyclethenumberofsecu award ritiesactuallyawardedwilldependonwhetherandto whatextentaninvestmentinrochesecuritiesshare inneswerereservedundertheplanformember andnesoutperformstheaveragereturnonan ofthecorporateexecutivecommitteeasshownin investmentinsecuritiesissuedbyapeersetofcom paratorcompaniescomparisonsarebasedon footnote performance share plan psp total estimate total estimate value value value psp award psp award psp award target number target number ne ne psp ne psp award psp value chf value chf value chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total member corporate executive committee total estimate value psp originally target ne award psp estimate value calculate yearend price december chf non vote equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time ie year board director vote actual allocation ne originally target december december respectively accord tsr achieve detailed calculation annual report lrochearengremuneration reportindd thetableonpagetheboardofdirectorswill nonvotingequitysecuritiesnesuptoanamount decideontheactuallevelofnesorcashequivalent equaltooftheirannualsalaryatadiscount awardsfor cycle nespurchasedunderthisplanaresubjecttoa close theandfinancialyears holdingperiodwhichisfouryearsinswitzerland respectivelytheaimofthepspistoprovidean incentivetoparticipantstoachievesteadyvalue f remuneration emolument loan growth gottliebkellerreceivedanonrecurringspecial payment swiss franc year attheendofthepspcyclebasedona serviceforthecompanyin pensionstotalle threemonthmovingaverageatconstantexchange swissfrancswerepaidtotwoformer rateswithdistributeddividendstotallingbil corporateexecutivecommitteemembersfour lionswissfrancsbillionswissfrancs membersofthecorporateexecutivecommittee billionswissfrancsbillion receivedatotalofusdollarsswiss swissfrancsthetsroftherochesecuritiesne francsforservingonthechugaiboard andsharesrankedcomparedwithitspeer setofcompaniesoperatinginthesameindustry g high total remuneration member thereforeaccordingtothetermsoftheplanthe board director participantsreceivednoneoftheoriginallytargete franzbhumerasthechairmanwasthemember nesseetableonpagefordetail oftheboardwiththehighesttotalremunerationfor seeremunerationofmembersoftheboard e indirect benefit ofdirectorspagetothechairmansremu employercontributionsmadeintosocialsecurity nerationconsistsofbasesalaryandbonusaward schemespensionplansandagroupwideemployee chairman board handover stockpurchaseplanrocheconnectinrespect executivefunctionasceoattheannualgeneral ofmembersofthecorporateexecutivecommitteeare meeting march receive showninthetableindirectbenefitsinbelow additionalssarsornesfromnewpspcyclesand rocheconnectisavoluntarystockpurchaseplan wasnolongerenrolledinanyrochestockoption offeringemployeestheopportunitytobuyroche planorssar indirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service chf chf chf chf schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit lrochearengremuneration reportindd roche business report remuneration report theboardofdirectorsintendstoreducethechair familieswhoarecloselyassociatedwiththembelong mansbasesalaryintomillionswissfranc toashareholdergroupwithpooledvotingright asofaprilhistotalremunerationinclude attheendofthisgroupheldshare bonusescontributionstopensionfundsandaddi ofissuedsharesdetailedinformationabout tionalcompensationexpenseallowancewilldepend thisgroupcanbefoundinthefinancereportnote ingontheachievementofobjectivesnotexceedthe totherochegroupconsolidatedfinancialstate maximumamountofmillionswissfrancs mentsrelatedpartiespageandinthenote tothefinancialstatementsofrocheholdingltd h high total remuneration member significantshareholderspageinadditiona corporate executive committee ofdecemberthemembersoftheboard severin schwan ceo member ofdirectorsandpersonscloselyassociatedwiththem corporateexecutivecommitteewiththehighesttotal andthemembersoftheexecutivecommitteeand remunerationforseeremunerationofmem personscloselyassociatedwiththemheldsharesand ber corporate executive committee af nesasshowninthetableonpage pagetopagenoadditionalremunerationwas pay current member corporate stock optionsstocksettle stock appreciation executive committee right ssar atdecemberfranzb humerbeingtheonlymemberoftheboardofdirec security holding directorsandrhoffmann torsholdingoptionsandasofjanuaryssar andandreasoeriandmembersofthefounder duetohisformerpositionasceoandthemember high total remuneration member board director chf chf salary cash bonus special stock award year block nonvoting equity security total performance share plan total award pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo annual report bonus form year block nonvoting equity security nonvoting equity security nes day value grant nonvoting equity security chf ne calculation value include contribution ahvivalv consideration reduction value block period reduce market value year franz b humer psp psp originally target ne award psp award mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include additional compensation committee member payment tax consulting service remuneration serve chugai board include employer contribution ahvivalv chf lrochearengremuneration reportindd high total remuneration member corporate executive committee chf chf salary cash bonus special stock award year block nonvoting equity security total ssar blackschole value grant minus performance share plan total pension fundsmgb roche connect total value detailed information annual report calculation remuneration member corporate executive committee b bonus blackschole value describe stock optionsstocksettle stock appreciation right ssar basic rule detailed calculation remuneration member corporate executive committee performance share plan footnote respectively mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance payment tax consulting service remuneration serve chugai board exclud e employer contribution ahvivalv payment ofthecorporateexecutivecommitteeheldoption forreasonsotherthanretirementwhileveste andstocksettledstockappreciationrightsssar optionsmustbeexercisedwithinalimitedperiodof firstintroducedonjanuaryasshowninthe timethefairvalueoftheoptionsiscalculatedat tablestockoptionsandssarson thedateofissueusingtheblackscholesformula andasiftheoptionsweretradablewithan alloftheoptionsshowninthetablewereissuedby deductionfortheaveragetwoyearvestingperiod rocheasemployeestockoptionseachoptionentitle theholdertopurchaseonerochenonvotingequity thessarsshowninthetableonwere securityne introducedbyrocheonjanuaryinplace ofstockoptionsssarsentitleholderstobenefit underthetermsofthismultiyearoptionplanthestrike financiallyfromanyincreaseinthevalueofroche priceforoptionsshownwastheclosingpricefor nesbetweenthegrantdateandtheexercisedate rochenesonthelastdayoftradingpriortotheroche thestrikepriceforssarsunderthetermsofthis annualmediaconferencealloftheoptionsshown multiyearplanwastheclosingpriceforrochene arenontradableonethirdoftheoptionsaresubject onthefirstdayoftradingaftertherocheannual toavestingperiodofoneyearonethirdhavea mediaconferenceallssarsvestwithinthreeyear vestingperiodoftwoyearsandonethirdaveste ofthegrantdateieonethirdvestattheendof periodofthreeyearsunvestedoptionslapsewithout oneyearonethirdattheendoftwoyearsandone compensationifemploymentisterminatedvoluntarily thirdattheendofthreeyearsvestedssarsmust lrochearengremuneration reportindd roche business report remuneration report security holding december close relative share ne security holding number number numbertype number board director fb humer stock option ssar b gehrig hoffmann ubs longshort certificate link roche bearer sharesroche nonvoting equity securities valor isin ch otc option ubs ag roche nonvoting equity securities valor p baschera ji bell p brabeckletmathe ljr de vink american depository receipts adr rhhby isin w frey da julius nes oeri ubs longshort certificate link roche bearer sharesroche nonvoting equity securities valor isin ch w ruttenstorfer h teltschik b weder di mauro total nes corporate executive committee schwan ne stock option ssar ayyoubi stock option ssar wm burn stock option ssar e hunziker stock option ssar ga keller ne stock option ssar jkc knowle stock option ssar j schwiezer stock option ssar p soriot stock option ssar total ne share hold shareholder group pool voting right list sharesettle loan transaction august report swiss exchange lrochearengremuneration reportindd stock option ssar number stock option ssar hold current member corporate executive committee december ssar issue total corporate execu tive committee schwan ayyoubi wm burn e hunziker ga keller jkc knowles j schwiezer p soriot total corporate executive commit tee member fb humer strike price chf market price ne december chf expiry date grant value option start ssar chf blackschole value minus ssar stock option franz b humer receive additional ssar beexercisedconvertedintoneswithinsevenyear strike price expiry date grant value ofthegrantdateandunexercisedssarslapse optionsandssarsareshowninthetableabove withoutcompensationthefairvalueoftheoption thenumbersofoptionsandssarsascalculate iscalculatedatthedateofissueusingtheblack atthetimeofissuehavebeenenteredasvaluesin scholesformulaandasiftheoptionsweretradable thetableremunerationofmembersofthecorporate withandeductionfortheaveragetwoyear executivecommitteecstocksettledstockappre vestingperiod ciationrightsssarsonpage lrochearengremuneration reportindd s sharpen weapon fight advanced breast cancer biotechnology infancy thirty year ago guessed day rise completely new class powerful target medicine monoclonal antibodie mab today mab successfully fight cancer treat rheumatoid arthritis take courage skilful management longterm commitment enable roche invest technology early stage skill dedication people vital transforming mabs medical business success story today third roche drug base biotechnology new approach join mab chemotherapy promise treatment cancer target few effect tdm novel antibodydrug conjugate combine antitumour strategy medicine direct bind monoclonal antibody highly express cancer protein lead target delivery potent chemotherapy agent selectively kill cancer cell minimise damage healthy tissue bildstreckeengsindd bildstreckeengsindd corporate responsibility lead healthcare company goal develop available product service address unmet medical need real value society aim provide tangible improvement patient health quality length life core contribution responsible sustainable manner respect need individual society environment possible committed finding retain talented people develop skill lrochearengcorporate responsibility partindd brief ourpursuitofscientificexcellenceenablesusto reportandonourwebsiteoureffortswererewarde addressunmetmedicalneedshelpingpatientslead inwhenrochewasnamedhealthcaresuper longerandbetterliveswepioneerdifferentiated sectorleaderinthedowjonessustainabilityindexe medicinesandtranslatethoseintobenefitsforpatient djsiforthefirsttimerochehasbeenincludedin throughoutreachprogrammesoureffortstounder thedjsiworldindexesforsixconsecutiveyearsand standdiseasebiologyandtodevelopmedicines isincludedintheftsegoodindex anddiagnosticsthatpreventdetectcorrectlydiag noseandeffectivelytreatdiseasehelpusachieve manage corporate responsibility ourgoalofpersonalisedhealthcarephcthroughout corporateresponsibilityisanintegralpartofourdaily ourvaluechain workratherthanthedutyofasingledepartment ourcorporatesustainabilitycommitteecscco asweseeitourgreatestresponsibilityistokeepup ordinatesourapproachwithrepresentativesfromall thisworkourmedicinestakebetweeneightand corefunctionsandbusinessesacrossthegroupthe twelveyearstobringtomarketsoafocusonlong cscreportstothecorporateexecutivecommittee termsuccessiscriticalwerunourbusinessina andtheboardscorporategovernanceandsustain sustainablemannerthatrespectsindividualssociety abilitycommitteethecscworkstoidentifyand andtheenvironmentandwefindretainanddevelop assesssignificantsocialethicalandenvironmental talentedpeopletomakethispossibleourvaluesof risksaswellasrelatedopportunitiesitalsodevelop integritycourageandpassionguidethedailybe andrevisescorporatepositionsandguidelineson haviouranddecisionsofallemployeesandweseek topicsofkeyinteresttoourstakeholdersinoctober evidenceofthesevaluesfromleadersinparticular thecschelditsfifthannualworkshop thesevaluesencapsulatetheworkingenvironment attendedbyaroundemployeesacrossthegroup andattitudesrequiredtocreateinnovativethinke maintopicsdiscussedwereaccesstohealthcare andthevalueofourproductsandservicesdure approach theyearthecscdevelopedfivenewpositionpaper wetrytobalanceeconomicprosperitysocialcommit ontopicsrelatedtocorporateresponsibility mentandenvironmentalprotectionineveryaspect ofourbusinesswebelievethiscreatesvalueforall objective ourstakeholdersandhelpsearntheirtrustand remainoneofthetophealthcarecompanie commitmentengagingwithrelevantgroupsensure inthedjsi ourapproachiseffectivewehaveidentifiedsix integratebestpracticesfromgenentech materialcorporateresponsibilityarea sustainabilityactivitie innovationcapacitie improveenergyefficiencygigajoulesper valueofrocheproductsandservice employeebybyfrom pricingandreimbursementcondition accesstorocheproductsandservice web relationshipwithstakeholder sustainability principle strategy management beinganattractiveandresponsibleemployer wwwrochecomprinciple stakeholder engagement wwwrochecomstakeholderdialogue wemonitortheeffectivenessofourapproachandour corporate sustainability committee charter progressintheseareasusingasetofkeyperfor wwwrochecomcsrcommittees manceindicatorskpisforwhichwenowhavetwo key performance indicator wwwrochecomsuskpipdf fullyearsofdatawhilethesekpisareforinternal safety health environment performance managementonlyweincludearangeofperformance wwwrochecomshefiguresandfact measuresthroughoutthissectionofourannual employee topline figure wwwrochecomemployee lrochearengcorporate responsibility partindd roche business report corporate responsibility responsible practice howwedothingsisasimportantaswhatwedo providinginstantreportsandinformationbasedon thetrustofthemanydiversegroupsweencounterin historicalinformationcustomerfeedbackandmarket thecourseofourworkdependsonuscarryingout analysistoaidourplanne eachandeveryaspectofourbusinessresponsibly asaninnovationdrivencompanywefocusonunder customersatisfactionisparticularlyimportantin standingthemechanismsunderlyingthedisease consumerbusinessespatientswithdiseasessucha andtranslatingthisintodevelopingproductsthat diabeteswhouseourproductsdailytendtogive improvepatientshealththisoftenmeansexploring regularfeedbackwhichispivotaltofutureproduct emergingtechnologiesastheycouldprovideim developmentwealsousedetailedmarketresearch portantmedicalbreakthroughsandformthebasisof andfocusgroupstodevelopproductsandservice ourproductpipelineinthelongtermatthesame thatsimplifydailydiabetesmanagement timewemustassessanyrisksorethicaldilemmas thatcuttingedgetechnologiesposewithgreat halfourdiagnosticsemployeesworkincustomer scrutinybeforeandwhileusingthem serviceandsupportwealsoencourageemployee withlittleornocontactwithcustomerstospend customer relationship timelearningabouttheirneedsforexampleroche ourcustomersrangefrompatientshealthcarepro diagnosticsinrotkreuzswitzerlandhasacustomer fessionalshospitalsandreferencelaboratoriesto orientationprogrammeduringwhichtechnical publicandprivatehealthcarepayersunderstanding specialistsspendninemonthsattendingworkshop andrespondingtotheirdifferentneedsandexpec visitinglaboratoriesandhospitalsandevaluate tationshelpstoimproveourcommercialeffectiveness whattheyhavelearnedbeforepresentingtheir variouscustomergroupsprovideinputinto findingstomanagementtheyworkedonproject productprofilesforexampletheeaseofuseof includinganonlinesurveytohelpimprovetheway medicationinstrumentspecification healthcareproviderscopewithmethicillinresistant clinicaldevelopmentplansforexampleby staphylococcus aureusamajorprobleminhospital designingandparticipatingintrial publicationoftrialresult pandemic preparedness regulatoryfile intheworldhealthorganizationwho developmentofhealthoutcomestudie declaredaglobalpandemicofhninfluenzainfor diseaseawarenessplansandproductinformation mationfromthewhoandtheuscenterfordis educationandawarenessprogramme easecontrolandpreventioncdcindicatedthat treatmentguideline tamifluwasoneofonlytwoapprovedantiviralswith activityagainstthenovelstraintheseeventstrig wealsoobtainfeedbackfromcustomergroups geredrochetoimplementitspandemicplanwhich throughourmedicalliaisonsandclinicalresearch hadbeenindevelopmentsincewithafocus associatesadvisoryboardsandeducationand onincreasingtamifluproductionanddistributionto awarenessprogrammesweareinvolvedin meetincreaseddemandandensurelowincome countrieshadaccesstothedrugourpoliciesforthe wecarryoutcomprehensivemarketresearchand prioritisationofdrugsupplywereinaccordancewith analysisoftenatadivisionalorlocalleveltohelpus prepare influenza pandemic role meetspecificmarketneedseachcountryorgani responsibility roche stakeholder sationisresponsibleformanagingitsrelationship publishedinmay withitscustomersandsharingrelevantinformation withinthegroupwehavearangeofinitiativesto tamiflu stockpile wehaveworkedwiththewho enablethissuchasuniteacompanywidedatabase andgovernmentstobuildstockpilesoftamifluand lrochearengcorporate responsibility partindd helpprepareforaflupandemicinwedo ahntestitallowsrapidandaccurateidentification natedthreemilliontreatmentcoursesforthewhos ofpatientsinfectedwiththevirussoappropriate rapidresponsestockpilewestoredthestockpile patientmanagementcanstartasearlyaspossible untilwhenthewhodistributedittoof theworldsneediestcountriesinwedonate emergingdataunderscoretheimportantrolethedrug andshippedanadditionaltwomilliontreatment playedinreducingtheimpactofthismostrecent coursesforthewhosregionalstockpilewhichha flupandemicforexamplearecentstudybyjainetal alsobeendistributedtocountriesinneed fromtheuscentrefordiseasecontrolpublishe inthenewenglandjournalofmedicinereportedon inmayweagreedtodonateafurtherfivemil theclinicaloutcomeofpatientshospitalisedwith lioncoursestoreplenishbothstockpileswealso hninfluenzainthestudyshowedthatanti agreedtoestablishastockpileoftreatment viraldrugsweretheonlytreatmentthatmadeastatis coursesofpediatriccapsuleswhichweprovide ticallysignificantdifferenceinhelpingpatientsto alongwithinstructionsformixingthecontentswith recoverandthatoseltamivirwastheantiviraltaken foodforchildrenunabletoswallowthemwhole inaroundofcase thisbringsthetotalnumberoftreatmentcourse donatedtoaroundmillion public policy theprivatesectorhasacrucialandlegitimaterole sincewehavebeenprovidinggovernment toplayindevelopingpublicpolicyweshareour tamifluatsubstantiallyreducedpricestoassisttheir expertisewithpolicymakerstohelpdevelopeffective pandemicpreparednesshoweverwerecognise lawsregulationsandpoliciesrelatingtopublic thatmanydevelopingcountrieswereunabletocreate healthaswellasmoregeneralareasaffectingour anadequatestockpileevenatreducedpricesinjuly businesssuchastaxpolicyourgoodpractice welaunchedthetamiflureservesprogramme guidelinesforworkingwithgovernmentofficialsguide toincreaseaccessinthesecountriesweproduce ouremployeesondoingsoinanappropriateand andstoretamifluforspecifieddevelopingcountriesat professionalmann asignificantlyreducedpriceandspreadthecost overanumberofyearswewillshipthestockpileif muchofourpublicpolicyworktakesplacethrough thewhoannouncesaflupandemicorwhenagov ourmembershipofindustrybodiessuchasthe ernmentrequestsittodealwithanationaloutbreak europeanfederationofpharmaceuticalindustriesand associationsefpiatheeuropeandiagnostic tofurtherincreaseavailabilitywehavelicense manufacturersassociationedmaandtheinterna companiesinchinaandindiatomanufacturegeneric tionalfederationofpharmaceuticalmanufacturers oseltamivirwehavealsosupportedtheeffortsofa andassociationsifpmaaswellastheirnational southafricanmanufacturerbygivingthemaccess memberswealsomeetdirectlywithpolicymaker totheknowledgeandskillsneededtoproduce suchasgovernmentspublichealthorganisation oseltamivirtheycannowproducethedrugfreelyas thinktanksandacademic wedonotenforcepatentsinsubsaharanafrica ourmajorpublicpolicyworkininclude rochediagnosticsproducedapolymerasechain workingwiththeworldbusinesscouncilfor reactionpcrbasedtestforthehnstrainofthe sustainabledevelopmenteuropeanroundtable fluvirususingourlightcyclersystemwithinweek ofindustrialistsandprinceofwalescorporate ofthevirusbeingidentifiedinnovemberthe leadersgrouponclimatechangeonpolicy usfoodanddrugadministrationgrantedemergency statementsaheadofthecopenhagenclimate useauthorisationofthisrealtimereadyinfluenza conferenceindecember lrochearengcorporate responsibility partindd roche business report corporate responsibility showingmembersoftheeuropeanparliament andareobtainedfromlivingsystemsusingadvance aroundouranimalfacilityinbaselduringthe processesthatareverydifficulttoreproducemore developmentoftheanimalresearchdirectiveto testingisneededtodemonstratethesimilaritysafety demonstrateourwelfarestandardsandthe andefficacyoffollowonproductscomparedwiththe importanceofanimalresearchinhealthcare original coorganisingadinnerdebateonanimal researchintheeuropeanparliamentwiththe webelievebiosimilarsshouldbesubjecttowell europeanplatformforpatientorganisation definedandtransparentregulationsthatcoverdevel scienceandindustryepposi opmentapprovalandpostauthorisationprocedure explainingourpositiononproposedlegislation basedonthosefortheoriginalproduct coveringpharmacovigilanceinformationto patientsandcounterfeitmedicinestomembers inweworkedwithregulatoryauthoritiesand oftheeuropeanparliament industrybodiesparticularlytheinternationalfedera tionofpharmaceuticalmanufacturersandassocia combat counterfeit counterfeitpharmaceuti tionstoensurepolicymakersfullyunderstandbiosim calanddiagnosticproductsareillegalandaserious ilarsciencethisworkwillsupportthecreationof globalpublichealthproblemtheyendangerpatient appropriatepoliciesregardingfuturebiosimilarmono undermineconfidenceinhealthcaresystemsand clonalantibodiesandthenamingofbiopharmaceuti companiesinfringeintellectualpropertyrightsand calsrochehasalsomadescientificandmedical wastevaluablehealthcarebudget presentationsonbiosimilarstoregulatorsscientist andotherkeyaudiencesandcontributedtoscientific wecontinuouslymonitorandimproveproductsecu journal rityandusetechnologytoquicklyidentifycounterfeits wetakepartinnationalandinternationalindustry political contribution rochedoesnotfinancially andgovernmentaleffortstostrengthenthelawim supportindividualpoliticiansanywhereusemploy proveenforcementtrainlocalofficialsandeducate eescanmakepersonalcontributionsthroughthe thepublic hoffmannlarochegoodgovernmentcommittee ggcavoluntarypoliticalactioncommitteeorpar inweupdatedourpositiononcounterfeite ticipateintherocheactionprogramme whichisavailableonourwebsitewearetakingpart inanefpiapilotprojectinswedenofatracke integrity compliance systemwhichtracesdrugsbacktotheirsource therochegroupcodeofconductguidesour improvingpatientsafetyweapplyauniquebarcode employeesbusinessbehaviour toeachpackofmedicineproducedwhichpharma cistsscanwhendispensingthemedicinetocheckit indecemberwelaunchedtherochegroup isauthenticwecontinuetoprovideinputthrough speakuptelephonelineandwebservicefor efpiaintotheproposedeulegislationoncounter employeestoraiseconcernsaboutcompliancewith feite thecodeofconductanonymouslyifpreferred athirdpartyorganisationoperatesspeakupand generic biosimilar product thepatentperi pricewaterhousecoopershasprovidedassurancethat odsforsomeinnovativebiologicalproductssuchas thesystemprotectsemployeesidentitie proteinsandantibodiesareexpiringandproduct claimingtobesimilarareappearingonthemarket inbusinessethicsincidentswerereporte whileitisrelativelyeasytocopychemicaldrugsbio tothechiefcomplianceofficerweinvestigatedthem logicalproductshavecomplexmolecularstructure allandtookcorrectiveactionswherenecessarywith lrochearengcorporate responsibility partindd employmentcontractsbeingterminatedasaresult inweintroducedasustainabilityriskmanage ofunethicalbehaviour mentprocessandtargetsforourmarketingagencie wealsointroducedanewstandardoperatingpro welaunchedseveralinitiativestostimulatetheshar cedureandrelatedtrainingtostrengthencompliance ingofbestpracticesamongrocheslocal withmarketingcodesinourpharmaceuticaland complianceofficersincludingacomplianceofficer diagnosticsbusinesse networkaseriesofregionalcompliancemeeting andadedicatedintranetsitethecomplianceofficer wedonotselloverthecountermedicinesandso helplinemanagerstocontrolriskslocallyandmeet donotadvertisedirectlytoconsumersinthemajority therequirementsofourgroupcodeofconduct ofourmarketsintheuswhereitislegaltoadver tiseprescriptionmedicineswehavedetailedpolicie wealsoupdatedourperformancemanagement inplacetoensurethisisdonelegallyandethically systemtoensureweassessemployeesnotjuston wesendalltelevisionadvertisingcampaignstothe whethertheyachievetheirobjectivesbutalsoon foodanddrugadministrationforapprovalbefore howtheyachievethem broadcast finallywesetupanexportcompliancecouncilto wedecidedtoendourmembershipofthepharma ensureourmanufacturinganddistributionsitesmeet ceuticalresearchandmanufacturersassociation thecomplexlegalrequirementsforsellingand phrmaintheunitedstatesandinsteadjointhe exportingourproduct biotechnologyindustryorganizationbioofwhich genentechwasalreadyamember risk crisis management ourriskmanagementcharterdefinesourrisk sustainable supply chain managementapproachandresponsibilitiesandis rochespentaroundbillionswissfrancsonprod availableonourwebsitealongwithafulllistof uctsandservicesintheserangefromraw riskstoourbusinessweincludesignificantsocial materialsandactivepharmaceuticalingredientsto environmentalandethicalrisksidentifiedinthe equipmentlaboratoryandofficesuppliesandser groupriskmanagementprocess viceslikeconsultancytravelandmarketingwemust ensurethesesuppliersmeetthenecessarysocialand responsible marketing environmentalstandardstosecurereliablesupplie therearestrictregulationsandindustryguideline andenablethesustainablegrowthofourcompany onthesaleandmarketingofmedicinesanddiagnos ticstomakesuretheyareprescribedadministere ourapproachisto andusedcorrectlyandthatpatientsunderstand raiseawarenesswithoursupplyofficer thebenefitsandrisksoftakingthem raiseawarenesswithsupplier helpsuppliersimprovetheirstandard healthcareprofessionalsneedtobeabletoselect developjointinitiativestoincreasetheirperfor thebesttreatmentoptionfortheirpatientswe mance providescientificandclinicallyrelevantinformation thatenablesthemtoprescribeoruseourproductsin weendorsethepharmaceuticalindustryprinciple circumstanceswhichdeliverthegreatestmedical psciprincipleswhichrequiresupplierstoimple benefittothepatientalistoftheexternalguideline mentresponsiblesupplychainmanagementinthe andcodesofpracticewefollowwhenmarkete areasofethicssafetyhealthandenvironmentshe ourproductsisavailableonourwebsite socialresponsibilitymanagementsystemsinnovation andeconomicsustainabilityandarecommittedto lrochearengcorporate responsibility partindd roche business report corporate responsibility integratingtheseprinciplesintoourbusinessin clinicalresearchsuchaswhatthedifferenttrial wedevelopedanewsuppliercodeofconductwhich phasesareandwhattheendofatrialmeansforthe includesthepsciprinciplesandnowrequireallour patientstakingpart supplierstosignourcodeofconduct aspartofourclinicaltrialsprogrammewestore ourpharmaceuticalsanddiagnosticsdivisionsaudit biologicalmaterialsuchastissueorgansbloodand businesscriticalsuppliersandassessnewsupplier otherbodilyfluidsinhumanspecimenrepositorie toidentifyandcorrectproblemsusingexternaland orbiobankstheseareinvaluableforlearningmore internalauditorsweshareourexpertiseandprovide aboutdiseaseandexploringpossibletreatment trainingtohelpsuppliersimplementanyrequire theyalsocontainsensitiveinformationaboutthe improvementsinternalauditorscarryoutfollowup personwhoprovidedthesamplewearededicatedto inspectionstoensuresuppliershavemadethe protectingdonorsprivacyandensuringtheyarefully necessarychangesinweauditedsocialand informedabouthowtheirsampleanddatawillbe safetyhealthandenvironmentalstandardsat usedbeforetheyagreetotakepart existingsuppliersandcarriedoutfollowupaudit atfivewerejectedorceasedtradingwithonesup wehaveaclearprocedureforresolvingethical plierthatwecouldnothelptoimprovethemain dilemmasemployeesencounterintheirworkifthey areaforimprovementourauditsflaggedupwa cannotresolvetheissuewithintheirteamemployee industrialhygiene cancontactourglobalethicsliaisonofficewhich willconsultpeersandinternalexpertstofinda weareintheprocessofextendingoursustainable solutionaninternalcommitteehandlesanyremaine procurementactivitiestosuppliersofnonproduction concernsandourindependentclinicalresearch materialsandservice ethicsadvisorygroupcreagprovidescounselon thetoughestchallengeswealsoprovideregular wehaveestablishedafinancialriskmanagement onlineethicstrainingforemployeesintheglobal processinprocurementtoidentifysuppliersatriskof ethicsliaisonofficereceivedqueriesallwere bankruptcyandtomitigatethoseriskswecontinue resolvedwithoutescalation toapplyoursupplychainriskmanagementprocess toallsuppliersofkeyrawmaterialsdrugsubstance thecreagmeetsannuallytoreviewconcernsraise anddrugproductswealsoworkedwithsupplier withtheglobalethicsliaisonofficeanddiscuss ofmaterialsforkeyrochedrugproductstoensure otherrelevanttopicsinweupdatedthecreag theyhavebusinesscontinuityplansforpandemicrisk onrecentquerieshandledbytheglobalethicsliai sonofficeaswellasonthestatusoftheemployee research practice ethicseducationprogrammesthecreagalso ethicalconcernssometimesariseaswepushscientific reviewedthelatestrevisionstothedeclarationof boundariesandexplorenewtechnologiestodevelop helsinkiastatementofethicalprinciplesformedical innovativenewtherapiesanddiagnosticswemust researchinvolvinghumansubjectsreleasedbythe exploreandcarefullymanagetheseconcernsto worldmedicalassociation ensuretheopportunitiespresentedarenotlost anotherindependentpanelthescienceandethics ethic r ourglobalpositiononclinical advisorygroupseagadvisesandguidesus researchcommitsustohighethicalstandardsand ongeneticsgenomicsandproteomicsinthe clarifiesourpositiononspecificareasofconcern seagadvisedonissuesincludingtheuseand weupdatedthispositionintoincludestraight storageofhumanbiologicalmaterialsinspecific forwardanswerstofrequentlyaskedquestionsabout researchprojectsweexpandedtheseagsadvisory lrochearengcorporate responsibility partindd breakdown animal research inthescientificcategoryfirstplacewenttoateam whichfoundanewinvitrotestfordetectingtoxic compoundsbeforetestingnewdrugsonanimalsour mouse diagnosticsbusinessdevelopedthetestwhichisnow rat availableforpharmaceuticalpreclinicalresearchthe winningprojectinthelabcareandanimalmanage guinea pig mentcategorygraduallyrehabilitatedmonkeysthat hamster hadbeenhousedindividuallybackintolargergroup gerbil increasingtheirsocialinteractionandimprovingtheir fish wellbeingwewillimplementtheseandotherproject frog intoouroperationswhereverpossibleandrunthe dog rsawardagainin rabbit primate inwecreatedanewjointscienceandtechnol ogylaboratoryinbaselbetweenthepharmaceutical anddiagnosticsdivisionsaimedatinvestigate organtoxicitiesofdrugsusinganinnovativecellana functionswiththeiragreementtocoverallinnovative lysersystemxcelligenceresearcherscant technologiessuchasnanotechnologyandstemcell whetherpharmacologicallyactivesubstancesare research likelytoprovetoxictoorganssuchastheheartand liverbycontinuousrealtimeviewingofthecell animal welfare werecogniseandtakeseriously reactiontothemoleculethiscanbeperformedin publicconcernaboutanimalresearchhoweverwe theearlypreclinicalstageofresearchmakingmany couldnotdeveloplifesavingmedicinessuchascan animalstudiesredundant cerdrugswithoutitwhileweworkhardtofindand usealternativemethodsthelimitationsofthose wealsoestablishedaninternalanimalwelfareethics methodsmeanwestillneedtotestnewdrugsand committeetoexamineallstudiesinnonhuman technologiesonanimalsforsafetyandlegalreason primatesbeforeregulatoryapprovalandtoadvise employeesworkingwithanimalsthiscommittee inweusedatotalofanimalsinour willbecomefullyoperationalin researchofwhicharoundweremiceandrat innovation new technologies evolvingtech wearecommittedtothersconceptofreplacing nologiessuchasnanotechnologystemcellresearch animaltestswherepossiblereducingthenumberof andsystemsbiologyhavemanypotentialbenefitsin animalsweuseandrefiningexistingscientificprac pharmaceuticalsanddiagnosticstheseadvantage ticesanimalwelfareandhusbandryallemployee mustbecarefullybalancedwiththeethicaldilemmas andcontractorswhoperformanimaltestingforus andpotentialrisksposedandweassessthesewith mustcomplywithapplicablelawsandmeetorexceed greatscrutinybeforeenteringnewfield industrystandards nanotechnologyisthemanipulationofmaterialson wecontinuedourrsawardforinnovationand ascaletimessmallerthanthediameterofa continualimprovementinanimalwelfarewithin humanhairithaspotentialinmanyareasparticularly rocheinfifteenteamsofscientistsandanimal drugdeliveryregenerativemedicineandsmallscale carespecialistsfromourresearchsitesenteredfor portablediagnosticshowevermanyquestion awardsintwocategorie remainabouttheeffectsnanotechnologymayhaveon lrochearengcorporate responsibility partindd roche business report corporate responsibility peopleandtheenvironmenttherisksandbenefit lobbythroughefpiaontheproposedeu havetobecarefullyevaluatedbeforenanotechnology legislationoncounterfeitmedicinalproduct isusedinmedicalproductswebelievethatexiste establisharsdatabaseforsharingbestpractice safetytestsandregulationsprovideanappropriate inanimaltestingwithinroche frameworkfordoingso launchrochesethicscommitteeonanimal welfare stemcellsandtheirapplicationsofferanenormous commenceauditofsuppliersinindirectspend potentialforthetreatmentandreliefofchronic painandevenforthecureofdiseasesextendingand web enhancingthequalityoflifehowevertheresearch responsible marketing risk management compliance alsoraisesethicalquestionsbecausesomepeople wwwrochecombusinessintegrityandresponsiblemarkete wwwrochecomriskmanagementandcompliance believeembryonicstemcellsarehumanswitha pandemic influenza tamiflu information righttolifeandshouldnotbeusedinresearchor wwwrochecomrocheinfluenza treatment wwwpandemictoolkitcom pharmaceutical industry principle responsible supply chain management rocheiskeenlyawareofthetremendouspotentialof httppharmaceuticalsupplychainorg thisresourceforbasicscienceandfuturehealth patent counterfeit biosimilar careapplicationswehavethereforeenteredinto wwwrochecommedicalvaluepatentsandpricing wwwrochecompatent researchcollaborationsforexampleweworkwith innovation new product technology stemcellssafermedicinesscsmintheuk wwwrochecomcsrresearchanddevelopment andwithcellulardynamicsinternationalincinthe wwwrochecominnovationandtechnologie usrochebeganstemcellresearchanditsrelated position paper wwwrochecompoliciesguidelinesandposition applicationasadiscoverytoolandweplantobegin researchtousestemcellsasapotentialtherapeutic modalityrochealsoplanstodevelopexpertise tobecometechnicallyenabledinthisresearcharea andtoconductresearchonhumanembryonicstem cellsandtheiruseindrugdiscovery inweheldastemcellresearchworkshopin partnershipwithcambridgeuniversityintheuk attendeesincludedrochespecialistsand academicexpertstheydiscussedstemcellscience andpossibleapplicationsaswellasstepsforindus trytotaketomaximisethemedicalandbusiness opportunitiespresente objective implementtherochegroupspeakupline launchtherevisedrochegroupcodeofconduct andupdatethebehaviourinbusinesselearne programme rolloutnewsuppliercodeofconductandinclude compliancewiththisinourexistingsupplieraudit programme lrochearengcorporate responsibility partindd patient patientsinallaspectsofhealthcarebenefitfromour themajorityofhealthcarepayersrecognisethemedical productsandservicesourdifferentiatedmedicine andeconomicvalueofourproductsforexample anddiagnosticscomefromdiverseapproachesto whilecancerdrugssuchasherceptinandxeloda researchanddevelopmentweconstantlypursue mayseemcostlynotonlydotheyextendthelivesof scientificexcellencewhichhelpsustailorourprod patientswithterminalillnessandpreventdisease uctsandservicesinawaythatensurespersonalised recurrenceinpatientswithearlierstagecancer healthcarethismeanspatientscanleadlonger theycanalsoeasepressureonhealthcarebudget andbetterlivesbecausetheyreceivetreatmentsthat byreducingorpreventinghospitalvisitssurgeryand moreeffectivelypreventandcurediseasealleviate theneedforpalliativecareinmanycasestheyhelp symptomsandhastenrecovery patientsreturntoworkmorequickly wecanamplifythiscontributiontosocietyby inwepublishedanewpositiononassessing helpingtoimproveaccesstoourproduct thevalueofourproductsandserviceswhichcontain ensuringtheyprovidevalueformoney aseriesofguidingprinciplesforcarryingoutsuch providingfactualinformationonourproduct assessmentsweemployexperiencedhealthecono listeningandrespondingtocustomersview mistswhoworkwithhealthauthoritiestounderstand andproviderobustevidenceregardingtheeconomic value medicine diagnostic andhealthbenefitsofourproductsandservice differentpeopleexperiencediseaseandrespond withintherelevantregionalandlocalhealthcare totreatmentindifferentwaysourapproachof system personalisedhealthcarephctakesthisintoaccount andfitstreatmenttodifferentgroupsofpatient wealsoengagewithhealthcarepayersthroughout weuseourdiagnosticexpertisetodeepenourunder aproductslifecycleweprovideguidanceonassess standingofdiseasehowtreatmentsworkandhow ingthevalueofourproductsandserviceshealth differentpatientsrespondthishelpsusdevelop technologyassessmenthtapriortothemdecid bettersaferdrugsandidentifythepatientswhowill ingreimbursementandfundingcondition benefitmostimprovingclinicaloutcomesand increasingcosteffectivenessinwepublishe global access healthcare anewpositiononpersonalisedhealthcareto patientscanaccessourproductsthroughdoctor describeourapproachinmoredetail hospitalslaboratoriesandpharmaciesinroughly countrieswhilewesellthemajorityofourprod healthcarepayershavetomakedifficultdecisions uctsindevelopedcountrieswithadvancedhealth aboutgrantingaccesstoorprovidingreimbursement caresystemsaroundathirdoftheworldspopulation forhealthcareproductsandservicesbasedon lacksadequateaccesstohealthcaretheworld costeffectivenessandbudgetconstraintsaswellas healthorganizationwholistsmanyofourproduct medicalneedandclinicalimpactthesedecision asessentialmedicine haveaprofoundeffectonpatientsandtheirfamilie andcaninfluencewhereresearchbasedcompanie ourindustryhasanimportantroletoplayinpart likerochefocustheirfutureinvestmentobjective oftheworldwherehealthcarestandardsandaware consistentandopenprocessesareessential nessofthecausespreventionandtreatmentof forassessingthetotalvalueofmedicalproduct diseasearelowerbuttherearemanyothersystemic toindividualpatientsandtosocietyasawhole problemscontributingtohealthinequalitiesand throughouttheirlifecyclesothatthedecisionsmade wecannottacklethesealoneweworkwithgovern arefair mentsnongovernmentalorganisationsngo patientgroupsandhealthcareproviderstotackle lrochearengcorporate responsibility partindd roche business report corporate responsibility healthinequalitiesandincreaseaccesstoour servicetospeedupthedeliveryofhivtestresultsin productswetailorourapproachindifferentregion remoteareas tocaterfortheirspecificneed cancerkillsmorepeopleindevelopingcountrieseach access need theworldsleast yearthanaidsmalariaandtuberculosiscombine developedcountriesldcsarehardesthitbydis morethanhalfofallcancercasesareinthedevelop easeandhavethepooresthealthcaresystemstodeal ingworldbutonlyaboutofglobalcancer withthisburdentherearetoofewhospitalslabora resourcesarespentthereinternationalhealthcare toriesandhealthcareprofessionalstomeetdemand programmesfocusoninfectiousdiseasesandthere weaimtoincreaseaccesstohealthcareinpoor isverylittleoncologyinvestmentinfrastructureor countriesinsustainablewaysthatinclude expertiseasaleadingproviderofcancertherapie fairpatentandpricingpolicie wehaveanimportantroletoplayintacklingthis rdintodiseaseswithunmetmedicalneed badlyneglectedproblem partnershipswithgovernmentsngosandother educationtrainingandknowledgetransfer inweevaluatednewpartnershipstoimprove trainingincancercareforhealthcareworkersinsub ourapproachistojointlydevelopaccessprogrammes saharanafricawewillfocusonsharingourexpertise thatraiseawarenesseducateandtrainandassist ratherthansimplycashordrugdonationsaswe indevelopinghealthcareinfrastructurethiscollabo believethatbuildinglocalcapabilitieswillmakeabig rativeapproachensuresneedsaremetwhilefuture gerdifferenceinthelongtermtrainingwilltake businessopportunitiesforbothsidesareenhance placelocallytoencouragehealthcareprofessional throughtheincreasedcapabilityofinstitutionsand tostayintheirhomecountryratherthanleavingfor organisationsindevelopingcountrie opportunitiesabroad theillustrationshowsthecircumstancesunderwhich wealsojoinedthechangingdiabetesinchildren wedonotfileorenforceanypatentsitalsoillustrate programmeinthisisapublicprivatepartn ournoprofitpricingpolicyinaction shipbetweennovonordisktheworlddiabete foundationandgovernmentsinafricancountrie inwecompletedourtechnologytransferini theprojectaimstomakelifebetterforthegrowe tiativettithroughwhichwesharedtheknowledge numberofdiabetespatientsinafricawherethe requiredtoproduceourhivtreatmentsaquinavir standardofcareisoftenpoortheobjectiveistopro withlocalmanufacturersfreeofchargeweworke ducecareguidelineseducatehealthcareworkersand withallinterestedmanufacturersandreache ensureallchildrenenteringtheprogrammeareregis agreementwithcompaniesintheldcswhichare teredandmonitoredsotheirconditioncanbecon nowfreetoproducesaquinavirorusethisknow trolledthefirstphasewilltargetcameroonthe ledgetoproduceotherproductswealsoheldthree democraticrepublicofcongoguineaconakry africangoodmanufacturingpracticegmptrain tanzaniaanduganda ingseminarstoimprovelocallyproducedessential medicine inwegavetheinstituteforoneworldhealth accesstoourchemicalcompoundlibrarysoitcould wealsocontinuedourpartnershipwiththeclinton searchfornewmedicinestotreatchildhooddiarrhea foundationshivaidsinitiativechaitogetherwe oneworldhealthcompletedthefirstscreeningin haveestablishedandtrainedsevenlabsforhivt andidentifiedcompoundstoinvestigateas ingdevelopedanovelsolutionfordiagnosingand possiblenewtreatment monitoringhivininfantsanddevisedatextmessage lrochearengcorporate responsibility partindd people live hiv cover profit price antiretroviral medicine global access healthcare pricing patent nopatentsfiledorenforcedonanymedicine leastdevelope country twoantiretroviralhivmedicinessoldatnoprofitcoveringofhivpatient valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus pricing patent nopatentsfiledorenforcedonantiretroviralhivmedicines subsaharan african country twoantiretroviralhivmedicinessoldatnoprofit valcytesoldatreducedpricestongostreatingaidsrelatedcytomegalovirus price low low twoantiretroviralhivmedicinessoldatreducedprofit middleincome economy plan pandemic influenza tamifludonatedtoworldhealthorganizationstockpilesforcountriesmostinnee tamiflusoldatreducedpricestodevelopingcountrie tamiflureservesprogrammecreatesstockpilesfordevelopingcountrie tamiflusublicensingagreementsinchinaandindiaandtechnologytransfer agreementinsouthafrica access programme rochepatientassistanceprogramandgenentechaccesssolutionsprovideadvice wealthy nation andfinancialsupportforuninsuredorunderinsuredpatient overpatientsbenefittedfromthesepatientassistanceprogrammesin tackle hivaid aidstechnologytransferagreementsinbangladeshethiopiakenyasouthafrica develop world tanzaniaandzimbabwe employeesecondmentsinethiopianigerswazilandandtogo unicefeuropeancoalitionofpositivepeopleaidsorphanprogrammesinmalawi amplicaresupplieshivviralloadtestsinsubsaharanafricasouthamericaand theleastdevelopedcountrie clintonfoundationhivaidsinitiativechaiinsubsaharanafrica broad healthcare partnership phelophepahealthcaretraininruralsouthafrica develop world newoncologysustainabilityinitiativeinsubsaharanafricain changingdiabetesinchildrenwithnovonordiskandtheworlddiabetesfoundation incameroonthedemocraticrepublicofcongoguineaconakrytanzaniaanduganda instituteforoneworldhealthoninfectiousdisease googleorgoninfectiousdiseasesinkenya lrochearengcorporate responsibility partindd roche business report corporate responsibility injulyweteamedupwithgoogleorgonanini access develop world weworkclosely tiativetohelppredictandpreventemerginginfectious withpayersinallcountriestodemonstratethemedi diseasesineastafricarochedonatedagenome calandeconomicvalueofourproductsandwe sequencingsystemtobeinstalledintheinternational establishpricesthatenableaccesshowevermany livestockresearchinstitutelaboratoryinnairobi peopleindevelopedcountriescannotaffordtreat kenyatheinitiativewillbeginbyinvestigatingrift mentortheinsurancetopayforitintheuswhere valleyfeveradiseasespreadbymosquitoeswhich asyetthereisnouniversalhealthcaresystemwe ispotentiallylethaltopeopleandlivestock providefreedrugstothoseinneedthroughboththe rochepatientassistanceprogrampapandthe weproducedourfirstaccesstomedicinesanddiag genentechaccesstocarefoundationgatcfin nosticsreportinthiscontainsmoredetailsof patientsbenefitedfromthepapand allourpoliciesandprogrammestoincreaseaccessto patientsreceivedfreetreatmentthrough ourproductsandisavailableonourwebsite gatcfwealsosupportindustryeffortstoraise awarenessofassistanceprogramsviathepartnership access emerge market healthcareinmiddle forprescriptionassistance incomecountriesisimprovingandpresentsasub stantialopportunityforrochehowevereachcoun infollowingthemergerofrocheandgenen tryshealthcaresystemisatadifferentstageof techgatcfwillassumeresponsibilityfortheroche developmentandhasitsownspecificneedswe pappatientstocreateoneofthefivelargestcharita workinpartnershipwithgovernmentsinthesecoun blefoundationsintheus triestohelpestablishprocessesandclinicaltrialpro grammesandimproveeducation gatcfispartofgenentechsbroaderprogramme tohelppatientsgainaccesstoprescribedtherapie ourdedicatedmedicalaffairsgroupdevelop thegenentechaccesssolutionsdepartmentcom specificprogrammesforindividualemergingmarket prisesnearlyemployeeswhohelppatientsnavi wheremanypatientscannotaffordthelongterm gatethecomplexusreimbursementlandscape treatmentnecessaryfordiseasessuchascancer hepatitiscandrheumatoidarthritisinchinafor forinsuredpatientsgenentechaccesssolution exampleweoffercostsharingprogrammesforour clarifiesbenefitscoverageandreimbursementre oncologydrugstoensureaccesstothepatientswho quirementshelpingfindwaystoassistincovere willbenefitmostinsouthkoreaourreducedprice patientexpenseswherepossibleuninsuredpatient forcancerdrugscovertheentirepopulationwhilein orpatientswhoqualifyforassistancecanobtainfree egyptwhichhasoneofthehighestratesofhepatitis medicinefromgatcf cinfectionintheworldweprovidepegasysata speciallowpriceforpublicsectorpatients intheserviceadvisedpeopleaboutcov erageandreimbursementissuesandgatcfprovide wealsosupplyourproductstoprivatepayersin patientswithfreetreatmentworthatotalof emergingmarketsandworkwithinsuranceand millionusdollar reinsurancecompaniesinchinaandrussiato expandprivateinsurancecoverageandincrease injapanchugaiestablishedtheacademyforad accesstoourmedicineswecontinuetosupply vancedoncologychaaointohelpbre twohivmedicinesatreducedpricesinthelow standardsofcancerresearchandtreatmentuptothe andlowermiddleincomecountriesdefinedbythe samestandardsasthoseineuropeandnorthamerica worldbank lrochearengcorporate responsibility partindd impact access programme patient facility benefit clinical trial exclude genentech hivinfecte patient live country eligible number clinical trial noprofit medicine number healthcare centre hivinfecte patient involve living country eligible number patient phase reducedprice medicine iiv clinical trial patient benefit usa patient assistance programme presentbothresearchandclinicalfindingsatmedical andscientificmeetingsandengagewithkeyleader clinical trial ineachfield clinicaltrialsareessentialtodemonstratethesafety andefficacyofnewdrugstheyalsoprovideeduca wecollecttheinformationgainedthroughclinical tionalfinancialandmedicalsupportforparticipating trialsandpostmarketingsurveillanceandusethisfor hospitalsandaccesstothelatesttreatmentsfor acontinuousassessmentofthebenefitsandrisk cancerarthritisandotherdiseasespatientstake ofaproductindevelopmentoranestablishedmedi partintrialsreceivefreeaccesstothemostadvance cinewealsouseittobetterplannewclinicaldevel therapiesduringthetrialandwhentherearenovalid opmentprogrammesweprovidethisinformationto therapeuticalternativesthiscontinuesuntilthedrug regulatoryauthoritiesasrequire isavailableforsaleoronprescriptionwedonot performclinicaltrialsincountrieswherewedonot weapplystrictdataprotectionprinciplestoall plantomarketthedrug personalmedicaldatacollectedduringclinicaltrial inlinewithourdirectiveontheprotectionofpersonal peopleseekingnewclinicaltrialstotakepartinor datatheseprinciplesapplyequallytodataabout wishingtolearnfromtheresultsofcompletedtrial ourcustomerssuppliersandemployee canaccessthisinformationatwwwrochetrialscom patient safety asofdecemberthesitecontaineddetail allmedicinesmaycauseadverseeffectssideeffect ofpharmaceuticalprotocolsdiagnosticproto insomepatientsourpriorityistomakesuretheben colsandtrialresultsthesestudiescovermore efitsoftakingourproductsinclinicaldevelopment thanconditionsincludingalzheimersdisease andourmedicinesoutweighanyidentifiedorexpec asthmaaroundcancerscardiovasculardisease tedsafetyriskwehaverobustprocessesoperate depressiondiabeteshepatitishivaidsinfluenza worldwidetounderstandourmedicinesandtheir andobesitythewebsitehadmorethan adverseeventsandtominimisetheirlikelihoodmedi pagevisitsinrepresentingmorethan cinesareregularlyanalysedagainstvariousreference visitorsdetailsofourclinicaltrialsarealsoavailable databasestohelpusdetectpotentialsafetysignal throughtheinternationalfederationofpharmaceu allourproductsinclinicaldevelopmenthavean ticalmanufacturersandassociationsifpmaclinical individualsafetymanagementplanandallourmedi trialsportalatwwwifpmaorgclinicaltrialsand cineshaveariskmanagementplanreviewedand theusnationalinstitutesofhealthsglobalregistry approvedbymajorhealthauthoritie atwwwclinicaltrialsgovwepublishourclinical trialdatatoensurethatalllessonsfromthesetrial continuousmonitoringandworkingwiththehealth aremadeaccessibletothewidercommunitywealso authoritiesenableregularupdatestoprescription lrochearengcorporate responsibility partindd roche business report corporate responsibility instructionslabellingandproductinformation wesupportwepubliclylistpatientgroupswegive includingemergingsafetyinformationcontraindica nonfinancialsupporttoifthesupportissignificantor tionandspecialprecautionsofusewhennecessary meaningfulasguidedbyeuropeanfederationof lettersaresenttophysiciansandhealthcareprovid pharmaceuticalefpiaindustriesandassociations ersallowingthemtoadjusttheirmedicalpractice examplesofpatientadvocacywesupportedin diagnosticsproductsmaygiveerroneousresult includetheworldhepatitisalliancesworktoraise causedbyaproductperformanceoruserhandle awarenessofviralhepatitisandpromoteactionto issuethiscouldeventuallyleadtoanincorrectther improvepatientcarewecontinuedtosupportthe apyforapatientduringthedevelopmentofdiagnos europeanpatientsrightsdayorganisedbyactive ticproductsextensivetestingisperformeduse citizenshipeachyearinpatientgroupsin patientsamplesundervariousrealisticconditionsto europeancountriescelebratedthethirdpatient ensureoptimalperformanceofthefinalproduct rightsday weinvestigateallreportedadverseeventstoascer education awareness tainiftheyarerelatedtoourproductsifthereisa ouraffiliatesoftengetinvolvedininitiativestoraise linkwereevaluatewhetherthebenefitsofthemedi awarenessofdiseaseforexamplerocheturkey cineordiagnosticproductstilloutweightherisk heldaonedaycyclingeventatashoppingmallin wealsohaverobustproceduresinplacetopromptly istanbulinpartnershipwiththeturkishbicycle informpatientsphysicianshealthcareprovider federationandtheministryofhealthscancercontrol andregulatorsofanynewproductsafetyinformation departmentrochemadeadonationtothepatient organisationhandinhandagainstcanceronbe wehavearobustprocesstoensurethatproduct halfofeachpersontakingpartdemonstration canberecalledrapidlyandwithdrawnfromcirculation onprostheticbreastshelpedtrainwomeninself ifunanticipatedissueswiththeirqualityarisein examination therewerenorecallsinvolvingthepublic inbrazilmillionpeoplehavediabetesbut patient advocacy donotrealiseitrochediabetescarechallenge wesharewithpatientgroupsaninterestinhelpe fashionstudentstodesignapracticalandfashionable patientsunderstandandmanagetheirdisease accessoryforcarryingaccuchekbloodsugartest andgainaccesstotheinformationandtreatment andotherdiabetescareitemstoraiseawareness theyneed ofthediseaseamongteenagersandyoungadult whiletheiraimsvaryeachpatientgroupinteract goal withmanypatientsandcarersunderstandstheir initiaterocheoncologysustainabilityinitiativein needsandprioritiesandknowshowtoprovideemo subsaharanafrica tionalsupportandpracticaladvicewedescribe expandpartnershipwithalberteinsteincollegeof ourapproachtoworkingwithpatientgroupsinour medicineinethiopiatoincludeoncologytraine positionstatementandguidelinesforworkingwith hostincollaborationwithnovonordiskandthe patientgroupswhichareavailableonourwebsite worlddiabetesfoundationwdfaleadership foruminafricatoaddressthediabetesepidemic transparencyisfundamentaltosuccessfulpartner shipswithpatientgroupsinwelistedallthe patientgroupswesupportfinanciallyonourwebsite bycountryandwithashortdescriptionoftheactivity lrochearengcorporate responsibility partindd web personalise healthcare wwwrochecomphcinrd roche position statement personalise healthcare access medicine diagnostic pricing neglect disease work patient group wwwrochecompoliciesguidelinesandposition access medicine report wwwrochecomsustaccesspdf programme ldc wwwrochecomprogrammesinleastdevelopedand developedcountrie programme develop country wwwpparxorg wwwgenentechaccesssolutionscom roche trials patient safety wwwrochetrialscom wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety list patient group support wwwrochecompatientgroup lrochearengcorporate responsibility partindd roche business report corporate responsibility people foroveracenturyrochehasstoodforinnovationand isillustratedbyourconsistentrankingasanemployer entrepreneurshipourhistoryofachievingourbusi ofchoiceseethetablebelowforaselectionofour nessgoalsandexcellinginscienceandinnovationis awards aresultofconsistentlyemployingthebestpeople itrulybelievethatwereinthegoldenageofdisease wesucceedbecauseofourpeoplepeoplewhoare researchanddrugdiscoveryitisnowpossibleto passionateaboutmakingadifferencetopatient tacklediseasebiologywiththesamerigourasbasic livespeoplewholeadanddrivechangepeoplewho biologybecauseofthisconvergenceofmedicine liveourcorporatevaluesintegritycourageand andscienceicantthinkofabetterplacetobethan passionwehaveemployeesbehindourcur genentechthequalityofthesciencehereison rentsuccess parwiththatoftopacademicinstitutionsitisexhila ratingtoexperiencethecombinationofscientific wekeepouremployeesengagedandperformingat excellencewithstateoftheartresourcesenormously thehighestlevelbycreatingaworkingenvironment talentedcolleaguesandthecultureofrisktakingwe inwhicheveryonefeelsvaluedandrespectedwhere havehere theycandeveloptotheirfullestpotentialandcan marc tessierlavigne phd executive vice president maketheirownmarkourprogressinachievingthis research chief scientific officer employer choice select external award ranking award roche site rank description science magazine employer genentech st genentech biopharmaceutical industry prize seventh time san francisco business times genentech st rank base employee response good place work questionnaire include company bay area employee total equality germany roche germany na total equality award second time roche successful sustain equal opportunity commitment arizona bioindustry association ventana medical st award recognise ventanas bioscience company year systemsroche development growth tissue diagnostic good place work survey roche denmark st roche vote good pharmabiotech good pharmabiotech company company denmark fourth consecutive year second sector actualidad econmica roche spain st roche rank st pharma industry good company work th overall trendence employer roche switzerland rd switzerland student vote roche countrys good employer technology science edition lrochearengcorporate responsibility partindd employee fte operating division engage employee thegloballisteningtoyousurveyconductedinearly variance aimedtomeasuretheeffectivenessofinternal new pharma communicationsandemployeesattitudestothecom chugai panyandtheirworkoveremployee diagnostic respond total overallofrespondentsexpressedsatisfactionin theirjobandfelttheywereappropriatelyengage fulltime equivalent fte byrochethevastmajorityfeltproudtowork employee contract type forrocheandwouldrecommendthegrouptoother asagoodplacetowork variance regular fte nearlysaidtheyhaveaccesstotheinformation temporary fte theyneedtodotheirjobwellemployeesfeltwell headcount informedaboutourmajorproductsbusinessstrategy time hc andfinancialperformancewewillcarryoutanother time hc surveyin roche employee worldwide employee variance europe todayweemploysome north america employees asia aroundmorethan inallofthem aredrivenbythesame spiritandpursuethe samegoaltocreate newandbetterwaysto preventdiagnoseand africa australia treatnewdiseases latin america lrochearengcorporate responsibility partindd roche business report corporate responsibility duringtherochegenentechintegrationwepro certaincandidatesandtodemonstrateprogress videdrelevantinformationtoemployeesquicklyand towardsgovernmentgoalsforwomenandminoritie transparentlyusinganintegrationwebportaland employeeroadshowstheelectronicplatformallowe wesponsorandsupportanumberofemployeeaffinity ustocommunicatemanagementdecisionsinstantly groupsassociationsandnetworksthegoe andattractedonaverageuniquevisitorsper genentechoutequalgroupaimstopromote weekbetweenaprilandaugustmainlyfromthe aworkplaceenvironmentthatembracesallemployees usandswitzerlandweheldroadshowsatallaffected regardlessoftheirsexualorientationaaib sitesandusedthemtointroducenewmembersof africanamericansinbiotechnologyisdedicate themanagementteamwefilmedtheseeventsand toachievingaculturallydiverseenvironmentwhich postedthevideosonlinetogetherwithkeypresenta improvesthedevelopmentofdrugstoaddress tionsthesevideosprovideddirectinputonstrategic theunmetmedicalneedsofamoreculturallydiverse directionandothernewsstoriespicturesandper patientpopulation sonalstoriesfromemployeeshelpedpeoplefrom eachcompanyconnectmoreeasily theintegraprojectatrochespainalsoencourage greaterunderstandingofdisabilityamongemployee asurveyatgenentechshowedthatemployeesremain andaimstoincreasethenumberofhireswithdis positiveafterthemergerdespitehavingexperi abilitiesinitalycollaborationwithlocalinstitutions enceduncertaintyandlossasaresultgenentech overthelasttwoyearshasenabledustorecruitand employeesremainproudoftheircultureanditsposi onboardfiveadditionaldisabledperson tiveimpactonpatientslive peoplefromovercountriesfromaustralia thesurveyalsoshowedthatgenentechsfocus uruguaytosouthafricaworkforrocheinswitzer onpatientsandcommitmenttoscienceinspiresand landintotalmorethannationalitiesarerepre motivatesemployeesalmostallemployees sentedworldwideatroche arecommittedtothesuccessofthemergedcompany wanttostaywiththecompanyforatleastayear womenaccountfornearlyhalfofemployeesand orwanttostayatgenentechforalongtime ofmanagersgloballywomenalsomakeupmore thanoftheworkforceinoverofouraffili atesinwomenaccountformorethanofman foster diversity agementexamplesincludeaustraliawherewoman ourfocusistoensurediversityinourworkforce accountforofemployeesandofmanage aninclusiveworkenvironmentallowsustoleverage mentandhungarywithandrespectively thepotentialofallemployeesirrespectiveofage genderethnicitydisabilityworkstyleexperience gender diversity familysituationorworkingneed wedonottoleratediscriminationofanyformas women total statedinourworldwideemploymentpolicywe workforce havemanagementtrainingprogrammesandawide woman management rangeofinitiativesataffiliateleveltoencourage woman senior andsafeguardemployeediversityforexampleour management nutleysiteintheushasadedicateddepartment woman executive tomanagediversityitsetsannualplanstoevaluate management position howemploymentdecisionsmayadverselyaffect ie lrochearengcorporate responsibility partindd womeninleadershipnetworkbaselandgenentech genentechchallengesourscientiststodiscovernew womenprofessionalsbothaimtoprovideaforum biologyandtotranslatethesefindingsintonovel forwomenwhichrecognisestheiruniquestrength medicinestohelppatientssuccessrequiresafear andtalentsandinwhichexperiencescanbeshare lessnessandwillingnesstoattackthemostdifficult andleverage scientificandclinicalproblemsandnottobedeterre bythetrialsandtribulationsofscientificdiscovery encourage innovation andunknownsofmedicineifeelfortunatetohavethe rocheisaglobalinnovationledcompanywehave opportunitytoworkalongsideourresearchdevelop tobalancetheneedforefficiencyandconsistency mentandclinicalscientiststomeetthesechallenge throughstandardisationwithacompetitiveenviron andrew c chan md phd senior vice president immunology mentinwhichinnovationthrive antibody engineering innovationisdrivenbydifferentandoftenconflicte approachesideasandexperienceswhileensure werecogniseinnovationamongouremployeesthrough thatourmainfunctionalprocessesarealignedacross internalawardstheseincludeprizesforimprove therochegroupincludinggenentechwedecide animalwelfareinourtrialsimplementinginnovative tokeeptheresearchanddevelopmentlaboratorie informaticssolutionsandproposalsthatimprove genentechresearchandearlydevelopmentgre patientslivestherochepharmaceoawardsrecog independenttoensureitsinteractionwithexternal niseteamsthathavepassionatelypursuedinnovative researchinstitutionswasnotdisruptedgredhasit solutionsforpatientscreativelyimprovedtheway ownbudgetportfoliomanagementandcultureall weworkandpushedsciencemarketingandopera ofwhicharefundamentaltoinnovationwecreate tionstothenextlevelinmorethanteam aparallelpharmaresearchandearlydevelopment fromeveryregiondiseasebiologyareaandfunction organisationpredcomprisingthevariousrd participatedintheprogrammewinningteam centresoutsidegenentechtostimulatethedifferent includedrocheemployeesateverystageintheir perspectivescriticaltosuccessfulinnovation careersfromyoungpostdocstoseniorresearcher withdecadesofexperience employee fte function ourpostdocfellowshipprogrammeawardsourb scientistswithgrantstoconductexploratoryresearch servicing whichhelpsusreinforceourtalentpipelineinrd manufacturing logistic knowledgeisanessentialaspectinrochethatmulti marketing plieswhenitissharedandcleverlyusedthekey distribution istodevelopaparticipatorymanagementstylewhere research teamssharetheirideasanddevelopdifferentway development ofdoingthingsinaframeworkofmutualunderstand general ingitisaprivilegetoworkinacompanythatrecog administration nisestheperformanceandpotentialofitstalent total regardlessoftheirbackgroundandexperienceseven wherethesemightnotreflectthetraditionalrouteor theexpectedprofilerocheencouragesitsemployee torisetoandfaceprofessionalchallengesthus allowingthemtogrowandreachdifferentposition mara jess alsar oncohematology director spain lrochearengcorporate responsibility partindd roche business report corporate responsibility attract employee turnover regular employee weworkhardtokeepourrecognitionasanemployer ofchoicethisiscriticaltoourabilitytohireand retainoutstandingpeoplewhoarecommittedtoour total goalofimprovingpeopleshealthandqualityoflife europe latin america rochesstrongandsustainablebrandenablesus north america toattracttherightpeoplewehavebuiltalargeand asia diversepoolofcandidatesdedicatedinhouse australia recruitmentteamsandgloballyalignedrecruitment africa processesstandardsandtechnologyourcareer include non standard temporary contract end websiteexpandedintoimprovethelocalvisibility ofallavailablepositionsincludingatgenentech thesitehadsometwomillionuniquevisitorsin reason leave andregisteredmorethanspontaneous applicationswealsocontinuedtorollouttaleoour globalerecruitingplatformlaunchedin employerrelate injustthreecountriestaleoisnowavailableinover employeerelate countriesworldwide neutral temporary contract end health issue retirement wecontinuedtodeployourglobalemployerbrand inmakeyourmarkimprovelivestoimprove rochesturnovershowsastrongdecreasingtrend awarenessofrocheasanemployerofchoiceand thistrendisconfirmedparticularlybythe todifferentiateusfromourcompetitor numberofemployeesleavingoftheirownaccord fromintoinoverofour hire retention alargeintegrationrequire employeeshavebeenwithrocheformorethan asharpfocusonretentionourdecisiontomaintain tenyear genentechsuniqueresearchoperationswasone measuretoaidretentionaccompaniedbyadditional develop employee healthbenefitsoutplacementservicesandcash developmentisapriorityforallemployeesinaninno paymentswehavecontinuedtoattracttopscientist vationdrivenorganisationwewantemployeesto andotherhighprofiletalentsincethedealwa developtotheirfullestpotentialandsupportthemat closedgenentechhiredpeopleinin everystageindoingso creasingitstotalworkforceby performance management regularfeedbackand staffing rate anopendialoguebetweenemployeesandtheir managersisacriticalactivityforwhichweholdboth managersandemployeesaccountablein number vacancy ofouremployeestookpartinperformancemanage new hire mentprogrammesandinformalcareerdevelop internal staffing rate mentplanne external staffing rate lrochearengcorporate responsibility partindd employee training potentialleadersoftotalheadcountofwhich onethirdarewoman total training spend million withinthegloballeadershipportfoliowehavepro chf grammesaddressingeachcategoryofhighpotential training spend employee leadersfromthosewhowillassumeaglobal chf leadershippositioninthelongtermtothosewhocan total number training hour succeedakeypositionholderintheshortterm million intheseprogrammestargetedthetopof average training hour employeesandincluded employee explorationsincludesanassessmentofleader number postdoc student shipskillsfeedbackandcoachingbysenior intern leadersearlyinanemployeescareertoenable themtobuildfocuseddevelopmentplan exclude genentech chugai inemployeesparticipatedwoman learn rocheoffersextensivesupporttoem perspectivesatwoyearprogrammeinwhich ployeesforthedevelopmentoffunctionalprofe weprepareearlyhighpotentialleadersfor sionalandleadershipskillsourmajordiagnostic significantmanagementresponsibilitiestheywork andeuropeanpharmaaffiliatesaccountingfor infourdifferentfunctionsandregionsin ofthetotalrochepopulationofferednearly participantsjoinedforthefirsttimewoman coursesinthroughourcommon horizonsgivesmidtermhighpotentialemploy chrisplatformovertrainingsession eesanacceleratedglobalandcrossfunctional classroomandwebtookplaceandweregistere developmentexperienceincriticalareassucha closetobooking leadershipinnovationrisktakingcustomer orientationandchangeinemployee succession talent management inanorgani participatedwoman sationcharacterisedbychangeleadershipskill reflectionsprovidesanassessmentofthemost areincreasinglyimportantduringweensure seniorhighpotentialemployeesontheirindividual fullcoverageofourgloballeadershipprogramme strengthsareasofimprovementandpotential portfolioprovidingkeyprogrammesateverystagein basedontherochevaluesleadershipcompe theleadershipdevelopmentpipelineinroche tenciesincandidateswomentook learninganddevelopmentdepartmentwillcreate acommonframeworkforleadershipdevelopment linkinggloballeadershipprogrammeswithexiste atatimeofsignificantorganisationalchangeswe localregionalandfunctionalinitiativesthiswill filledmorethanofouropenpositionsinternally giveemployeesandmanagersaccesstoacatalogue ofleadershipprogramme international mobility whilesomevacancie ofthetotalarefilledbyexternalcandidate highpotentialleadersarepeoplewiththeabilityto weofferprofessionalandpersonaldevelopment takeoncriticalseniorrolesintheshortmidor opportunitiestoourownemployeesthroughinternal longtermidentifyinganddevelopingtheseemployee movesthisnotonlyhelpsrocheretainkeypersonnel ensureswehavearobustanddiversepoolofcan itenablesustoleveragepotentialwithinthegroup didatesforcriticalpositionsweidentifyandconfirm anincreasingamountoverofthismobility theseindividualsintalentassessmentsandreviews goesacrossaffiliateandnationalboundariesofour duringtheyearinweidentifiedhigh expatriatesandcrossboundaryemployee lrochearengcorporate responsibility partindd roche business report corporate responsibility arewomenallofthemrepresentingdifferent wealsoreviewedcompensationpracticesatroche nationality andgenentechandmovedgenentech employeestorochelongtermincentivesthismean toencouragemobilitywithinthegroupinwe thatapartfromchugaiemployeesalllongterm introducedtheintercompanytransferandlocal incentivesinthegrouparenowonthesameroche foreignhirepolicythisfacilitatestherecruitmentand holdingssecuritiesmorechangestoalignroche relocationofforeignhiresandofpermanentcross andgenentechcompensationpracticesandthe bordermoveswithinthegrouplocalmobilityinitia performancemetricsusedforincentiveswillcome tivessuchasourlocalpluspolicyinchinahelp intoeffectin attracttoptalenttochinaespeciallyindividualswho haveinternationalexperienceandwanttoreturn benefit throughcompetitivebenefitsprogramme wehelptocreateanattractiveworkplace wehavealsorevisedourinternationalassigneespolicy toimprovetheflexibilityneededtoaddressmarket overofouraffiliatesofferextensivebenefitsplans trendschangingdemographicsandevolvingbusiness mostgobeyondgovernmentschemesandinclude needsthisrevisionrespondstothefindingsof healthchecksandfreeaccesstoawiderangeof asurveyofassigneesandtheirpartnersthe medicalserviceswehavealsointroducedprogramme revisedpolicieswillberolledoutin thatencourageahealthylifestylethroughwellness programmeshealtheducationfitnesscentresswim rewarding recognise employee mingpoolsandrelaxationinitiativeswenowhave thetotalcompensationpackageweoffermake taichiclassesatourbrazilianitalianandmexican asignificantcontributiontoattractingrewarding affiliatesandhaveincorporateditinworkshop recognisingandretainingtherightpeople appliedbyourlifecycleteamswehavebeentrialling powernappingandareofferinghealthyfoodoption ourtotalremunerationcostsinamountedto atourheadquartersinbaselwecontinuetooffer billionswissfrancsanincreaseoffrom benefitstoourretireesatseveralofouraffiliatessuch ourbasepaypackagesrewardindividualperform asswitzerlandincludingaccesstoemployee ancerecognisingbothwhatwasachievedandhow restaurantssportsandleisureactivitiesandtravel itwasdonethroughvariablepayweincentivise check employeeswhocreatenewopportunitiesandstrive foroutstandingresultsvariablepayisdrivenby wehaveincreasedourfocusonflexibleworking individualandteamobjectivesandbythegroupdivi arrangementsaftersuccessfulpilotsatourwelwyn sionalandaffiliateperformance siteintheukourbaselheadquartersintroduced apilottoaccommodatedifferentworkingstyle wewantouremployeestoshareinoursuccess orfamilysituationsthroughhomeworkinganddesk throughrocheconnectemployeesinmostcountries sharingthepilotaimedtoidentifymoreattractive canpurchaserochesnonvotingequitysecuritie andflexibleworkingarrangementsforofficeworker atadiscountofuptoinemployee aswellastestingefficientandsustainableuseof incountriesofthoseeligibleparticipate officespaceandinfrastructure inrocheconnectmorethaninwealso awardnonvotingequitysecuritiestomanagersbase genentechintroducedanonlinetoolallowe ontheirperformancethroughtherochelongterm employeestoassesswhethertheirtasksareeligible incentivesplanatotalofmanagerstookpart forflexibleworkarrangement inwithjoiningforthefirsttime lrochearengcorporate responsibility partindd wealsoaimedtoincreasetheconsistencyofour human right labour relations benefitsprogrammesaroundtheorganisationour rochehasacomprehensiveemploymentpolicy goalistoalignbenefitprogrammeswithincountrie whichcovershumanrightsthegroupcompliance sowecanofferattractivebenefitstoallourem officermonitorsthispolicyandservesasacontact ployeesregardlessofaffiliateordivisionconsistently forallemployee andefficiently rocherespectstherightofemployeestofreedom inwestartedtheharmonisationofthebenefit ofassociationandcollectivebargainingmorethan plansofournorthamericanaffiliatescoincide ofouremployeesareunionmembersand withthegenentechintegrationwewilllaunchthenew overaremembersoforganisationsthatfreely programmeinoctoberanditwillcomeinto representthemincountrieswherethisislegal effectonjanuarysimilarbenefitharmonisa therocheeuropeforumrepresentsnearly tionprogrammesareongoinginswitzerlandspain employeesincountriesatgloballevelwehave franceandtheunitedkingdom recentlyinstalledanemployeerelationsofficer asaresultofthefinancialcrisisandthefallinglobal ourdirectiveontheprotectionofpersonaldatasafe equitymarketssomeofourpensionfundsaroundthe guardsinformationaboutemployeesandcomplie worldfacedchallengesmaintainingahealthyfunde withtherelevantlocallegislationwhereappropriate positionwhereunderfundinghasarisenroche wehavenegotiateddataprivacyagreementsbetween hastakenstepstodevelopappropriatestrategie differentpartsofthebusinessorwithworkscouncil inaccordancewiththelocalstatutoryregulation andpracticesandinconsultationwithemployee web representativesincludingadditionalcashinjection employee wwwrochecomemployee andrecoveryplanssomeofourmajorpension group policy position guideline wwwrochecompoliciesguidelinesandposition fundshaveremovedearlyretirementincentivesand global career portal httpcareersrochecom haveintroducedmoreflexibleretirementmodel employment policy wwwrochecomemploymentpolicypdf anticipatetheimpactofanageingworkforce core standard wwwrochecomcommitment simplify aligning process human resource allofourhrprocessesexceptthoseatgenentech andchugainowrunononecommonhrinformation solutionchristhisusestransactionalandreport ingsystemsandisalignedwithtaleoourglobal erecruitingsolution introducedinjulychrisreplacesseveral legacysolutionsandenablesstandardisedstreamline andsimplifiedhrprocessesacrosstherochegroup ouraimistoensureconsistenthrservicesand increasedefficiencychriscoversaffiliatesand representativeofficesandofrocheemployees genentechandpharmanorthamericawillfully joininchrisismanagedbyaglobalsupport organisationandnetworkofservicinghub lrochearengcorporate responsibility partindd roche business report corporate responsibility society oursupportforcommunitiesfocusesonprogramme community support area andareasthatarealignedwithourbusinessmodel webelievewecanenhancetheinnovationsustainabil total ityandimpactofourbusinessthroughappropriate humanitarian social project donationssponsorshipandemployeevolunteere science education thisinspiresandmotivatesourstaffandensure art culture rocheremainsacommittedcorporatecitizen community environment monitoringtheimpactofourcommunityworkgive support future science amoreaccurateassessmentofourprogramme youngscientistsareourfutureemployeesnurture successthanpublishingdetailedfinancialinformation theirtalentensuresrocheremainsaninnovative aboutourdonationsforexampleourgenetic andsuccessfulcompanyforexamplewehavefoun educationprogrammeforeducatorsinswitzerland dationstosupportresearchandeducationpro andgermanyreachednearlypeoplewith grammesaroundtheworldincludingthefondation teachersenrolledintheworkshopsthesubsequent dentrepriserocheinfrancetheglobalroche knowledgetransferreachedtheircolleaguespupil organtransplantationresearchfoundationandthe andevenfriendsandfamilywewillexpanditin genentechandrochefoundationsintheus switzerlandandneighbouringregionsofgermany therochepostdocfellowshipprogrammecomplete itsfirstfullyearintheprogrammeaims allphilanthropicdonationsandnoncommercial toencouragecreativityinscienceandstrengthen sponsorshipsaremonitoredinternallythroughthe academicnetworksthroughsupportfortalente financialgroupreportingsystemthecorporate postdoctoratestudentsontwotofouryearresearch sustainabilitycommitteeisresponsibleformonitore projectswithleadingacademicinstitutionsin theirimpact weofferedpostdoctoratestakingourtotalsince theprogrammelaunchedintopeople intherochegroupapprovedanupdatedcorpo weplantoincreasethatnumbertobytheend ratepolicyonphilanthropicdonationsandnon ofnextyear commercialsponsorshipthepolicystipulatesthatall philanthropicprojectsshouldfocusoninnovation inwepilotedtheresearchexchangescholar collaborationqualityandsustainabilityitcomfirm programmetheinitiativesupportsscienceeducation ourpriorityareasashumanitarianandsocialscience bygivinggiftedsecondaryschoolstudentsthechance andeducationcultureandartsandcommunityand togooninternationalexchangesthefirstexchange environmentourhumanitarianandsocialprogramme featuredtwobiotechnologyspecialistschoolsfrom involvepromotingsustainableaccesstoourmedi theusandgermanythreestudentsfromeach cinesanddiagnosticsweonlydonatedrugsindisas schoolundertookasixweekinternshipattheother terandpandemicsituation whichincludedindividualmentoringat alocaluniversity thepolicyalsoensuresourdonationstargeta focusednumberofnongovernmentalorganisation thecongressoftheeuropeansocietyformedi ngostowhichwecanmakeasignificantdiffer caloncologyesmoawardedrocheinrecognition enceratherthandilutingourdonationsamong ofoursupportforitsyoungoncologistfellowship alargenumberofngosweexcludegovernmental programmewehavesupportedesmosinceitwas politicalandreligiousorganisation foundedinthroughclinicalandtransnational fellowshipsthesehavehelpedyoungoncologistsgain lrochearengcorporate responsibility partindd researchexperienceinrenownedeuropeancancer wesetuptherocheemployeeactionandcharity centresourongoingeducationprogrammesinclude trustreactinasanindependentcharity atwodaybioethicsteachingworkshopforsecondary organisationtomanageemployeedonationsit schoolteachersintheusandourpartnershipwith distributesfundstocommunityprojectsanddisaster thenewjerseyinstituteoftechnologytosupport reliefeffortsaroundtheworldsinceanearthquake aonedayeducationprogrammeforprimaryand inreacthasmaintainedongoingassistance secondaryteacher andreconstructioninthetownofchocosperu intheprojectbuiltacommunitycanteenand encourage innovation art newhomescapableofwithstandinganother wesupportmusicandtheartsbecausethecreativity quakeaswellascompletingthecommunitysdam andinnovationofthosedisciplinesreflectsour businessmodelwebelievelessonscanbeshare theannualrochechildrenswalkhasbeengoe betweenartsandscienceinweheldthe sincehoweveritdidnottakeplaceinas thirdrochecontinentseventtoencourageartistic ithasbeenmovedfromdecembertojulytoincrease involvementamongyoungpeoplearoundfuture participationnonethelessreactsworkwith chemistsbiologistsmedicspsychologistsmusi theeuropeancoalitionofpositivepeopleandunicef cianssetdesignersrecordingengineersandopera switzerlandwhichbothhavelongtermproject singersfromuniversitiesallovereuropeattende tosupportchildrenimpactedbyhivaidsinmalawi artandscienceworkshopsandcontemporaryclassical continuedrocheemployeeswerestillinvitedto musicperformancesatthesalzburgfestival donateinandweguaranteedfinancialcoverage toensurethechildrendonotsufferintheinterim roche commissionsseesussponsoranewmusical todatethewalkhasraisedenoughmoneytobuildand piecebyanoutstandingcontemporarycomposer furnishnewclassroomsaccompanyingteacher everytwoyearstoshiohosokawawillpresenthis officesandsanitationandhygienefacilitiesfornearly workininadditionchugaiagainsponsoredthe primaryschoolchildrenthesponsoredwalk starphilharmonicchristmasconcertinyokohama hasalsohelpedfundeducationforsecondary japanwhichsupportsearlycancerdiscoveryand schoolstudentsandfivefurthereducationstudents treatment inruralsouthafricathereisjustonedoctorforevery support community patientsthephelophepahealthcaretrain wewantemployeestocontributetotheirlocalcom aimstoreducetheburdenbyprovidingamobilehealth munitiessoweencouragethemtoidentifythe clinictomorethanpeoplewehavesupporte projectsthattheyfeelwouldbemostworthwhile theservicesinceitbeganyearsagoandin whilerochehasarangeofgroupprojectswe additionalfundingfromrochecontributedtoacancer encouragestafftofundraiseandvolunteeralongside healthawarenessservicethenewserviceinclude theirworkcommitment cancerscreeningtrainingforstaffcommunitycancer awarenesseventspatientcounsellingandeducation genentechgoestotownisacommunityrelation focusedonbreastcervicalandprostatecancer projectsetupingenentechgivesemployee usdollarsworthofvoucherstospendinlocal web shopsovertwoweeksencouragingthemtodevelop roche social programme localbusinessestheprogrammehasspentmore wwwrochecomsociety roche n jazz wwwrochenjazznet thanmillionusdollarsinlocalshopssinceincep act httpreactrochecom tionwithmorethanbusinessesparticipate lrochearengcorporate responsibility partindd roche business report corporate responsibility safety security health environmental protection safetysecurityhealthandenvironmentalprotection wetrainemployeeswhohandlechemicalsaspartof shearecriticalforourbusinesswetakeshe theirworktousethemproperlyandweprovide intoconsiderationinallouractivitiestherochecor safetydatasheetsforoverspecificchemical porateprinciplesandshepolicycommitustothe onourwebsite highestshestandardsinweinvestedmil lionswissfrancsinsheinfrastructureandmillion weholdourecompetitioneverythreeyearstoraise swissfrancsinsheoperatingcost awarenessofenvironmentalissuesamongemployees byencouragingthemtosuggestnewwaystoreduce management ourimpactsthecompetitionourfifthelicite astrongteamcoordinatesshewithinrochewe morethanproposalsfrompeopleatsites havefulltimesheemployeestoensureour thewinnersinclude performancenewsheofficersattendedatraining rochepaloaltousretrofittingcoolingequip weektolearnaboutourshepolicystrategyguide menttoreplacehalogenatedhydrocarbon linesandprocessesattendeesdiscussedroche hcfcwithhydrocarbonrefrigerantspropane sheresponsibilitiesandhowtoaccessrelevant orpropylene expertisetheyalsolearnthowtoestablishandmain rochejacarepagubrazilrecoveringsolution tainariskmanagementsystemattheirsiteswe fromtubingusingapolystyreneplugratherthan heldregionalworkshopsforexistingsheofficerson waterandnitrogen topicssuchasenergyefficiencysecurityandindus chugaipharmajapanregeneratingemergency trialhygiene batteriesinuninterruptedpowersuppliesinstead ofreplacingthem everyoneatrocheisresponsibleforensuringhealth andsafetyandforminimisingtheenvironmental theannualrocheresponsiblecareawardsencour impactsofouroperationsweneedeveryonetounder agesitestosuggestenergyefficiencyimprovement standourshestandardssoweoffersitespecific insubmissionsfromsitesstoodout trainingincludinglecturesandpracticalcourseswe include havealsobegunabasiconehoursheelearne rochebezaresmexicosolarboilersinstalle moduleforallemployeesinemployees toprovidehotwater receivedanaveragehoursofshetrainingeach rochediagnosticsuscontrolledlighte duringquietperiod itisimportanttounderstandsherisksacrossthe rochediagnosticsindiaaspecialglassfaade businesssowecandeveloplocalsafetymeasuresas wasinstalledtosaveenergycost wellasgrouplevelresponseswelistallsherisk onawebbasedinventoryaccessiblebyallmanager security acrossthebusinessindividualsitemanagersand weappointedacorporatesecurityofficercso sheofficersimplementtheshepolicyandguide ininwesetupanetworkofmore lineslocallyinthepharmaceuticalsanddiagnostic thansitesecurityofficersssosandissue divisionsecodelegatesraiseawarenessofenviron acorporatedirectivetodefinetheirresponsibilitie mentalissue aswellasoursecurityprinciplesandgeneral processesthedirectivedescribesminimumstand wemonitortheimplementationoftheshepolicy ardstoprotectemployeesvisitorsphysicalasset usingregularsiteauditsandweusetheresult productsandbusinesssensitiveinformation toimproveperformanceinweconducte auditsrevealingnomajordeficienciesbut wealsointroducedaglobalsecurityincident highlightingtheneedtoupdatesiteriskanalyse reportingtoolthatallowsssosandthecsotoanalyse lrochearengcorporate responsibility partindd incidentsandestablishcorrectivemeasuresin agrouplevelbodyinvestigatessignificantshe wefocusedoncounterfeitproductsandpreventedthe incidentsandcommunicatestherelevantfinding saleofsignificantquantitiesoffakeproduct acrossthecompanyincludingforuseintraine programmeswheresuitable health safety therocheaccidentraterarmeasuresthe environmental footprint numberofworkingdayslostduetooccupational ourenvironmentalfootprinttakesintoconsideration accidentsperemployeeperyear researchandproductionaswellasproductpackag ingdistributionuseanddisposal intherarwasthisrepresentsa improvementfromandiscomfortablybelowthe weusetheswissagencyfortheenvironment groupgoalfor bafuecobalancemethodtocalculateourenvi ronmentalfootprintitreflectsresourceuseas health safety wellasemissionsandwasteinourecobalance wasanimprovementoffromthis reflectssignificantlyreducedemissionstoairand roche accident rate organicmaterialsdischargedtowaterweare occupational accident currentlyoperatingwithinourtargetecobalanceof occupational illness workrelate fatality workrelate accident wealsomeasureenvironmentalexpenditureinrela million work tiontosalestohelpensurewetargetourinvestment hour intheareaswhereitwillhavethemostimpact thecalculationgivesusanecoefficiencyrateeer weexpectcontractorswhoworkonrochepremise asshowninthetablebelowthiscombinesdata tofollowthesamesafetyrulesasemployees onenergyusewasteemissionstoairandwaterwith contractorswereinvolvedinaccidentsin expenditureonenvironmentalprotectionandsale inadditiontothosereportedforemployee adetaileddefinitionisavailableontherochegroup resultinginaninjuryfrequencyrateofaccident websiteinoureerwasanimprove perworkinghour mentof employeessufferedcasesofoccupationalillnesse ecoefficiency rate inadecreasefrominthenumber ofworkingdayslostwasthesamelevelasin locomotordisordersespeciallyrepetitivestrain sales million chf injuriesaccountedformorethantwothirdsofthe environmental expend totalweworktoreducetheseinjuriesthroughlocal iture million chf ergonomicprogrammesimprovedofficeequipment environmental damage andindividualassessmentsgenentechsergonomic millions environ programmeaddressescumulativetraumaand mental damage unit includesadedicatedtrainingwebsitethesouthsan eer franciscositehasthreeergonomicsshowroom allowingstafftotestproductsfortheofficeplantand therocheenvironmentalawarenessinchemical laboratory technologyreactprogrammepromotessustainable chemistrypracticesinourrdlabsaroundtheworld lrochearengcorporate responsibility partindd roche business report corporate responsibility reactsetssustainablechemistryguidelinesto energy use type measurethebenefitsforexamplethemassintensity factormeasurestheratioofinputsofrawmaterial fuel againstoutputswhilesolventselectionguidelineshelp company vehicle employeeschooselessharmfulsolventsthepro oil grammeaimstosupportrochessustainabilitygoal fuel business sharebestpracticesaroundthegroupraise air travel employeeawarenessincreaserecognitionforrd sustainabilityworkandreducecost grid electricity energy climate change ourpositionpaperongreenhousegasesandclimate district heating changeguidesourgroupstrategyfordecrease waste emission renewable energy natural gas weregularlyanalyserochesvulnerabilitytothe changingclimatewehavenotidentifiedanysig nificantriskstoourbusinessfromclimatechange sionsfactorsatsomesiteswhoseelectricityprovider oranyspecificbusinessopportunitie recalculatedthelessemissionintensiveproportionof theirenergymix rochesenergyandfueluseintotalle terajoulesanincreaseoffromthis greenhouse gas emission tonne co equivalent ismainlyduetotheinclusionofgenentechscar fleetforthefirsttimeenergyuseisapproximately gigajoulesperemployeeasmalldecreasesince total emission total emission million chf energy use terajoule sale thereductioninemissionsinrelationtosale total energy use showsthatrocheisreducingenergyusewhilethe total energy use businessgrow million chf sale total energy use inwedevelopedastandardforintegrate employee energyefficiencymanagementintobuildingproject thisaccompaniedanewgroupwidemanualon ourclimatestrategyfocusesonenergyusewhich energyefficientdesignwhichwillhelpusdesign accountsformostofourcarbondioxideco emis futurefacilitiesandrefurbishedbuildingstominimise sionsweconvertamountsofco andothergreen energyuse housegasghgemissionssuchashalogenate hydrocarbonsleakingfromrefrigerationequipment milanhasaproblemitisoneofthemostpolluted intocoequivalentsinweemittedthou citiesineuropesmogisatarecordlevelfarabove sandtonnesofcoequivalentsanabsolutedecrease europeanunionlimitsrochemonzaitalybegan offromthisreductioncomesdespite aprogrammetoreduceitsenvironmentalimpactsin increasedenergyconsumptionduetorevisedemis bymodifyingtransportincreasingrecyclingand lrochearengcorporate responsibility partindd reduce total energy consumption greenhouse gas emission energy use select type fuel company vehicle introducedanewtargetforoureuropeancom panycarfleettoincludeonlyvehiclesproduce nomorethangramsofcarbondioxideco perkilometrebytheendof fuel business air travel videoandteleconferencingfacilitieshavebeen establishedatallsitesandarewidelysupporte employeesareencouragedtousetrainsand toconsolidateseveralbusinesstripsintoone grid electricity natural gas ourfirstpriorityistoreduceusageofenergy fortheenergywedousewelookforwaysof improvingtheefficiencysuchasheatrecovery inadditionweencouragetheuseofgreen energywhereversensibletohelpdrivethisin wereleasedourgroupwidemanual onenergyefficientdesignfortheconstruction offuturefacilitiesthatminimiseenergyuse reducingenergyusethroughsensorlightsand genentechmetitsownghgemissionsreduction energysavinglightbulbsinthesiteincrease goaltwoyearsaheadofscheduleitwillnowjointhe itsfocuslifegateanexternalenvironmentalorgani restofrochesusaffiliatesinpursuinganewgoalof sationbasedinmonzanowmonitorsenergyand decreasingemissionsbyby waterusewastedisposallogisticsandemployee transportthesitehasalsostartedbuyingofit rochehasagroupdirectiveonenergyconservation energyfromrenewablesourcesinadditionaninter whichpromoteslocalinitiativesitincludesenergy nalawarenesscampaignhasencouragedemployee efficiencystandardsfornewandexistingelectrical togetinvolvedinenergysavinginitiativessofar equipmentandrequiressitestoconductenergy thesitehasreducedco emissionsbyaround audits theusenvironmentalprotectionagencyepahas theauditsidentifiedopportunitiestoimprove commendedourusaffiliatesformeetingtheirgoalto ourbuildingsutilitiesplantsandprocessesinclude reduceghgemissionsbybetweenand thoseatgenentechtheseincludeimprovedmetering aheadoftimerocheushaspledgedtoreduce andmonitoringretrocommissioningbuilding emissionsbyafurtherfromto andadaptinglightingandairconditioningsystem lrochearengcorporate responsibility partindd roche business report corporate responsibility despitethesecentralfunctionswegivesitesthe ozone depletion freedomtodeveloptheirownemissionsreduction thetargetdateforrochesdirectivetophaseout strategieswebelievethisapproachimprovesresult halogenatedhydrocarbonscfcsandhcfcswhich becausesitesaremorefamiliarwiththeirownneed damagetheozonelayerandaffecttheclimatehas andcircumstancesforexamplerocheshanghai beenextendedfromtoordepende hasanongoingprojecttoincreaseenergyefficiency onthelocalsituationthisisduetoalackofaccepte theprogrammehasseentheintroductionoftriple alternativesinsomecountriesgenentechhasnot anddoubleglazingoptimalinsulationgeothermal yetdefinedatargetdatebutiscommittedtophase heatingandcoolinglowpowerenergysystemsand thesegasesout solarwaterheate replacementsforhcfcsandcfcssuchashfcs businesstravelaccountsforapproximatelyof hydrofluorocarbonsandpfcsperfluorinated ourtotalco emissionsoverallandourcarfleetis carbonsdonotaffecttheozonelayerbuttheycan responsibleforapproximatelyemployeesare contributetoclimatechangeandarepersistentin encouragedtousetrainswhentravelisnecessary theenvironmentsowedonotconsiderthemalong andtoconsolidateseveralbusinesstripsintoone termalternativerochehasatargettophaseout videoandteleconferencingfacilitiesalsohelpusmini hfcsandpfcsbygenentechandotherrecent misetravelforexamplerochefinlandworkedwith acquisitionswillworktoaseparatedeadlinetobe wwffinlandtohosttheamericansocietyofclinical definedinsometechnicalproblemscontinueto oncologysannualmeetingvirtuallyinjune preventusfromreplacingtheseinallapplication aroundcustomersattendedtheconferencefrom butweareworkingtofindalternativetechnologie theirclinicsparticipatingthroughvideostreame severalsitesnowusetelepresencesystemswhich ozonedeplete chemical tonne significantlyimprovethequalityofvideoconference encouragingincreasedusage halogenate anewtargetforoureuropeancompanycarfleet hydrocarbon holding aimstoensurewewillusevehiclesproducingnomore halogenate thangrammesofco perkilometrebytheend hydrocarbon ofthiswillcutco emissionsbytonne emission andsavetwomillionlitresoffuelperyear rocheshalogenatedhydrocarbonsinventoryincrease anumberofsiteshavelaunchedinitiativestoencour induetotheintroductionofgenentechs agestaffnottouseprivatecarstocommutetowork holdingstothegrouptotalwithoutthisincrease atgenentechforexamplethegrideprogrammehas rochesholdingswouldhavedecrease promotedalternativessuchasvanpoolingmass transitcyclingwalkingandgenenbusshuttlessince emission air theshuttleswereupdatedinwithnewer emissionstoairfromouroperationsincludevolatile moreefficientmodelsthatmeettheusepas organiccompoundsvocsparticulatesnitrogen standardforparticulateemissionsatrotkreuz oxidesnoandsulphurdioxideso weaim x switzerlandwehaveintroducedanannualbonusof toreducetheseemissionswhichcancontributeto swissfrancsforstaffwhocommutetowork airpollutionsmogandacidraininwereduce withoutusingacarormotorbike vocemissionsbytotonnesouremis sionsofparticulatesno andso weretonne x lrochearengcorporate responsibility partindd tonnesandtonnesrespectivelythesefluctuate wemonitorlandfillsitestoensureourchemicalwaste atlowlevelsfromyeartoyear doesnotposearisktohumanhealthortheenviron mentsomelandfillsneedtobesustainablyremedi emission air tonne atedinwecompletedaprojecttoremediatethe hirschackerlandfillingrenzachgermanyroche voluntarilyfinancedthisprojectinwemade vocs availableapproximatelymillionswissfrancsfor particulate othersuchproject nitrogen oxides sulphur dioxide water weneedcleanwaterformanufacturingbutwe waste understandtheneedtoreduceourwaterusebased aroundofourchemicalwasteisincinerate ontheglobalreportinginitiativesdefinitionof thedisposalmethodwiththeleastenvironmental waterconsumptionwaterusedinproductscoole impactinweproducedtonnesofchemi andirrigationouruseincreasedbywe calwasteandecreasefromthisdoe usedmillionmofwaterin notincludewastethatcanbereusedasrawmaterial byothercompaniesinwesoldaround thewaterweusecanbecontaminatedduringmanu tonnesmostlysolventsforreuse facturingsowetreatwastewatertoensureitis safeforpeopleandtheenvironmentwecontinueto inweengagedinsignificantbuildingactiv developwaystoincreaseourcapacitytotreatwaste itywhilewascharacterisedbybuilde wateraroundthegroup demolitionwegeneratedlessgeneralwaste tonnesbutourrecyclingratesincrease oneofthewinningsubmissionsofecompetition duetotonnesofbuildingrubblemade camefromrochepenzberggermanythesubmission availableforrecyclingmostlymetalsandconcrete outlinesaproposaltouseresidualwaterfromthe soldtoothercompaniesforreuseexcludingthis distillationofpurifiedwatertogeneratesteamforthe buildingrubblewerecycledtonne plantsboiler morethanlastyearwedecreasedgeneralwastesent tolandfillbyofthetotaltwere inwedecreasedtheamountoforganicmaterial incinerate dischargedintowatercoursesaftertreatmentby totonnesthisismainlyduetoarecalcula waste tonne tionofdatafromtwositesbecauseinvestigationsinto differencesatsimilarsitesrevealedthattheyhad overreportedinpreviousyearswealsorelease general waste kilogramsofheavymetalssuchaschromium produce copperandzinclessthanin general waste million chf ournewgoaltoreducetoxicityofdischarged sale wastewaterreflectsthegenerallylowertoxicityof chemical waste organicmatterfrombiotechoperationsthanfrom produce chemicalproduction chemical waste million chf sale lrochearengcorporate responsibility partindd roche business report corporate responsibility water compliance incident rochedidnotreceiveanysignificantshefinesin wemeetalllocallawsorregulationsasaminimum water withdraw howeverourgrouppoliciesareoftenstricterthan million cubic metre thesewecontrolsubstancesthatcouldbemisused water toproducenarcoticstoxinsorchemicalandbio million cubic metre weaponsthesesubstanceswhichwekeepinsmall wastewater discharge supplyareoftenregulatedandweensurecompliance treatment plant withallapplicablelegislation million cubic metre organic matter objective discharge reducetherocheaccidentratebyby watercourse fromthebaseline treatment tonne improvetotalecobalancebybyfrom heavy metal baselinepointsemployee discharge reducetotalenergyconsumptionbyby watercourse frombaselinegigajoulesemployee treatment receivenosignificantsherelatedfine kilogramme medium longterm objective pharmaceutical environment pie averagefourhoursofshetrainingperemployee tracesofpharmaceuticalproductsendupintheenvi reducetherocheaccidentraterarto ronmentraisingfearsthattheymaylaterbefoundin andworkrelatedaccidentspermillionworke foodandwatersourcesthisisusuallyduetonormal hourstobelowby patientusealthoughmanufacturingandimproper improveourecobalancebybyfrom disposalalsocontributeweofferretailersfinancial abaseline incentivestoreturnunusedoroldproductssowecan improveenergyefficiencymeasuredasgigajoule discardthemproperlyweanalysetheriskofpharma peremployeebybyandby ceuticalsenteringtheenvironmentinourlifecycle comparedwith approachtoproductdevelopmentminimising increasetheproportionofrenewableenergyuse releaseswherepossiblemanufacturingsitesare toby designedandoperatedtoreduceactiveingredient reducethetoxicityofdischargedwastewaterby enteringwastewater byfromabaseline althoughcurrentevidencesuggestslittlepresenceof web piewerecognisetheneedformoreresearchinto performance longtermeffectsinweundertookathorough wwwrochecomsheperformance safety security health environmental protection riskassessmentoftheactiveingredientoseltamivir wwwrochecomenvironment tamiflubeingexcretedintotheenvironmentdure safety security health environmental protection heavypandemicusetheassessmentfoundno signifi policy cantriskourpositionpaperonpiedescribe wwwrochecomsafetyhealthandenvironmental protectionpdf ouraimtomonitorrisksandrocheisamemberof group fact sheet position policy guideline internationalandlocalbodiesstudyingtheimpactsof wwwrochecompoliciesguidelinesandposition tracechemicalsinsurfaceandgroundwater genentech sustainability report wwwgenecomgeneaboutenvironmental lrochearengcorporate responsibility partindd independent assurance report tothecorporatesustainabilitycommitteeof therochecorporatesustainabilitycommitteeisresponsible rocheholdingltdbaselroche forboththesubjectmatterandthecriteriaourresponsibilityis toprovideaconclusiononthesubjectmatterbasedon wehaveperformedassuranceprocedurestoprovideassurance ourassuranceproceduresinaccordancewiththeinternational onthefollowingaspectsofthecorporateresponsibility standardonassuranceengagementsisae reportingofroche main assurance procedure subject matter ourassuranceproceduresincludedthefollowingwork dataandinformationdisclosedinthecorporateresponsibility evaluation application group guideline reportingofrocheanditsconsolidatedsubsidiariesexcluding reviewingtheapplicationoftherocheinternalcorporate chugaipharmaceuticalcoltdforthebusinessyearende responsibilityreportingguideline decemberonthefollowingaspect site visit visitingselectedsitesofrochespharmaceuti themanagementandreportingprocesseswithrespectto calsanddiagnosticsdivisionsinswitzerlandgermany thecorporateresponsibilityreportingandtothepreparation francespainitalyandchinatheselectionwasbasedon ofsheandpeoplekeyfiguresaswellasthecontrol quantitativeandqualitativecriteria environmentinrelationtothedataaggregationofthese interviewingpersonnelresponsibleforcompliancematter keyfigure internalcorporateresponsibilityreportinganddata theshekeyfiguresinthetablesonpagestoand collectionatthesiteswevisitedandatthegrouplevelto someselectedpeoplekeyfiguresdisclosedonpage determinetheunderstandingandapplicationofroche tooftherocheannualreportand internalcorporateresponsibilityguideline complianceinformationconcerningthecompliance visitingthepremisesofpeopleintouchinamsterdam functionsthecomplianceorganisationandthemanagement interviewswithpeopleintouchstaffinvolvedindesign ofcasesreportedthroughtherochegroupspeakupline implementationandoperationsofthespeakupsolution thelatterwithafocusondataprivacyandprotectionof assessment key figure performingtestson individualsanonymityasdisclosedonpageoftheroche asamplebasisofevidencesupportingselectedsheand annualreportexcludingethicalincidentdata peoplekeyfiguresrocheaccidentrateenergyconsump tionco emissionsrelatedtoenergyconsumptionrelease criterion ofhalogenatedhydrocarbonsuseofwaterfinesinrelation therochegroupinternalcorporateresponsibilityreporte tosafetyandenvironmentalprotectionheadcountftedata guidelinesbasedontheresponsiblecareprogramme staffturnoverseniormanagementpositionsandlabor healthsafetyandenvironmentalprotectionreporting practicesinformationconcerningcompletenessaccuracy guidelinespublishedbytheeuropeanchemicalindustry adequacyandconsistency councilceficandthesustainabilityreportingguideline review documentation analysis relevant gpublishedonoctoberbytheglobalreporting policy basic principle reviewingtherelevant initiativegriand documentationonasamplebasisincludinggroupsustain thedefinedproceduresbywhichsheandpeoplekey abilitypoliciesmanagementandreportingstructuresand figuresaregatheredcollatedandaggregatedinternally documentation therochegroupbusinessprinciplestheinternalgroup assessment process datum con solidation speakupguidelinesbasedonthedirectiveonuseof reviewingtheappropriatenessofthemanagementand rochegroupspeakuplineandgoodpracticeprocedure reportingprocessesforcorporateresponsibilityreporte bywhichcompliancefunctionsandspeakuplinesare andassessingtheconsolidationprocessofdataatthe designedmanagedandoperate grouplevel assessment speakup process system responsibility methodology case management walkthroughthespeakupprocess theaccuracyandcompletenessofcorporateresponsibilityindi byusingapracticalexampleandassessingthefollowe catorsaresubjecttoinherentlimitationsgiventheirnatureand protectionagainstunauthorisedaccessconnectionsand methodsfordeterminingcalculatingandestimatingsuchdata processestoexternalserviceprovidersandexternal ourassurancereportshouldthereforebereadinconnection businesspartnersprocessesinplaceforadministration withrochesinternalguidelinesdefinitionsandprocedureson loggingmonitoringandbackuprestoreallinrelationtothe thereportingofitscorporateresponsibilityperformance dataprivacyandanonymity lrochearengcorporate responsibility partindd roche business report independent assurance report conclusion global reporting inouropinion initiative sustainability theinternalcorporateresponsibilityreportingguidelinesare beingappliedproperly report guideline theinternalreportingsystemtocollectandaggregateshe andpeoplekeyfiguresisfunctioningasdesignedand withthisyearsannualreportwecontinueourapproachof providesanappropriatebasisforitsdisclosureand aligningoursustainabilityreportingtotheguidelinesofthe therochegroupspeakuplinesystemsandprocessesare globalreportinginitiativegri designedfollowinggoodpracticeprocedureswithregardto dataprivacyandanonymity forthethirdtimerocheisoftheopinionthatthealevel ofthegrigguidelinesappliestoitsannualreport basedonourworkdescribedinthisreportandtheassessment thiswascheckedwithandconfirmedbythegri ofcriterianothinghascometoourattentionthatcausesusto believethatthedataandinformationmentionedinthesubject detailsofhowwereportagainsteachindicatorcanbefound matteranddisclosedwiththesustainabilityreportingin atwwwrochecomreportingandindice therocheannualreportexcludingethicalincidentdata doesnotgiveafairpictureofrochesperformance zurichjanuary pricewaterhousecoopersag drthomasscheiwiller stephanhirschi severinschwan lrochearengcorporate responsibility partindd publish cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooke state tel ment forwardlooke statement identify fax word believe expect anticipate project intend seek estimate future similar expression discussion thing strategy medium office goal plan intention factor cause actual group communication result differ materially future reflect basel switzerland forwardlooke statement contain annual report tel price product initiative competi fax tor legislative regulatory development eco nomic condition delay inability obtain regulatory investor relation approval bring product market fluctuation currency exchange rate general financial market condi basel switzerland tion uncertainty discovery development tel marketing new product new use exist product fax include limitation negative result clinical trial research project unexpected effect pipeline world wide web market product increase government pricing pre wwwrochecom sure interruption production loss inability obtain adequate protection intellectual property right corporate sustainability committee litigation loss key executive employee adverse publicity news coverage tel email corporatesustainabilityrochecom statement earning share growth profit forecast interpret mean order publication roche earning earning share tel subsequent period necessarily match exceed fax historical publish earning earning share roche email baselwebmasterrochecom trademark mention enjoy legal protection annual general meeting link party page provide convenience march express opinion content party page expressly disclaim liability party information use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communication cover photograph show ribbon diagram rituximab therapeutic protein heart mabtherarituxan target bio logic medicine treat nonhodgkin lymphoma chronic lymphocytic leukemia rheumatoid arthritis lrochearengimprintindd e roche annual report key figure key figure index figure annual report exceptional item index global reporting initiative gri propose board director indicator report development phase iv wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment e lrochearengkey figuresindd roche finance report fr hyr eng ceonvge rc ver uhr usheri es eite rroocchhee afinnnaunacle r reeppoortrt fhopfufmbalinshnelda bryoche ltd f bhaosfefml asnwnitzlear lranodche ltd basel switzerland aallll ttrraaddeemmaarrkkss mareen lteiognaellyd pernojtoeyc lteegdal protection trademark mention enjoy legal protection wwwrochecom roche halfyear report wwwrochecom lead biotechnology improve patient care excellence science umschlagausgeschossenengindd lrochearengfront coverindd